Extrathymic Aire-Expressing Cells

Permalink
https://escholarship.org/uc/item/74m9h40d

Author
Gardner, James Morgan

Publication Date
2010

Peer reviewed|Thesis/dissertation
Extrathymic *Aire*-Expressing Cells

by

James Morgan Gardner

DISSERTATION

Submitted in partial satisfaction of the requirements for the degree of

DOCTOR OF PHILOSOPHY

in

Genetics

in the

GRADUATE DIVISION

of the
Acknowledgements

I would like to thank my parents for their unconditional love and support.

Mark Anderson, for his generous and enthusiastic guidance, patience, and thoughtful mentorship.

Art Weiss and Jason Cyster for their wisdom and kindness.

The members of the Anderson Lab for help, advice, and friendship; in particular Todd Metzger, who contributed significantly to many experiments.

And Helen, for everything else.


Chapter II is modified from “Deletional tolerance mediated by extrathyemic Aire-expressing cells” J.M. Gardner et al., Science 2008;321: 843-7

Chapter III is a modified from “Prevention of Autoimmune Diabetes by Self-Antigen Expression in Extrathyemic Aire-Expressing Cells” J.M. Gardner et al., submitted manuscript.
Extrathymic *Aire*-Expressing Cells

James Morgan Gardner

Abstract

Clonal diversity within the adaptive immune system, while endowing organisms with the ability to respond to a broad range of potential pathogens, presents a substantial risk for autoimmunity. Numerous complementary mechanisms have evolved to prevent such deleterious outcomes, and to establish and maintain appropriate tolerance to self. Medullary epithelial cells of the thymus play an essential role in this process by displaying a diverse set of tissue-specific antigens via a mechanism dependent on the Autoimmune regulator (*Aire*) gene. Here we describe a discrete population of extrathymic *Aire*-expressing cells (eTACs) in the secondary lymphoid organs. We show that *Aire* regulates a diverse range of tissue-specific antigen genes in eTACs distinct from those presented in the thymus. To define a potential role for this population in immune tolerance, we demonstrate that self-antigen expression in eTACs is sufficient to prevent T cell-mediated autoimmune diabetes mediated by CD4+ or CD8+ T cells. We demonstrate that such tolerance is established via anergic or deletional mechanisms for CD4+ or CD8+ cells, respectively, and does not require the presence or induction of regulatory populations. Further, we show that tolerance induction by eTACs is highly resistant to conversion to immunogenicity. Finally, we describe the development of a novel transgenic mouse model for depletion of mTECs and eTACs, and suggest that the absence of these populations predisposes to autoimmunity. Together this work identifies self-antigen expressing eTACs as a population with potential significance in both physiologic and therapeutic maintenance of self-tolerance.
# Table of Contents

Title Page ............................................................................................................... i

Chapter I: *Aire* and Immune Self-Tolerance ......................................................... 1
   Adaptive immunity and self-tolerance .................................................................. 2
   *Aire* is essential for immune self-tolerance ....................................................... 6
   The mechanism of *Aire* deficiency ................................................................... 17
   Extrathymic *Aire* and TSA expression ............................................................. 37

Chapter II: Identification and Characterization of Extrathymic Aire-Expressing Cells ..................................................................................................................... 48
   Introduction ........................................................................................................ 49
   Results ............................................................................................................... 49
   Discussion ......................................................................................................... 77
   Materials and Methods ...................................................................................... 79

Chapter III: Self-Antigen Expression in eTACs Prevents Autoimmunity .......... 91
   Introduction ....................................................................................................... 92
   Results ............................................................................................................. 94
   Discussion ....................................................................................................... 131
   Materials and Methods .................................................................................... 137

Chapter IV: The *AireDTR* Mouse and Autoimmunity .................................... 149
   Introduction ................................................................................................... 150
   Results ........................................................................................................... 151
Discussion ........................................................................................................ 172
Materials and Methods.................................................................................. 177
Chapter V: Discussion .................................................................................. 181

eTACs exist in the secondary lymphoid organs and express diverse
TSAs .............................................................................................................. 183
eTAC interactions with T cells are tolerogenic and prevent
autoimmunity .............................................................................................. 185
The *AireDTR* mouse: a tool for the study of immune tolerance ............... 186
The mechanism of eTAC-mediated T-cell tolerance .................................. 188
eTACs and Tregs ......................................................................................... 191
The role of Aire in eTACs .......................................................................... 192
The identity and origin of eTACs ............................................................... 194
Why eTACs?.............................................................................................. 195
Theraputic self-antigen expression in eTACs? ........................................... 197
Appendix: Selected Protocols...................................................................... 203
Thymectomy/Thymic Transplant/Bone Marrow Chimerism ..................... 204
Stromal Preparation for FACS .................................................................. 218
List of Tables

Table S2.1: Genes significantly upregulated in $\textit{Aire}^{+/+}$ vs. $\textit{Aire}^{-/-}$ eTACs ............ 67

Table S2.2: Genes significantly downregulated in $\textit{Aire}^{+/+}$ vs. $\textit{Aire}^{-/-}$ eTACs........ 69
List of Figures

Chapter 1

Figure 1.1. The mouse and human Aire protein and gene ........................................ 8

Figure 1.2. Histology of Aire-knockout tissues shows multiorgan lymphocytic infiltrate and tissue destruction ............................................................. 12

Figure 1.3. Organ-specific disease incidence in APS-1 patients and characterized Aire-deficient mouse strains ............................................................. 15

Figure 1.4. Aire regulates TSA expression in mTECs, preventing escape of tissue-specific autoreactive thymocytes ................................................. 21

Chapter 2

Figure 2.1. The Adig transgene recapitulates Aire expression in the thymus and mediates negative selection of autoreactive T cells ................................. 50

Figure S2.1. The Aire-driven Igrp-Gfp transgene introduces a novel antigen into the thymus which faithfully reflects thymic Aire expression and causes deletion of cognate T cells ......................................................... 53

Figure 2.2. Aire-expressing cells exist in the secondary lymphoid organs .......... 56

Figure S2.2. Extrathymic Aire BAC-driven Igrp-gfp is expressed selectively in lymphoid structures ................................................................. 58

Figure S2.3. Transgenic Igrp-gfp is expressed by both hematopoietic and radioreistant populations in the secondary lymphoid organs .................... 60
Figure S2.4. eTACs do not express markers characteristic of other lymphoid stroma................................................................. 62

Figure 2.3. Aire regulates the expression of a unique set of tissue-specific antigens in eTACs....................................................................................................... 65

Figure 2.4. eTACs directly interact with autoreactive lymphocytes and mediate deletional tolerance................................................................. 73

Figure S2.5. The relative absence of 8.3 T cells after adoptive transfer into Adig transgenic mice is not due to egress................................. 75

Chapter 3

Figure 3.1. The Adbig transgene recapitulates Aire expression in mTECs and eTACs......................................................................................... 96

Figure S3.1. GFP+ mTECs and eTACs from Adbig mice are significantly enriched for Aire transcript................................................................. 99

Figure 3.2. eTACs directly interact with CD4+ T cells and induce functional T-cell unresponsiveness ............................................................ 102

Figure S3.2. Efficiency of reconstitution in wildtype and Adbig NOD mice lethally irradiated and reconstituted with MHC II-/- bone marrow ...... 104

Figure 3.3. Cognate antigen expression in eTACs prevents BDC2.5-mediated insulitis and autoimmune diabetes............................................. 108

Figure 3.4. eTAC-induced self-tolerance in BDC2.5 T cells is cell-intrinsic and does not require the presence of regulatory T cell populations .......... 111
Figure S3.3. Efficiency of depletion of FoxP3+ regulatory T cells in FoxP3-DTR BDC2.5 mice ................................................................. 114

Figure 3.5. eTAC-mediated tolerance induction in BDC2.5 T cells is not abrogated by CD40/TLR stimulus or PD-L1 blockade......................... 117

Figure S3.4. Anti-PD-L1 treatment regimen induces rapid diabetes onset in wildtype NOD mice ................................................................. 120

Figure 3.6. αDEC1040 treatment induces proliferation but not tolerance of BDC2.5 T cells ................................................................. 123

Figure 3.7. IGRP expression in eTACs leads to peripheral deletion of 8.3 T cells and prevention of CD8-mediated diabetes................................. 127

Figure S3.5. Efficiency of reconstitution in Adig mice lethally irradiated and reconstituted with Thy1.1+ 8.3 bone marrow................................. 129

Chapter 4

Figure 4.1. The AireDTR transgene is expressed in mTECs and eTACs........ 153

Figure 4.2. DT administration induces effective depletion of AireDTR transgene-expressing cells in the thymus and secondary lymphoid organs ........ 156

Figure 4.3. Kinetics of DT depletion and recovery....................................... 159

Figure 4.4. Continuous depletion of Aire-expressing cells in the thymus induces complete loss of medullary epithelium and architecture ................. 164

Figure 4.5. Thymocyte profile is globally normal in “amedullary” AireDTR thymi, but shows decreased CD4+ Tregs ......................................................... 167
Figure 4.6. AireDTR NOD mice treated with DT from weeks 1-3 do not show

growth retardation or mortality but are predisposed to autoimmunity ........ 170
Chapter I

*Aire* and Immune Self-Tolerance

*I resist any thing better than my own diversity,*

*Breathe the air but leave plenty after me*

—*Walt Whitman, Song of Myself*
1. Adaptive immunity and self-tolerance

Multicellularity in living organisms permits astounding degrees of specialization, but requires a continuous negotiation between individual cells tethered to a common fate. One of the most important challenges for multicellular organisms is to define the collective “self,” and to defend that self from invasion by “non-self” pathogens in order to avoid destruction by parasitism, neoplasm, and infection. The immune system is responsible identifying and neutralizing such non-self agents, while trying to avoid attacking one's own diverse and specialized tissues. The immune system thus serves to protect organisms from external microbial threats, while remaining “tolerant” of its own varied constitutive parts. Furthermore, while increasing size, complexity, and longevity among multicellular organisms provide numerous advantages, they also pose unique problems: as an organism’s lifespan increases, the number and diversity of pathogens it may encounter, and the number of generations during which those pathogens may evolve in the organism’s lifetime increase dramatically. Long-lived organisms thus suffer an acute adaptive handicap with regard to defense against the organisms that try to invade them—they lack the ability to evolve quickly, and therefore to adapt genetically to the incredible and ever-changing diversity of potential pathogens.

The adaptive immune system represents an elegant solution to this problem—the ability to generate islands of genetic hypervariability within specific populations of somatic cells, and then select from these variants—that allows the system both to generate staggering diversity and to constantly adapt to novel microbial variants. While
many organisms ranging from plants to insects have some forms of innate immune protection involving phagocytic cells with fixed receptor specificity, it appears that only vertebrates seem to have evolved such a complex system for responding to the ever-changing microbial environment (1).

Functionally, the adaptive immune system consists of clonal populations of antigen-specific cells each with their own unique cell-surface receptor. Two principal cell types constitute the adaptive immune system, B and T cells. B cells recognize antigen through membrane-bound immunoglobulin in the form of the B-cell receptor (BCR), and upon activation they proliferate and produce antibodies, generating a soluble immune response against free (extracellular) pathogens. T cells recognize antigen through the T-cell receptor (TCR), and in contrast to B cell-generated immunoglobulins which recognize free soluble antigen, the TCR recognizes antigen displayed in the context of specialized antigen presentation molecules termed multiple histocompatibility (MHC) proteins. T cells thus respond principally to intracellular pathogens or to pathogens that have been consumed, processed, and presented by other antigen-presenting cells (APCs).

The singular feature of adaptive immunity which endows it with the ability to respond to such an diverse range of potential pathogens is that the genes encoding the BCR and TCR are themselves composed of multiple cassettes, and these cassettes undergo somatic and permanent BCR or TCR gene rearrangement during B and T cell development, respectively. A number of complementary mechanisms aid in generating additional and truly random diversity in the antigen-binding regions of the BCR and
TCR during gene rearrangement (2), the end result of which is random and irreversible gene rearrangement endowing each T or B cell with a unique receptor. The system as a whole therefore generates a population of immune cells with an almost limitless diversity of antigen-specificity, composed of individual B and T cell clones each with the ability to recognize a single unique antigen. As these cells are selected to survive, divide, and differentiate, they and all their daughter cells retain the same receptor, and thus the same antigen-specificity. This “clonal selection” paradigm, which developed gradually through the work of numerous investigators ranging from Paul Erlich (3), to Niels Jerne (4), David Talmadge (5), and F. Macfarlane Burnet (6), has come to centrally define our understanding of adaptive immunity and immunologic tolerance.

However it is precisely this combinatorial diversity within the adaptive immune system that also constitutes the most substantive risk for autoimmunity. While random somatic generation of B- and T-cell receptors affords the immune system with the ability to respond to diverse pathogens, it also generates an enormous number of B and T cells with potentially autoreactive receptors that recognize some component of the host organism itself. Thus, in addition to the complex machinery needed to generate this receptor diversity, the adaptive immune system also requires an equally complex set of mechanisms to properly educate immune cells how to distinguish “self” from “nonself.” For B cells this education occurs initially in the bone marrow, but for T cells, the primary site of this education is the thymus.
T-cell progenitors derived from bone marrow hematopoietic stem cells migrate to the thymus, a mediastinal organ essential for T-cell development and maturation. In the thymus, individual T-cell progenitors (called thymocytes) sequentially rearrange their TCR genes to generate a random receptor and undergo selection, both positively to select for those cells that have generated a functional MHC-binding receptor, and negatively to select against those T cells whose functional receptors strongly recognize self-antigen. The process of negative selection takes place preferentially in the medulla, where thymocytes with self-reactive TCRs encounter self-antigen on specialized antigen-presenting cells (APCs) and either die or become repurposed as regulatory T cells. While negative selection of self-reactive thymocytes has been characterized and understood for quite some time, until recently it was unknown precisely how this process might account for the breadth of immune self-tolerance against the entire diversity of the body's proteome. For example, while this process might effectively delete developing thymocytes specific for ubiquitous self-antigens (like actin or ribosomal subunit proteins) present in all cells, it was more challenging to imagine how the same process might occur for T cells reactive against one of an organism's diverse and specialized tissue-specific antigens (TSAs) like insulin, thyroglobulin or interphotoreceptor binding protein (IRBP) whose expression are highly restricted to single peripheral tissues in the body.

This suggested that perhaps many potentially autoreactive T cells escaped thymic negative selection simply because of the absence of exposure to cognate antigen during thymic development, and thus that the burden of maintaining immune tolerance fell
principally to peripheral mechanisms like second-signal requirement for activation, the presence of inhibitory co-stimulatory molecules, regulatory T cells, and antigen sequestration in sites of immune privilege.

While such mechanisms are clearly indispensible for the maintenance of tolerance, recently a number of lines of evidence have converged to suggest that expression of diverse TSAs in centralized sites of T-cell education might also play an essential role in the maintenance of tolerance. Surprisingly, the principal set of findings that codified this paradigm were related to the genetic mapping of a rare monogenic autoimmune disease in humans, and the resultant discovery of the essential role played by this gene in human and mouse immunologic self-tolerance.

2. *Aire* is essential for immune self-tolerance

A. APS-1 in humans: a monogenic autoimmune disease caused by *AIRE* mutations

Autoimmune polyglandular syndrome type 1 (APS-1) is a rare autoimmune disease characterized principally by immune-mediated destruction of the endocrine organs. Clinically, the diagnosis is made by meeting two of the following three criteria—hypoparathyroidism, adrenal insufficiency, and mucocutaneous candidiasis. In addition, most APS-1 patients exhibit a diverse range of other autoimmune symptoms including type I diabetes, gonadal atrophy, hypothyroidism, autoimmune hepatitis, and autoimmune pneumonitis, among others (7, 8). The disease generally manifests during childhood, but the diverse symptoms may emerge throughout a patient’s life. Though the
precise manifestations vary from individual to individual, and even between siblings (7), the overall clinical picture is one of a profound failure in the immune system’s ability to properly distinguish self- from non-self-tissues, and a consequently devastating attack on primarily the endocrine organs.

While the manifestations of this disease are diverse, the genetics are uniquely simple. APS-1 is an autosomal recessive disease caused by mutations in a single gene, the autoimmune regulator (AIRE). Though rare, with an estimated total of 500 cases worldwide, APS-1 has uniquely elevated frequency among genetically isolated groups including Sardinians (1/14,400), Iranian Jews (1/9000), and Finns (1/25000) (9). Linkage analysis of families with the disorder led to the identification of AIRE (10, 11), with almost all affected APS-1 patients containing either homozygous or compound heterozygous mutations of the gene. To date over 40 such mutations have been identified, the majority of which are either premature stop codons or large exon deletions (12).

The AIRE gene itself encodes a ~57-kDa protein of 545 amino acids comprised of multiple domains common to transcriptional regulators and nuclear proteins (Figure 1.1). Located on chromosome 21 in humans and chromosome 10 in mice, Aire is a single-copy gene whose orthologues have been identified in all gnathostome (jawed vertebrate) classes except the cartilaginous fish, and whose sequence and structure is broadly conserved between these classes (13). Suggestively, this places the emergence of the Aire gene approximately 500 million years ago, roughly coincident with the
Figure 1.1. The mouse and human Aire protein and gene.
Figure 1.1

Dimerization
Nuclear Import
Putative DNA Binding
Histone Interaction
Transcriptional Coactivator Binding

human

mouse

0 2000 4000 6000 8000 10,000 12,000 14,000

(Chromosome 21)

(Chromosome 10)
emergence of the adaptive immune system (14). This relationship between Aire and the adaptive immune system may speak to its central role in maintaining self-tolerance in the adaptive immune system.

The murine Aire gene, in particular, is highly homologous to the human gene, sharing all major protein domains, all exons, and having 71% nucleotide and 73% amino-acid sequence homology (Figure 1.1) (15, 16). As such, and because the mouse is such a well characterized system for the study of the immunology, it has proven an attractive candidate for modeling human APS-1, and for studying the mechanisms of Aire biology and immune self-tolerance in general.

B. The mouse model of APS-1 broadly recapitulates the autoimmunity observed in human APS-1

Due to the significant interest in the mechanisms underlying APS-1 upon the identification of the AIRE gene and its murine homologue Aire, a number of independent groups generated Aire-knockout mice. In all cases, these mice exhibited significant autoimmunity including multi-organ lymphocytic infiltration, autoreactive antibodies in serum, and tissue destruction, though the precise phenotypes differed somewhat depending on the strain and the influence of genetic background.

The first Aire-knockout mouse was generated by insertion of a termination codon in exon 6, replicating a common mutation observed in APS-1 patients (17). This knockout, though generated in a relatively autoimmune-resistant Sv/129/C57BL/6
mixed background, still exhibited both multiorgan lymphocytic infiltration and the presence of autoreactive antibodies in serum, as well as infertility among both males and females. Specific endocrine organs including the ovaries and liver showed distinct lymphocytic infiltrates, and consistent with human APS-1, adrenal glands were absent in a significant portion of the Aire-knockout mice suggesting their complete destruction. Further, Aire-knockout mouse serum demonstrated antibody reactivity against the liver, testis, pancreas, and adrenal glands. A second Aire-knockout mouse, also in the Sv/129/C57BL/6 mixed background, was generated by targeted deletion of exon 2 of the murine Aire gene which resulted in a frameshift early termination (18). These mice demonstrated lymphocytic infiltrates of the salivary gland, ovary, retina, thyroid, liver, and stomach, and serum autoantibodies were also detected against the salivary gland, ovary, retina, thyroid, pancreas, and stomach (Figure 1.2). Further, this study showed a distinct correlation between organ-specific autoantibodies and lymphocytic infiltrates of that organ. Finally a third group generated a unique Aire knockout by targeted deletion of a region spanning from exon 5 to exon 12, removing the sequences coding for the SAND domain as well as both PHD domains (19). This third knockout showed a similar phenotype of infertility and autoimmune lymphocytic infiltrates of the salivary and lacrimal glands, as well as some infiltration of the pancreas and stomach.

Overall, these overlapping models suggest a consistent picture of the Aire-knockout mouse as predisposed to autoimmunity that generally resembles the diverse but organ-specific autoimmunity seen in APS-1 patients. As in APS-1 patients, Aire-
Figure 1.2. Histology of *Aire*-knockout tissues shows multiorgan lymphocytic infiltrate and tissue destruction (*images courtesy of J. DeVoss*).
Figure 1.2

<table>
<thead>
<tr>
<th>Aire-/-</th>
<th>Salivary Gland</th>
<th>Pancreas</th>
<th>Retina</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>![Salivary Gland Image]</td>
<td>![Pancreas Image]</td>
<td>![Retina Image]</td>
</tr>
<tr>
<td>WT</td>
<td>![Salivary Gland Image]</td>
<td>![Pancreas Image]</td>
<td>![Retina Image]</td>
</tr>
</tbody>
</table>
knockout mice begin with relatively mild disease that spreads in both the number of targeted organs and the severity of tissue damage. Further, the disease seen in Aire-knockout mice is both disseminated and organ-specific—while numerous and diverse organs can be targeted, specific organs are affected while others are spared, and the organs targeted differ from individual to individual or strain to strain.

The influence of genetic modifier loci on the disease phenotype of Aire-knockout mice was further demonstrated when the Aire mutation was backcrossed into diverse genetic backgrounds (20). In autoimmune-prone strains like the non-obese diabetic (NOD) mouse, for example, lymphocytic infiltration affects a diverse set of organs including the retina, cornea, stomach, salivary gland, lung, liver, prostate, ovary, pancreas, and thyroid gland, while only a small subset of these organs (retina, salivary gland, lung, and prostate) are infiltrated in the autoimmune-resistant C57BL/6 strain (Figure 1.3). Further, Aire-knockout NOD mice experience wasting and die by 15 weeks of age, while Aire-knockout C57BL/6 mice do not waste and have survival curves similar to wildtype. Thus, the presence or absence of other genetic modifiers affects both the spectrum of organs targeted and the severity of tissue damage.

In this sense, the Aire-knockout mouse broadly reflects the heterogeneity of disease manifestations in human APS-1, where genetic modifiers and environmental factors likely influence the spectrum of affected organs (though it should be noted that the exacerbation or elimination of innate immune stimuli appears to have little to no discernable effect on the spectrum of disease in Aire-knockout mice (21)). However,
Figure 1.3. Organ-specific disease incidence in APS-1 patients and characterized Aire-deficient mouse strains (7, 8, 20, 50, 89, 90; M. Su, J. DeVoss, M. Cheng, T. Shum, personal communication).
## Figure 1.3

<table>
<thead>
<tr>
<th>Condition</th>
<th>APS-1 Pts</th>
<th>Aire -/-</th>
<th>G228W/+</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrenalitis</td>
<td>![Icon]</td>
<td>![Icon]</td>
<td>![Icon]</td>
</tr>
<tr>
<td>Parathyroiditis</td>
<td>![Icon]</td>
<td>![Icon]</td>
<td>![Icon]</td>
</tr>
<tr>
<td>Ovarian Failure</td>
<td>![Icon]</td>
<td>![Icon]</td>
<td>![Icon]</td>
</tr>
<tr>
<td>Thyroiditis</td>
<td>![Icon]</td>
<td>![Icon]</td>
<td>![Icon]</td>
</tr>
<tr>
<td>Type I Diabetes</td>
<td>![Icon]</td>
<td>![Icon]</td>
<td>![Icon]</td>
</tr>
<tr>
<td>Autoimmune Hepatitis</td>
<td>![Icon]</td>
<td>![Icon]</td>
<td>![Icon]</td>
</tr>
<tr>
<td>Exocrine Pancreatitis/Malabsorption</td>
<td>![Icon]</td>
<td>![Icon]</td>
<td>![Icon]</td>
</tr>
<tr>
<td>Gastritis</td>
<td>![Icon]</td>
<td>![Icon]</td>
<td>![Icon]</td>
</tr>
<tr>
<td>Uveitis</td>
<td>![Icon]</td>
<td>![Icon]</td>
<td>![Icon]</td>
</tr>
<tr>
<td>Bronchiolitis</td>
<td>![Icon]</td>
<td>![Icon]</td>
<td>![Icon]</td>
</tr>
<tr>
<td>Salivary Disease</td>
<td>![Icon]</td>
<td>![Icon]</td>
<td>![Icon]</td>
</tr>
<tr>
<td>Candidiasis</td>
<td>![Icon]</td>
<td>![Icon]</td>
<td>![Icon]</td>
</tr>
<tr>
<td>Vitiligo</td>
<td>![Icon] N/A</td>
<td>![Icon] N/A</td>
<td>![Icon] N/A</td>
</tr>
<tr>
<td>Alopecia</td>
<td>![Icon]</td>
<td>![Icon]</td>
<td>![Icon]</td>
</tr>
<tr>
<td>Peripheral Neuropathy</td>
<td>![Icon]</td>
<td>![Icon]</td>
<td>![Icon]</td>
</tr>
</tbody>
</table>

- ![Icon]: Present
- ![Icon]: Not Present
- ![Icon]: Data not available
- **Aire -/-**
  - NK: Not known
  - Percentages: 1-25%, 25-50%, 50-75%, 75-100%
  - not observed

- **G228W/+**
  - NK: Not known
some of the targeted organs clearly seem to differ between humans and mice; for example, the endocrine pancreas is targeted in many APS-1 patients but spared in mice, while the retina is targeted in mice but rare in humans. Indeed even among those organs that are shared between man and mouse, the precise antigens recognized may in fact differ between the species (22). Some disease manifestations of APS-1 in humans are never observed in mice, for example mucocutaneous Candidiasis, though this may be partly explained by the fact that Candida is a commensal organism in humans but not in mice (23, 24). Regardless of these differences, however, the mouse model of APS-1 provides a broad recapitulation of the autoimmunity seen in the human disease, and therefore presents an invaluable tool to learn about both the pathogenesis of this disease as well as more fundamental mechanisms of immune self-tolerance.

3. The mechanism of Aire deficiency

Aire’s expression in the thymus provides clues to its function

While the phenotypic characterization of Aire-knockout mice demonstrated a broad recapitulation of the autoimmunity seen in APS-1, this still did not provide immediate answers to the fundamental pathogenesis of the disease. Indeed, while the described Aire-knockout mouse models all reported autoimmune sequellae, they also reported few or no detectable changes in the immune system itself. The number of thymocytes and lymphocytes, the ratios of CD4+ and CD8+ T cells and B cells, the activation and death
of thymocytes, the responsiveness of T cells to in vitro stimulation, and the number and function of regulatory T cells are all grossly normal in Aire-knockout mice (17-19).

One clue to Aire's function, however, lay in its highly tissue-restricted expression pattern. While early attempts to characterize this expression were somewhat discordant, all concurred that Aire was most highly expressed in the thymus (15, 25, 26). As the organ in which T cells develop and are selected, the thymus plays an important role in shaping a T-cell repertoire. As discussed, because the adaptive immune system generates individual receptors for each T-cell precursor essentially at random through V(D)J recombination, many T-cell precursors are born with either a completely nonfunctional receptor or with a receptor that recognizes self. One of the principal functions of the thymus, therefore, is to provide permissive signals for those developing T cells that express a functional T-cell receptor (positive selection), while eliminating those that recognize self-antigen (negative selection), or diverting such self-reactive T cells to a regulatory lineage (27, 28).

As discussed, the thymus therefore shoulders a heavy burden in trying to prevent the development of self-reactive effector T cells—it must eliminate not just T cells that recognize ubiquitous self-antigens expressed in all cells, but also those T cells that might recognize tissue-specific antigens (TSAs). Without some mechanism to account for this, T cells specific for such antigens might escape thymic negative selection simply because the self-antigen was sequestered in the target organ. Numerous complementary systems could, and do, exist to prevent the development and activation of such tissue-specific autoreactive T cells, including the migration of antigen-presenting cells from the
periphery back to the thymus (29), the peripheral development of regulatory T cells (30), and the inactivation or anergy of those naïve T cells that undergo inappropriate activation upon exposure to self-antigen (reviewed in 31). However the thymus also contributes to tolerance against TSAs through an elegant mechanism partially dependent on Aire.

**Aire-expressing medullary thymic epithelial cells are unique sources of TSA expression**

Unlike most epithelium, thymic epithelial cells (TECs) do not form a continuous barrier or define a topological space; rather, they are interdigitated among the developing T-cell precursors throughout the entire parenchyma of the thymus. Broadly speaking, cortical thymic epithelial cells (cTECs) play an important role in the positive selection of T cell precursors, while medullary epithelial cells (mTECs) play a role in the negative selection of those T cells that recognize self antigen (reviewed in 14). While ectopic expression of individual tissue-specific antigens like insulin in the thymus was first described more than a decade ago (32, 33), until recently the scope of such TSA expression, its physiologic significance, and the cell populations responsible were unknown. Thus, the discovery that mTECs were in fact the principal cell population responsible for this thymic TSA expression, and that mTECs expressed thousands of such TSAs (34), suggested that these cells might play an important role not only in tolerizing the immune system against ubiquitous antigens but also against many tissue-restricted ones as well. However this theory, while compelling, lacked evidence of physiologic relevance as no direct examples of autoimmunity caused by defects in thymic TSA expression were known.
The contemporaneous discoveries that APS-1 was caused by mutations in the \textit{AIRE} gene, that mTECs were the source of TSA expression in the thymus, and that \textit{AIRE} was highly expressed in mTECs led investigators to hypothesize that perhaps the autoimmunity observed in APS-1 patients and \textit{Aire}-knockout mice resulted from a failure of tissue-specific antigen expression in the thymus \cite{18,34}. Indeed, using microarrays and quantitative PCR to compare TSA expression in mTECs from \textit{Aire}-wildtype and \textit{Aire}-knockout mice it was shown that \textit{Aire} is required for mTECs to produce this diverse set of TSAs, and in the absence of \textit{Aire} this reduction in expression of “peripheral self” in the thymus leads to autoimmunity in these mice \cite{18}. Thus in \textit{Aire}-knockout mice, mTECs are unable to promiscuously transcribe tissue-specific antigens like insulin, thyroglobulin, and interphotoreceptor retinoid-binding protein, and therefore T cells reactive against these antigens can escape thymic negative selection without ever seeing these antigens (Figure 1.4). Further, loss of \textit{Aire} in the thymic epithelium is sufficient to cause this autoimmunity, as transplantation of \textit{Aire}-deficient thymic stroma into Nude mice (which lack a thymus due to mutation of the \textit{FoxN1} gene) causes these mice to develop autoimmunity \cite{18}.

To confirm that loss of thymic TSA expression in \textit{Aire}-knockout mice leads directly to autoimmunity, additional studies have been done using \textit{Aire}-dependent tissue-specific antigen promoters to drive expression of exogenous neo-antigens in the thymus and study negative selection of T-cell receptor transgenic T cells specific for those antigens in the presence and absence of \textit{Aire}. For example, investigators used the insulin
Figure 1.4. *Aire* regulates TSA expression in mTECs, preventing escape of tissue-specific autoreactive thymocytes.
Figure 1.4

[Diagram showing Normal T Cell and Self-Reactive T Cell with Ubiquitous and Tissue-Specific Antigens in Wildtype mTEC and Aire-/- mTEC with text: Exit from Thymus]
promoter to drive expression of hen egg lysozyme (HEL) in both the pancreas and the thymus, and then examined the thymic negative selection of HEL-specific T cells in Aire-wildtype and Aire-knockout mice (35, 36). Because mTECs normally transcribe insulin at low levels in an Aire-dependent manner, these transgenic mice produce insulin promoter-driven HEL within the thymus, and when HEL-specific T cell precursors are introduced, they are negatively selected and die before leaving the thymus. However in the absence of Aire, mTECs no longer produce this insulin-driven HEL, and thus HEL-specific T cells do not undergo negative selection in the Aire-knockout thymus. Instead, these cells now mature normally and exit the thymus, encountering HEL protein in the pancreatic islets and causing autoimmune diabetes. Such transgenic approaches provide mechanistic insight into the breakdown of tolerance that occurs in the absence of Aire, offering clear evidence that autoimmunity in Aire-knockout mice can result from failures in thymic TSA expression.

It is important to note that while promiscuous expression of tissue-specific antigens in the thymus represents a large sample of the body’s transcriptome, and Aire regulates a significant percentage of these TSAs, it is also clear that both these sets are incomplete—that some TSAs, like islet-specific glucose-6-phosphatase related protein (IGRP), a major autoantigen in type I diabetes, are not expressed at all in mTECs (37), while others like C-reactive protein (CRP) from the liver, are clearly expressed in mTECs but in an Aire-independent fashion (18). Indeed, mature mTECs themselves appear to promiscuously express at least 3000 TSA genes, of which Aire regulates perhaps
250-1000, in addition to other, non-TSA genes \((18, 38, 39)\). Thus \textit{Aire} appears to regulate the thymic expression of a subset of the TSAs expressed in mTECs, and these TSAs themselves represent a subset of the body’s total transcriptome. This incredibly diverse but incomplete representation of self in the thymus suggests, not surprisingly, that other complementary mechanisms must also be in place to help reinforce self-tolerance.

Such transcriptional de-regulation is itself a remarkable feat, as it requires uncoupling the normally tissue-restricted expression program of specific genes, allowing them all to be simultaneously expressed in this one remarkable cell population. Precisely how \textit{Aire} functions to accomplish this is still not completely understood, though the molecular mechanism of Aire’s action has been the subject of significant recent study.

**The molecular mechanism of Aire function**

Even before \textit{Aire} was implicated as a regulator of tissue-specific antigen gene transcription in mTECs, the homology of its predicted domains to other known proteins (Figure 1.1) led investigators to speculate that it might act as a transcriptional regulator \((10, 11)\). Like other transcriptional regulators, Aire contains a nuclear localization sequence which is necessary \((40)\) and sufficient \((41)\) to target it to the nucleus; a caspase recruitment domain (CARD) involved in homodimerization \((42)\); four LXXLL nuclear receptor boxes that mediate interaction with transcriptional coactivators \((43)\); a SAND (Sp100, Aire, NucP41/P75, and Deaf1) domain whose other family members have
DNA-binding ability (44); and two zinc-finger containing plant homeodomains (PHD1 and 2) that may be involved in histone binding (45, 46).

The subcellular localization of Aire also provides clues that suggest it might act to regulate transcription. Immunofluorescent staining shows that Aire in mTECs localizes to the nucleus, specifically into punctate nuclear bodies (47, 48) that may associate with the nuclear matrix (49). More specifically, Aire appears to localize within or adjacent to nuclear speckles, which are often sites of splicing, polyadenylation, capping, and other RNA processing, as well as sites of RNA polymerase II stabilization and elongation (50). Indeed, Aire has been suggested to play a role in transcriptional elongation through recruitment of P-TEFb, a positive elongation factor (51). Further, in *in vitro* assays Aire has been shown to interact with the transcriptional coactivator CBP, and to have direct and cooperative transcriptional transactivation capabilities (52, 53) as well as direct DNA-binding activity (45, 54). However the relevance of these *in vitro* findings to Aire’s function *in vivo* is still uncertain, and its role in directly binding to *cis*-acting regulatory sequences of target genes remains unclear. Further, genomic analyses of the thousands of Aire-regulated gene promoters have failed to identify any common sequence elements that might define a consensus binding site for Aire.

Because Aire exerts such large-scale effects on transcription of diverse genes across the genome, it has also been suggested that it may exert its effects epigenetically, perhaps by interacting with and modifying chromatin. Indeed, a number of groups have observed that Aire-regulated genes cluster into groups within a chromosome (39, 55).
However, the clustering of *Aire*-regulated genes is not a simple case of broad transcriptional derepression. For example, in the casein gene cluster (normally expressed in mammary epithelium of lactating females but also in *Aire*-expressing mTECs), individual *Aire*-repressed genes sit between groups of *Aire*-induced genes, while other genes within the same cluster are unaffected by the presence or absence of *Aire* (39). This suggests that while Aire may mediate large-scale epigenetic changes such as chromatin remodeling, such changes alone are not sufficient to explain its transcriptional regulatory effects.

Recent reports have also described potentially significant interaction between Aire’s PHD1 domain and unmethylated histones. The importance of the PHD1 domain to Aire’s function is underscored by the fact that it is highly conserved between species (13), and is also the site of a number of deleterious point mutations in human APS-1 patients (56). Furthermore, other PHD domains have been found in chromatin-associated proteins and these domains appear to bind histones in a manner that is sensitive to the methylation status of specific lysine residues on the histone (57, 58). Indeed, these reports have now shown that the PHD1 domain of mouse and human Aire bind directly to Histone H3 and that methylation of this histone on lysine 4 inhibits interactions with Aire and Aire’s ability to bind chromatin-associated DNA (46, 59). Importantly, these groups have shown that transfected Aire directly binds to and upregulates expression of a number of TSA genes *in vitro*, that this effect is dependent on the histone-binding residues of its PHD1 domain, and that those genes upregulated by
Aire also show a higher ratio of unmethylated to methylated histone H3K4. This interaction provides an attractive rudimentary model for Aire’s function, as unmethylated H3K4 is generally associated with sites of transcriptional repression. Thus, perhaps Aire employs histone methylation status to aid in targeting it to quiescent genomic regions to upregulate transcription of otherwise repressed TSA genes.

This hypothesis was supported and extended by a recent study extensively describing the binding partners of Aire through immunoprecipitation and mass spectroscopy (60). While Aire binds to histones themselves, it also appears to interact with large multimolecular complexes that include chromatin modifying enzymes, transcriptional regulation machinery, DNA manipulation and repair enzymes (e.g. DNA-PK, TOP2a), nuclear transport proteins, and splicing/pre-mRNA processing machinery. The relative contributions of each of these components to Aire’s regulation of TSA gene transcription has yet to be fully dissected, but these results provide a number of suggestive clues to Aire’s potential function. The association with chromatin-modification enzymes suggests that in addition to Aire reading the local chromatin environment for signs of transcriptional repression, Aire may also modify this same chromatin to promote transcription. The association with DNA manipulation and repair enzymes like Top2a and DNA-PK, which are also involved in transcriptional elongation and processivity, suggests that Aire binding may promote transcription through the introduction and repair of double-stranded breaks (DSBs) in DNA. In support of this, DNA-PK deficient mice have reduced thymic TSA expression (relative to Rag-/-
controls), Aire appears to induce such DSBs in transfected cells, and artificial introduction of DSBs upregulates expression of certain TSA genes in vitro (60). Finally, association with pre-mRNA processing machinery suggests that Aire may be involved in stabilizing RNA splicing of TSA transcripts. In support of this, while Aire clearly upregulates the level of spliced TSA transcripts in mTECs, analysis of pre-spliced levels of the same candidate TSA transcripts shows no difference between Aire-wildtype and Aire-deficient thymi. The generalizability of this finding to all Aire-regulated TSAs remains to be determined, but if valid, it suggests that pre-mRNA processing may play a central role in Aire function. Indeed, it is interesting to speculate that if this hypothesis is generally true (that Aire wildtype and Aire-deficient thymi have equivalent levels of all pre-spliced transcripts and only differ in the levels of post-spliced transcripts), it implies that stabilization of pre-mRNA splicing may be the primary role for Aire in unregulating gene expression. Indeed, this suggests that all the other suggested chromatin/DNA modification/transcriptional stabilization components of Aire function that generate pre-spliced mRNA may not play a significant role in promoting TSA expression if the pre-spliced mRNA levels are equivalent even in the absence of Aire. Clearly, the analysis of Aire’s binding partners has provided many new insights into its function, but it is clear that such association methods produce a complex picture of the mechanistic reality.

In addition to this recent surplus of data regarding Aire’s binding partners, there is also growing evidence that Aire may regulates transcription of individual genes in a stochastic manner, turning on certain genes in some mTECs and other genes in others. It
is believed that only mature, postmitotic mTECs make *Aire* (61), and these mature mTECs collectively express by far the greatest number of TSAs of the thymic cell populations (39). However, there is substantial mouse-to-mouse variability in transcription of Aire-regulated genes in the thymus between mice of the same background, and even significant variability between the two thymic lobes of individual animals (62). Furthermore, single-cell sorting of *Aire*-expressing mTECs has shown similar variability between individual cells, suggesting that each mature mTEC may only produce a small number of these TSAs (63, 64). Within an Aire-regulated locus like the casein gene cluster, for example, one mTEC will express one casein gene and not others, while another mTEC will express different casein genes or none at all. Single-cell sorting also reveals that the TSAs expressed in each mTEC do not appear to follow any tissue-specific regulatory pattern—a cell that expresses some lactation genes like the caseins will simultaneously express genes from other tissues, like insulin. This stochastic mechanism even applies at the individual gene level; whereas autosomal genes in differentiated tissues are normally expressed biallelically, in single mTECs there is often expression of only one allele (64). Together, these data suggest that while Aire acts to globally stimulate transcription of a wide range of genes in mTECs, in any one cell it appears to activate only a small and random subset of these genes.

Finally, some additional insight has been gained into Aire’s function through the study of a novel autosomal dominant inheritance pattern of *AIRE* mutations in an Italian kindred. This disease manifested a unique phenotype including predominant thyroiditis
as well as some of the conventional hallmarks of APS-1, but all affected family members were reported to be heterozygotes with one functional \textit{AIRE} allele (65), and one allele carrying a missense mutation causing substitution of a tryptophan for a glycine at amino acid 228, within the putative DNA-binding SAND domain. Consequently, we recently knocked this G228W mutation into the \textit{Aire} locus to generate a mouse model of this APS-1-like disease (50). As in humans, G228W heterozygous mice developed spontaneous autoimmunity targeting a diverse range of organs including the lacrimal and salivary glands, as well as background-dependent infiltration of the retina, exocrine pancreas, thyroid gland, and sciatic nerve (Figure 1.3).

In addition to confirming the unique genetics of this mutation, two interesting observations have arisen out of the generation of this mouse. First, this study suggests a link between Aire's subnuclear localization and its function, because the introduction of the G228W allele causes Aire, which is normally distributed in nuclear dots, to form large, ubiquitin-containing aggregates within the nucleus that resemble nuclear inclusion bodies. Second, this G228W system provides unique insight into the levels of thymic TSA expression that are required to maintain self-tolerance. For each \textit{Aire}-regulated TSA gene examined, the presence of the heterozygous G228W mutation reduced but did not abolish expression of that gene in mTECs, whereas complete \textit{Aire}-knockout mice showed undetectable or nearly undetectable expression. For example the retinal antigen IRBP, which is both necessary and sufficient to prevent autoimmunity against the target organ, was still expressed in mTECs of the G228W mouse but at lower levels. In the
complete absence of thymic IRBP, all examined strains develop uveitis, but in the 
G228W mouse, this lower level of IRBP expression led to uveitis only certain, 
autoimmune-prone backgrounds like the NOD mouse (50). This finding suggests that 
not only do the presence of absence of thymic TSAs matter, but the levels of expression 
may be critically important as well. Such results are also indirectly supported in certain 
human autoimmunity, where it has been found that type I diabetes is associated with 
decreased levels of intrathymic insulin expression (66, 67).

Recent evidence has thus provided many clues to understand Aire’s function at 
the molecular level, from description of its binding partners to the molecular biology of 
target gene transcription. However we remain far from understanding the fundamental 
nature of Aire’s function, from decoding the Aire regulation of specific genes, or 
ultimately from being able to understand or predict which genes are Aire-regulated. 
Furthermore, in addition to its role in regulating TSA expression, there is also evidence 
that Aire may play other roles in mTECs including affecting development and 
facilitating antigen presentation of or negative selection against non Aire-regulated 
antigens (55, 68, 69). Much work therefore remains in order to resolve the basic 
molecular biology of Aire function, and to understand how a single protein exerts such 
broad-ranging but pleiotropic transcriptional effects. In contrast, much more is now 
known about the cellular mechanisms of disease.

**Cellular mechanisms of disease in Aire-deficient mice**
While early studies of *Aire*-knockout mice implicated TSA expression in the thymic stroma as playing a causative role in disease pathogenesis, the cellular mechanisms of the resulting disease were not immediately clear. One question that arose was whether the disease resulted from a failure to delete autoreactive effector T cells that destroyed self-tissue, or a failure to produce autoreactive regulatory T cells that protected self-tissue. Indeed, the thymic development of regulatory T cells is indispensable in maintaining self-tolerance (28), and the expression of a self-antigen within the thymus does lead to the development of regulatory T cells specific for that antigen (70, 71).

*Aire*-deficient mice, however, appear to have no gross defects in regulatory T cells, as the number and percent of FoxP3+ Tregs are unchanged in *Aire*-knockout animals from multiple strains (18, 19). Further, the ability of Tregs to suppress proliferation of effector T cells in a dose-dependent manner, a classic hallmark of Treg function, is equivalent in *Aire*-wildtype and *Aire*-knockout mice, as is the ability to rescue immunodeficient recipients from Treg-depleted adoptive transfer mediated autoimmunity (19, 68). Because the tolerance mediated by regulatory T cells is a dominant form of tolerance which can be transferred, experiments have also been done to combine equal numbers of *Aire*-wildtype and *Aire*-knockout thymi or splenocytes and determine whether the presence of *Aire*-wildtype Tregs can therefore complement the tolerance defect observed in *Aire*-knockout animals. In all such cases, the presence of *Aire*-wildtype thymic stroma or *Aire*-wildtype splenocytes does not prevent the autoimmunity caused by the *Aire*-knockout counterpart, suggesting that the
autoimmunity in the Aire-knockout could not be rescued by replacing the regulatory T cell compartment (68). Finally, crossing the Aire knockout onto the Scurfy knockout strain, which lacks FoxP3 and therefore functional regulatory T cells, accelerates disease over either individual knockout alone (72), suggesting that the defects are complementary and not redundant. Thus, while an altered regulatory T-cell repertoire may still play some role in the pathogenesis of autoimmunity in Aire-knockout mice, it appears secondary to a defect in negative selection of autoreactive effector T cells.

The effector cells themselves that mediate disease in Aire-knockout mice have also been characterized. Since the initial description of the Aire-knockout mouse it has been known that the transfer of bulk lymphocytes from an Aire-deficient mouse into an immunodeficient recipient causes autoimmunity in the recipient, and therefore that lymphocytes themselves are sufficient to mediate disease (18). Histological examination of affected organs in Aire-knockout mice also shows a clear lymphocytic infiltrate, with a preponderance of CD4+ T cells but also some CD8+ T cells and B cells (73, 74), with the relative ratios depending on the tissue targeted and the severity of the lesion. Further, the pathogenesis of disease has been shown to require T cells, as Aire-knockout mice that lack T cells do not develop autoimmunity (74). Among T cell subsets, CD4+ T cells appear to play the most important role, as depletion of CD4+ T cells, but not CD8+ T cells, before transfer of Aire-deficient bulk lymphocytes, prevents autoimmunity. The CD4+ T cells isolated from the infiltrated tissues of Aire-knockout mice show a distinct skewing toward a Th1-like phenotype, and produce high levels of INF-γ and TNF-α but
low levels of Th2 or Th17 cytokines like IL-4, IL-10, and IL-17 (74). In support of the relevance of Th1-skewing in the pathogenesis of Aire-deficiency, Aire-knockout mice lacking the Stat4 gene, which is necessary for Th1-like polarization, exhibit significantly reduced autoimmunity, while those lacking the Stat6 gene, which is necessary for Th2-like polarization, exhibit in some cases worse disease.

The role of CD4+ T cells in the pathogenesis of autoimmunity in Aire-knockout mice is further supported by the fact that treatment with a depleting anti-CD4 antibody dramatically reduces the tissue infiltration and organ destruction across a range of organs from the eye to the liver, lung, pancreas and salivary glands (74). As in other models of autoimmune disease (75), treatment with a depleting anti-CD4 antibody appears to largely prevent the severe manifestations of disease in Aire-knockout mice, and may be of future therapeutic interest in the treatment of APS-1. The role of B cells in the model is currently less clear (74, 76). Sera transfers are unable to promote autoimmunity, suggesting a limited role for autoantibodies. However, B-cell depletion with Rituximab appears to ameliorate disease in the mouse model (76). Taken together, these results suggest that B cells may serve as a contributor through their APC function, but more detailed study is needed.

Defining the antigen-specific response in Aire-knockout mice: identification of disease-relevant autoantigens
While the role of B cells and antibodies in the pathogenesis of disease in the *Aire*-knockout mouse appears to be limited, these autoantibodies can be used as tools to identify disease-relevant autoantigens. One such example from the *Aire*-knockout mouse is the identification of the retinal antigen interphotoreceptor retinoid-binding protein (IRBP), whose *Aire*-dependent thymic expression is both necessary and sufficient to prevent retinal autoimmunity in mice (73). Using serum from *Aire*-deficient mice as a tool, the investigators found a ~150kD protein that was the target of consistent antibody reactivity in *Aire*-knockout mice, and identified this protein as IRBP. To test whether IRBP expression in the thymus was required to prevent uveitis, thymic tissue from IRBP-knockout mice (which still retain functional *Aire*) was then transplanted into athymic recipient mice, and surprisingly it was found that these mice did in fact develop retinal autoimmunity. Thus, IRBP presents both a promising model antigen to study central tolerance and a potentially exciting therapeutic target for antigen-specific therapy of autoimmune uveitis.

Additional organ-specific antigens have also been identified in *Aire*-knockout mice using similar techniques. A stomach antigen, Mucin 6, was shown to be the target of autoantibodies in *Aire*-knockout serum and to be *Aire*-regulated in the thymic stroma (77). Other organ-specific autoantigens identified include an exocrine pancreatic protein, protein disulfide isomerase, PDIp (78), and as well as a salivary antigen, α-fodrin (19), though these last two are not *Aire*-regulated in the thymus, and their causative role in the pathogenesis of organ-specific autoimmunity is therefore less clear. It is perhaps
surprising, given the vast array of self-antigens regulated by *Aire* in the thymus, that only a restricted number of organs are targeted in *Aire*-knockout mice and in APS-1 patients, and within those organs only specific antigens are recognized. The reason for this telescoping, oligoclonal immune response to self is not entirely clear, but may reflect the limited autoreactive T-cell repertoire in the model.

Finally it is important to note that there may be some differences in autoantibody reactivity profiles between APS-1 patients and *Aire*-knockout mouse strains (22). Indeed, some of the proteins recognized by APS-1 patient serum may be different than those targeted in *Aire*-knockout mice; this would, in fact, not be surprising given the significant divergence in MHC molecules observed between the two species. However some overlap clearly exists, as evidenced by the recent identification of the NALP5 protein as an important parathyroid antigen in APS-1, and the parallel reactivity to NALP5 seen in *Aire*-knockout mouse serum (79, and T. Shum, M. Cheng, O. Kampe, M. Anderson, unpublished results).

**The mechanism of *Aire* deficiency: important questions remain**

Studies to date have thus firmly established the relevance of *Aire*-mediated thymic TSA expression in the maintenance of immunologic tolerance, and have begun to shed light on the mechanisms by which Aire may accomplish this. Naturally, however, this model remains incomplete, and numerous questions remain. For example, although thymic expression of many disease-relevant TSA genes like insulin are clearly *Aire*-dependent
Aire-deficient mice fail to develop autoimmunity against the target organs of many of these antigens (e.g. insulitis or diabetes; (17-19)), suggesting that perhaps peripheral mechanisms are acting to prevent disease despite the absence of thymic negative selection. Conversely, while an incredible diversity of TSAs are expressed in the thymus, many are entirely absent, and yet mice generally do not develop autoimmune disease against such antigens. Finally, while many antigens identified in Aire-knockout mice are in fact regulated in the thymus, these mice also develop autoreactivity to non-Aire-dependent antigens (19), though epitope spreading may account for some such reactivity. Numerous overlapping systems exist which could help explain why such autoimmunity fails to develop, but one intriguing possibility is that perhaps lymphocyte self-education continues even after thymic egress. To this end it is tantalizing to note that there is a growing body of evidence for expression of both Aire and TSA transcripts outside the thymus.

4. Extrathymic Aire and TSA expression

In addition to its established role in thymic tolerance, there is recent evidence that Aire and tissue-specific antigens may also be expressed outside the thymus in the secondary lymphoid organs. Indeed the original report identifying the AIRE gene showed Northern blot data detecting AIRE transcript in both the thymus and lymph nodes (10). Subsequent attempts to characterize the distribution of Aire expression in mouse and human tissues by PT-PCR analysis found detectable levels of transcript in the thymus,
spleen and lymph nodes (as well as the gonads (18, 25)). However the identification and characterization of specific populations of genuine Aire-expressing cells outside the thymus has remained difficult. A number of studies have described Aire transcript expression in dendritic cells in both the thymus and the secondary lymphoid organs (25, 80), and another recent study described a cell-intrinsic effect of Aire on dendritic cell production of the tumor necrosis family member BAFF (81). Conversely, Aire transcript has also been described as enriched among CD45- non-hematopoietic stromal fractions in the secondary lymphoid organs (82), while still other reports have described expression among lymphocytes (48, 83) and even in non-lymphoid populations such as the hepatocytes and Purkinje cells of the cerebellum (17). Furthermore, it remains controversial whether such reports of Aire transcript outside the thymus correlate with the presence of functional protein, and one recent report suggested specifically that Aire protein was only observed in the thymus, and was not made in the secondary lymphoid organs (84). Thus the presence, identity, and function of extrathymic Aire-expressing cells remains an area of significant uncertainty.

Recent evidence has also begun to suggest that the secondary lymphoid organs may be sites of promiscuous TSA expression. These studies have generally shown that a particular tissue-specific antigen gene is expressed or can drive transgene expression in the secondary lymphoid organs, and that such self-antigen expression leads to deletion of naïve T cells specific for that antigen. One such report employed a transgenic system in which ovalbumin (OVA) was expressed under the control of the intestinal fatty-acid
binding protein (iFABP) promoter (82). Upon adoptive transfer of CFSE-labeled OVA-specific OT-I CD8+ T cells, they observed proliferation of OT-I cells not only in mesenteric lymph nodes draining known (intestinal) sites of iFABP expression, but also in distant peripheral lymph nodes, and found that this early proliferation ultimately led to deletion of adoptively transferred OT-I cells. Using β2M-deficient bone marrow to reconstitute transgenic adoptive transfer recipients, the authors argued that radioresistant cells were sufficient to induce this OT-I proliferation and deletion in peripheral lymph nodes. This CD45-negative population was also shown to have detectable levels of both Aire and other TSA transcripts.

A subsequent report (85) employing a TCR-transgenic mouse designated “FH,” reactive to the melanocyte antigen tyrosinase in the context of a humanized class I MHC, discovered that albino FH mice (which lack tyrosinase) had increased tetramer-positive T cells relative to wildtype FH mice. Surprisingly, however, reciprocal thymic transplant experiments revealed that such T cells were not undergoing thymic negative selection, and that tyrosinase expression in the secondary lymphoid organs mediated this apparent deletion. Indeed adoptive transfer of FH cells showed antigen-specific CFSE dilution in all secondary lymphoid organs at three days post-transfer, and antigen-specific deletion of FH cells by two weeks. B2M −/− bone-marrow chimeras further suggested that this deletion was mediated by a radioresistant population of cells. Other studies have described expression of both Aire and Insulin2 (Ins2) transcripts in the lymph nodes (86), and one recent report (87) described detection of Ins2 and a number of other islet specific
TSA transcripts in the pancreatic lymph nodes, finding that the expression of these TSAs correlated chronologically with diabetes progression in NOD mice.

There is also some limited evidence suggesting that TSA expression may occur in subpopulations of hematopoietic cells. Zheng et al. (88), using TRAMP mice in which the promoter of mouse Probasin (mPb), a prostate-specific antigen, drives expression of SV40 T-antigen (SV40Tag), found that in addition to thymic expression of SV40Tag, which induced negative selection of cognate TG-B CD8+ T cells, they observed mice reconstituted with TRAMP+ bone marrow caused activation-induced cell death of TG-B T cells. Similarly, Garcia et al. (89) identified a population of dendritic cells in the thymus, spleen, and peripheral blood which they suggest both display proinsulin peptides on their surface and endogenously express the insulin gene. Collectively, these studies suggest that some expression of both Aire and certain tissue-specific antigens may be occurring in the secondary lymphoid organs. However the very presence and certainly the identity of Aire–expressing cells outside the thymus, and their relationship to tissue-specific antigen expression, have remained largely unclear, as has the role of Aire and the contribution of such populations to the maintenance of self-tolerance.

The following chapters directly examine the nature and function of extrathymic Aire-expressing cells (eTACs). Chapter two describes the identification of this population containing both Aire transcript and protein, and examines the nature of Aire-regulated TSA expression in these cells. It then describes the ability of eTACs to interact directly with autoreactive CD8+ T cells, and the outcome of such interactions. Chapter three
examines the ability of self-antigen expression in eTACs to directly prevent autoimmune disease. In the process it identifies direct interaction between eTACs and CD4+ T cells, and begins to define the mechanism by which these cells induce tolerance in both CD4+ and CD8+ T cell populations. Finally, chapter four describes preliminary results developing a mouse model to selectively deplete mTECs and eTACs and better define their contribution to the physiologic maintenance of self-tolerance. Together these results will aim to define the population of extrathymic *Aire*-expressing cells, and suggest a role that this population may play in the maintenance of immunologic self-tolerance.

**References**


Chapter II
Identification and Characterization of Extrathymic *Aire*-Expressing Cells
Introduction

Mechanisms of central tolerance are mediated in part through the expression of a wide array of otherwise tissue-specific self-antigens (TSAs) in specialized medullary thymic epithelial cells (mTECs; (1-3)). The thymic expression of many of these TSAs is dependent on the Autoimmune Regulator (Aire) gene (4, 5), and mutations in Aire lead to severe, multi-organ, tissue-specific autoimmunity in both mice (4, 6) and humans (7, 8). Although these results reveal a role for thymic Aire, self-tolerance must continue to be enforced after T cells leave the thymus. Consistent with this, Aire expression is also detectable outside the thymus, notably in the secondary lymphoid tissues (4, 9), although the identity and function of such extrathymic Aire-expressing cells remains unclear (10, 11). Here we identify a population of extrathymic Aire-expressing cells and examine a potential role for Aire in maintaining peripheral tolerance.

Results

To accurately label Aire-expressing cells in vivo, we employed a bacterial artificial chromosome (BAC)-transgenic approach (12) using the murine Aire locus modified to drive expression of green fluorescent protein (Gfp) fused to an autoimmune diabetes-related self-antigen gene, islet-specific glucose-6-phosphatase related protein (Igrp, Figure 2.1A). IGRP is a pancreatic β-cell specific protein against which autoreactive CD8+ T cells are produced in both mouse and human autoimmune diabetes (13-16). We
Figure 2.1. The Adig transgene recapitulates Aire expression in the thymus and mediates negative selection of autoreactive T cells. (a) Schematic of Igrp-gfp transgene targeting into the Aire BAC. Targeting replaces Aire exon 2, the coding portion of exon 1 and part of exon 3, such that the transgene does not make functional Aire (b) Immunofluorescent staining of GFP (green) and Aire (red) in thymic frozen sections of Adig mice. (c) Flow cytometry of CD45-, DAPI-, Ly51lo-gated thymic stromal cells from wildtype (left) and Adig (right) NOD mice. (d) Flow cytometry of CD45-, DAPI-, Ly51lo, EpCAM+ mTECs from Adig NOD mice gated as GFP- (yellow) or GFP+ (green) and stained for MHC II (left) and CD80 (right). (e) Thymocytes from 8.3 TCR-transgenic mice (top panels) or double-transgenic 8.3/Adig mice (bottom panels) stained for CD4/CD8 (left panels), or pre-gated as CD4- CD8+ and stained for IGRP-mimotope (red) or mock (green) peptide/K\({d}\) tetramer reactivity (right panels). (f) Diabetes incidence curves for 8.3 TCR-transgenic mice (N=6) and 8.3/Adig double-transgenic mice (N=10).
Figure 2.1

a) Diagram showing the genetic constructs involving Aire Ex1, Aire Ex2, Aire Ex3, b-globin splice SV40 pA, and Egrp splice neo. Genes are represented on a linear scale with pBACe3.6 RPCI23-461e7 as the reference point.

b) Images showing fluorescent staining with GFP and AIRE expression.

c) Images showing GFP expression in WT and Adig tissues with EpCAM and GFP expression levels indicated.

d) Flow cytometry profiles showing MHC II and CD80 expression in GFP- mTEC and GFP+ mTEC for mock, IGRP, and tetramer.

e) Images from thymus and CD8+ cells showing CD4 and tetramer expression in 8.3 and 8.3/Adig samples.

f) Graph showing percent non-diabetic over age (weeks) for 8.3 and 8.3/Adig.
elected to include \textit{Igrp} in our transgenic construct because it is not detectable in the thymus (Figure S2.1A) and because an IGRP-specific T-cell-receptor transgenic line \((8.3; (13))\) can be used to monitor interactions of \textit{Igrp-Gfp}-expressing cells. To verify the fidelity of the BAC transgene in recapitulating endogenous \textit{Aire} expression in the resultant \textit{Adig (Aire-Driven Igrp-Gfp)} transgenic mice, thymic sections were co-stained for \textit{Aire} and GFP, revealing thymic GFP expression highly restricted to \textit{Aire}-expressing cells in the medulla (Figure 2.1B, Figure S2.1B). By flow cytometry GFP+ cells were detectable specifically within the mTEC compartment (Figure 2.1C), with approximately 30-40\% of mTECs being GFP-positive. GFP+ mTECs expressed uniformly high levels of class II MHC and CD80 (Figure 2.1D), similar to previous studies of \textit{Aire}-expressing mTECs (3, 11, 17).

To test how the introduction of IGRP into the thymic medullary epithelium might affect T-cell selection, we compared \(8.3\) TCR-transgenic and \(8.3/Adig\) double-transgenic mice. Tetramer staining confirmed that the \(8.3/Adig\) double-transgenic mice showed a significant decrease in the percent and avidity of IGRP-specific CD8+ T cells in the thymus (Figure 2.1E) and in the periphery (Figure S2.1C). Further, while IGRP-reactive CD8+ T cells were readily detected in the polyclonal wildtype NOD background, they were completely absent in \textit{Adig} NOD mice (Figure S2.1D). To test the functional impact of this negative selection, \(8.3\) and \(8.3/Adig\) mice were followed for diabetes incidence, and \(8.3/Adig\) mice were completely protected from disease (Figure 2.1F).
Figure S2.1. The Aire-driven Igrp-Gfp transgene introduces a novel antigen into the thymus which faithfully reflects thymic Aire expression and causes deletion of cognate T cells. (a) Real-time PCR analysis of Aire, Igrp, and Ins1 transcripts in the thymus and pancreas. (b) Immunofluorescent per-cell quantitation of coexpression of Aire and GFP in mTECs from four independent founder lines (solid, empty, gray, striped), showing the percent of double-positive (Aire+/GFP+, DP) and single-positive (Aire+/GFP-, AireSP or Aire-/GFP+, GFPSP) cells among Aire+ or GFP+ cells of the thymus. (c) CD4/CD8 (top panels) and IGRP peptide/mock tetramer staining of pancreatic lymph nodes from nondiabetic wildtype (left), 8.3 (middle), and 8.3/Adig (right) NOD mice gated on forward/side scatter (top panels) and CD4- CD8+ status (bottom panels). (d) CD8 and IGRP/Kd tetramer staining of thymus (top panels) and pancreatic lymph node (bottom panels) from nondiabetic wildtype (left and right panels) and Adig NOD mice (middle panel) gated on forward/side scatter and CD4- CD8+ status.
Figure S2.1

(a) Relative expression of Aire, Igrp, and Insulin in Pancreas and Thymic Stromal cells.

(b) Percentage of cells with different marker combinations.

(c) Flow cytometry plots showing CD4 and CD8 T-cell populations in WT, 8.3, and 8.3/Adig conditions.

(d) Tetramer staining of Thymus and Panc. LN for WT, Adig, and WT Mock conditions.
In a broad tissue survey using immunofluorescent anti-GFP staining, expression of the transgene was undetectable in most tissues, but distinct populations of extrathymic transgene-expressing cells were observed within the lymph nodes and spleen (Figure S2.2A). These extra-Thymic Aire-expressing Cells (eTACs) were generally confined to the T-cell zones of the secondary lymphoid organs and preferentially localized to T cell-B cell boundary regions (Figure 2.2A, B). Immunofluorescent costains showed these cells to be negative for B cell (B220), fibroblastic reticular cell (gp38, ERTR-7), and dendritic cell (CD11c) markers, but positive for class II MHC (Figure 2.2A, B). Reciprocal bone-marrow chimeras demonstrated that many of these cells were radioresistant (Figure S2.3A). Given this, we isolated secondary lymphoid stroma for flow cytometry and found that, as in the thymus, a unique population of GFP+ cells was present that was CD45-, MHC II+ (Figure 2.2C). These CD45-low eTACs shared some characteristics with mTECs (e.g. MHC II+, PDL1+, EpCAM+), but were distinct in that eTACs did not express the costimulatory molecules CD80 and CD86 (Figure 2.2D). While GFP+ eTACs represented a significant percentage of the EpCAM+ cells in the periphery (8.5% ± 2.4%), eTACs failed to bind the mTEC marker UEA-I or the FRC marker gp38, suggesting they are distinct from previously described self-antigen-expressing stromal populations (9, Figure S2.4). eTACs also appeared to be ubiquitous in lymphoid organs, as they were detected in mesenteric lymph nodes, Peyer's patches (Figure S2.2B) and in the tertiary lymphoid structures that form in the infiltrated pancreatic islets of NOD mice (Figure S2.2C). By flow cytometry GFP+ cells were also detected in the
Figure 2.2. *Aire*-expressing cells exist in the secondary lymphoid organs. (a and b) Representative immunofluorescent costains of lymph node (a) and spleen (b) sections co-stained for GFP (green, all sections) and B220 (a-d), gp38 (c), ERTR-7 (f), CD11c (g), or MHC II (h; all red). Images a, b, and d-h are from *Adig* NOD mice, images c are from wildtype NOD mice. (c) Flow cytometric analysis and gating from *Adig* and wildtype NOD thymus, spleen, and lymph node stroma analyzed for CD45, DAPI, MHC II, and GFP. (d) Flow cytometric analysis of *Adig* NOD thymus (T), spleen (S), and lymph nodes (L), showing expression of indicated markers (red) or isotype staining (blue) in mTECs and eTACs respectively, defined as CD45-, DAPI-, MHC II+, GFP+. (e) Real-time PCR analysis of *Aire* expression relative to endogenous control in cell-sorted mTECs/eTACs (CD45-, PI-, MHC II+, CD11c-, EpCAM+) and DCs (CD45+, PI-, MHC II+, CD11c+, EpCAM-) of nontransgenic NOD thymus, spleen, and lymph node. (f) Immunofluorescent GFP (green)/Aire (red) costains of lymph nodes from *Adig* NOD mice.
Figure 2.2

a

Lymph Node

b

Spleen

c

Relative AIRE Expression

d

Thymus Spleen LN

e

CD80 CD86 PD-LI ICOS-L EpCAM

f

Thymic DCs Splenic DCs LN eTAC Thymic mTEC Thymic DCs Splenic eTAC Splenic DCs LN DCs
Figure S2.2. Extrathymic Aire BAC-driven Igrp-gfp is expressed selectively in lymphoid structures. (a) Immunofluorescent tissue survey of indicated Adig NOD mouse organs stained with anti-GFP (left panel, green) and DAPI (right panel, blue). (b) Immunofluorescent staining of Peyer’s patch from Adig (left) and wildtype NOD mice (right) with anti-B220 (red) and anti-GFP (green). (c) Immunofluorescent staining of lymphocyte-infiltrated islet with anti-B220 (red) and anti-GFP (green) from nondiabetic Adig (left) and wildtype (right) NOD mice.
Figure S2.2

(a) GFP and DAPI images of various organs:
- Liver
- Retina
- Thymus
- Heart
- Salivary gland
- Spleen
- Cerebellum
- Lung
- Lymph node

(b) B220/GFP images of Peyer’s Patch:
- Adig
- WT

(c) B220/GFP images of infiltrated islet:
- Adig
- WT
Figure S2.3. Transgenic *Igrp-gfp* is expressed by both hematopoietic and radioresistant populations in the secondary lymphoid organs. (a) Immunofluorescent staining for B220 (red) and GFP (green) of bone-marrow chimeric lymph nodes from *Adig* mice reconstituted with wildtype bone marrow (WT→TG) or wildtype mice reconstituted with *Adig* bone marrow (TG→WT). (b) Flow cytometry of secondary lymphoid organs; representative pooled lymph node samples from a nontransgenic (upper panels) and an *Adig* NOD mouse (lower panels) are shown, with the common gating strategy shown for both in the top-most two panels. (c) Flow cytometric histogram showing distribution of CD11c expression among GFP+ cells in the stromal (blue; CD45-, DAPI-, MHC II+, GFP+) and hematopoietic (red; CD45+, DAPI-, MHC II+, GFP+) compartments of *Adig* NOD mice. (d) GFP fluorescence in hematopoietic GFP+ cells (red; CD45+, DAPI-, MHC II+, GFP+) relative to stromal GFP+ cells (blue; CD45-, DAPI-, MHC II+, GFP+), by flow cytometry. Representative of four independent experiments.
Figure S2.3

(a) Images showing the transition from WT to TG and TG to WT.

(b) Flow cytometry plots showing the distribution of cells based on CD45 expression.

(c) Histograms illustrating the relative GFP intensity for CD45- and CD45+ populations.

(d) Graphs comparing the relative fluorescence intensity for CD45- and CD45+ populations.
Figure S2.4. eTACs do not express markers characteristic of other lymphoid stroma. (a) Flow cytometry of thymus (T), spleen (S), and lymph node (L) mTECs (thymus, red) and eTACs (spleen and lymph node, red) and DCs (blue) from Adig mice stained with UEA-I. (b) Flow cytometry of spleen (S) and lymph node (L) eTACs and fibroblastic reticular cells (defined as CD45-, gp38+) from wildtype and Adig mice analyzed for expression of GFP (top) and gp38 (bottom).
Figure S2.4

(a) UEA-I staining of T, S, and L compartments.

(b) Flow cytometry plots showing CD45 and gp38 expression.

Legend:
- mTECs (thymus)/eTACs (spleen/LN)
- Dendritic Cells
- Adig eTAC
- Adig FRC
- WT FRC
- FRC gp38
- eTAC gp38
- eTAC isotype
CD45+ compartment that expressed CD11c, although the level of GFP expression in these cells was significantly lower than in the CD45- cells and less enriched for Aire message (Figure 2.2E, S2.4).

To validate that Igrp-Gfp transgene expression in eTACs reflected endogenous Aire expression, the eTAC surface markers identified in Adig mice (CD45-, MHC II+, EpCAM+) were used to sort eTACs from non-transgenic mice, and Aire transcript was indeed found to be abundant in these cells, confirming that this population expressed high levels of Aire (Figure 2.2E). Co-staining of secondary lymphoid organs for Aire and GFP also demonstrated Aire protein localized to perinuclear speckles within a subset of eTACs (Figure 2.2F). The number of GFP+ cells in which Aire protein can be detected was smaller in the periphery (24.8% ±4.6%) than in the thymus (85.0% ±4.5%), and the Aire staining much weaker—near the limit of detection—which may explain why previous attempts to identify these cells in the absence of the transgenic reporter have been difficult (11).

Because Aire has been shown to play an important role in the transcriptional regulation of self-antigens in mTECs, we sought to define its function as a transcriptional regulator in eTACs. GFP+ eTACs were sorted for microarray analysis from the spleens and pooled lymph nodes of Adig mice crossed onto the Aire+/+ or Aire−/− background. As in mTECs, the number of genes upregulated by Aire in eTACs was greater than the number downregulated (Figure 2.3A, Tables S2.1, S2.2; array data available online at the Gene Expression Omnibus, record number GSE12388). Both the
Figure 2.3. *Aire* regulates the expression of a unique set of tissue-specific antigens in eTACs. (a) Heat map and unsupervised clustering of *Aire*-regulated genes in eTACs. Pooled eTACs were sorted from lymph nodes and spleens from cohorts of 3–6-week-old *Adig Aire*+/+ and *Adig Aire*−/− NOD mice. Each of the 8 arrays represents 3–5 pooled mice. (b) Schematic diagram of the unique and common genes regulated by *Aire* in eTACs and mTECs. (c) Classification of *Aire*-regulated genes in eTACs based on tissue-specificity, as compared to mTECs and to a random gene set. (d) Real-time PCR analysis of *Aire*-regulated TSAs in eTACs, normalized to endogenous control. eTACs were sorted from pooled nontransgenic *Aire*+/+ (black bars) and *Aire*−/− (white bars) NOD spleens based on the surface marker profile CD45−, PI−, CD11c−, MHC II+, EpCAM+, and characterized for expression of glutamate receptor NMDA2C (*Grin2c*), ras-related associated with diabetes (*Rrad*), ladinin (*Lad1*), gulonolactone (L-) oxidase (*Gulo*), and desmoglein 1 alpha (*Dsg1a*) (e) Expression of antigen processing and presentation genes in eTACs relative to other lymphoid cell populations after median-centered normalization to the expression of all genes in each array. (f) Global expression profile similarity of eTACs (left) and mTECs (right) to other relevant cell types based on Pearson correlation values calculated for population-specific centroids.
Figure 2.3

(a) Heatmap showing fold change in Aire-induced genes (109) and Aire-repressed genes (61) across different tissues.

(b) Venn diagram illustrating the overlap of Aire-regulated genes in eTAC and mTEC, with expected overlap by chance and distinctiveness, p<0.02.

(c) Bar chart showing similarity index for eTAC and mTEC genes across WT and KO samples.

(e) Heatmap illustrating expression levels of genes involved in various biological processes across different cell types.

(f) Bar charts depicting similarity index for eTAC and mTEC genes across different cell types.

Legend:
- eTAC Aire-induced genes
- mTEC Aire-induced genes
- WT
- KO

Gene expression values are shown with log2 scale.
Table S2.1. Genes significantly upregulated in Aire+/+ vs. Aire +/- eTACs. Genes are labeled according to accession number, gene symbol, and gene name, and ranked in descending order by fold change. Genes are color-coded according to whether they can be categorized as tissue-specific antigens (TSAs, pink), are below the detection threshold in all tissues (yellow), are housekeeping genes expressed in more than 5 tissues (gray), or were not accessible in the expression databases employed (white).
## Table S2.1

### Aire-induced genes in eTACs

<table>
<thead>
<tr>
<th>EntrezGeneID</th>
<th>Gene Symbol</th>
<th>Gene Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>150466</td>
<td>Ppp1r4c</td>
<td>Protein phosphatase 1C (PPP1C)</td>
</tr>
<tr>
<td>192174</td>
<td>Rad51d</td>
<td>RAD51 homolog D (B. subtilis)</td>
</tr>
<tr>
<td>12515</td>
<td>Cdh1</td>
<td>Cadherin 1</td>
</tr>
<tr>
<td>32072</td>
<td>Mecoc4</td>
<td>MECOS domain-containing protein 4</td>
</tr>
<tr>
<td>73553</td>
<td>Tm7sf2</td>
<td>Transmembrane 7 superfamily member 2</td>
</tr>
<tr>
<td>76350</td>
<td>Btg3</td>
<td>BTG3</td>
</tr>
<tr>
<td>214894</td>
<td>Ekr1</td>
<td>EARLY-KINASE 1</td>
</tr>
<tr>
<td>11634</td>
<td>Aire</td>
<td>AIRE (autoimmune regulator)</td>
</tr>
<tr>
<td>17320</td>
<td>Mfn2</td>
<td>Mitofusin 2</td>
</tr>
<tr>
<td>12633</td>
<td>Cth</td>
<td>Cysteine-thiolase</td>
</tr>
<tr>
<td>20351</td>
<td>Tmem44</td>
<td>Transmembrane 44</td>
</tr>
</tbody>
</table>
| 268759        | Gna4        |GNA4 (G proteins)
| 79518         | Rgs2        |RGS2 |
| 54199         | Ccdc92      | CDCC92 |
| 53769         | Ear1        |EAR1 (tumor suppressor) |
| 21094         | Dor2        |DOR2 (CUB domain-containing protein 2) |
| 19656         | Nfr1        |NFR1 (nuclear receptor-related factor 1) |
| 13026         | Povta       |PVP10A |
| 7803          | Hsp20       |HSP20 (heat shock protein 20kDa) |
| 214854        | Lincr       |LINC0029 |
| 11634         | Aire        |AIRE (autoimmune regulator) |
| 17320         | Mfn2        |Mitofusin 2 |
| 217166        | Nr1b1       |NR1B1 |
| 217166        | Nr1b1       |NR1B1 |
| 217166        | Nr1b1       |NR1B1 |
| 670356        | St13        |ST13 |
| 56424         | Stub1       |STUB1 |
| 214854        | Lincr       |LINC0029 |
| 11634         | Aire        |AIRE (autoimmune regulator) |
| 17320         | Mfn2        |Mitofusin 2 |
| 217166        | Nr1b1       |NR1B1 |
| 217166        | Nr1b1       |NR1B1 |

- **TSA:** 1-5 tissues
- **Below threshold in all tissues**
- **Housekeeping:** >5 tissues
- **Not accessible**
Table S2.2. Genes significantly downregulated in $Aire^{+/}$ vs. $Aire^{-/-}$ eTACs. Genes are labeled according to accession number, gene symbol, and gene name, and ranked in descending order by fold change of Aire-repression.
### Table S2.2

<table>
<thead>
<tr>
<th>EntrezGeneID</th>
<th>Gene Symbol</th>
<th>Gene Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>71198</td>
<td>Otud1</td>
<td>OTU domain containing 1</td>
</tr>
<tr>
<td>32024</td>
<td>Tittf</td>
<td>tubulin tyrosine ligase-like family, member 5</td>
</tr>
<tr>
<td>17276</td>
<td>Mela</td>
<td>Melanoma antigen</td>
</tr>
<tr>
<td>81513</td>
<td>Sgpp1</td>
<td>sphingosine-1-phosphate phosphatase 1</td>
</tr>
<tr>
<td>20307</td>
<td>Ccl8</td>
<td>chemokine (C-C motif) ligand 8</td>
</tr>
<tr>
<td>12202</td>
<td>C10c</td>
<td>complement component 1, q subcomponent, C chain</td>
</tr>
<tr>
<td>74588</td>
<td>Gvtn1</td>
<td>GTPase, very large interferon inducible 1</td>
</tr>
<tr>
<td>17533</td>
<td>Mrcl1</td>
<td>mannose receptor, C type 1</td>
</tr>
<tr>
<td>230787</td>
<td>BC013712</td>
<td>cDNA sequence BC013712</td>
</tr>
<tr>
<td>58203</td>
<td>Zbp1</td>
<td>Z-DNA binding protein 1</td>
</tr>
<tr>
<td>228406</td>
<td>Gbp6</td>
<td>guanylate binding protein 6</td>
</tr>
<tr>
<td>67932</td>
<td>B27</td>
<td>interferon, alpha-inducible protein 27</td>
</tr>
<tr>
<td>110454</td>
<td>Ly6a</td>
<td>lymphocyte antigen 6 complex, locus A</td>
</tr>
<tr>
<td>16145</td>
<td>Gpp</td>
<td>interferon gamma induced GTPase</td>
</tr>
<tr>
<td>66798</td>
<td>Lap3</td>
<td>leucine aminopeptidase 3</td>
</tr>
<tr>
<td>76192</td>
<td>Abhd12</td>
<td>abhd12</td>
</tr>
<tr>
<td>24487</td>
<td>Zcch12c</td>
<td>zinc finger CCCH type containing 12C</td>
</tr>
<tr>
<td>74774</td>
<td>110015c26</td>
<td>RIKEN cDNA 110015c26 gene</td>
</tr>
<tr>
<td>99101</td>
<td>Ail851523</td>
<td>expressed sequence Ail851523</td>
</tr>
<tr>
<td>14277</td>
<td>Gp49a</td>
<td>glycoprotein 49 A</td>
</tr>
<tr>
<td>26891</td>
<td>Cops4</td>
<td>COP9 (constitutive photomorphogenic) homolog, subunit 4</td>
</tr>
<tr>
<td>12524</td>
<td>Cd86</td>
<td>CD86 antigen</td>
</tr>
<tr>
<td>20452</td>
<td>St8sid4</td>
<td>ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4</td>
</tr>
<tr>
<td>14619</td>
<td>Gli2</td>
<td>gap junction membrane channel protein beta 2</td>
</tr>
<tr>
<td>93834</td>
<td>Pdia2</td>
<td>peroxiredoxin 2</td>
</tr>
<tr>
<td>21388</td>
<td>Thy1</td>
<td>thymus cell antigen 1, theta</td>
</tr>
<tr>
<td>107568</td>
<td>Wap1</td>
<td>WW domain containing E3 ubiquitin protein ligase 1</td>
</tr>
<tr>
<td>20620</td>
<td>Pik2</td>
<td>polo-like kinase 2 (Drosophilia)</td>
</tr>
<tr>
<td>216008</td>
<td>Ub2d1</td>
<td>ubiquitin-conjugating enzyme E2D 1, UBC4</td>
</tr>
<tr>
<td>12563</td>
<td>H47</td>
<td>interferon gamma inducible protein 47</td>
</tr>
<tr>
<td>14313</td>
<td>Fcr3</td>
<td>Fc receptor, IgG, low affinity III</td>
</tr>
<tr>
<td>20363</td>
<td>Sep7</td>
<td>selenoprotein P, plasma, 1</td>
</tr>
<tr>
<td>20715</td>
<td>Sema3d</td>
<td>semaphorin 3d, (soluble)</td>
</tr>
<tr>
<td>12524</td>
<td>Ctsc</td>
<td>cathepsin C</td>
</tr>
<tr>
<td>15566</td>
<td>Htr7</td>
<td>histone H3.3</td>
</tr>
<tr>
<td>15569</td>
<td>Htr7</td>
<td>histone H3.3</td>
</tr>
<tr>
<td>15570</td>
<td>Htr7</td>
<td>histone H3.3</td>
</tr>
<tr>
<td>15571</td>
<td>Htr7</td>
<td>histone H3.3</td>
</tr>
</tbody>
</table>

**Note:** Additional genes may be present in eTACs but were not included in this table. Further research is needed to identify all repressed genes in eTACs.
total number of Aire-regulated genes in eTACs and the fold change of expression of those genes were smaller than has been observed in mTECs, perhaps reflecting the lower and potentially transient expression of Aire in the periphery. Strikingly, there was little overlap between Aire-regulated genes in eTACs and those in mTECs (Figure 2.3B), suggesting that Aire in the periphery may regulate expression of a unique set of self-antigens. Despite these differences, however, we found a significant enhancement for TSAs among the positively Aire-regulated genes in eTACs (Figure 2.3C), several of which were confirmed by quantitative RT-PCR (Figure 2.3D). The list of genes regulated by Aire in eTACs also included a number of self-antigens whose human homologs have been described as autoantigens in human autoimmune diseases, including desmoglein 1a (pemphigus foliaceus; (18)) ladinin 1 (linear IgA dermatosis, (19)), and the NMDA receptor 2C (systemic lupus erythematos, (20)). Like other professional APCs, eTACs also expressed a large number of antigen-processing and presentation genes, suggesting a likely role for T-cell interaction (Figure 2.3E). Comparison of global gene expression profiles between eTACs, mTECs, cTECs, thymic DCs and macrophages indicated that eTACs were most similar to DCs and mTECs (Figure 2.3F).

To directly test the ability of eTACs to promote tolerance by interacting with and deleting autoreactive T cells, adoptive co-transfer of CFSE-labeled congenic 8.3 and polyclonal CD8+ T cells was employed. Upon transfer into wildtype hosts, 8.3 CD8+ T cells proliferated only in the pancreatic lymph nodes, and persisted in all lymph nodes for
up to two weeks (Figure 2.4A). When transferred into Adig hosts, however, the entire population of 8.3 T cells proliferated rapidly in all secondary lymphoid organs by three days (Figure 2.4A), and had nearly disappeared by two weeks (Figure 2.4A, C). To confirm that the absence of 8.3 T cells in transgenic recipients was due to cell death and not egress, these experiments were repeated in the presence of the S1P1 inhibitor FTY 720 (21, Figure S2.5). Further, to determine whether a radioresistant eTAC population was sufficient to directly mediate this deletion, irradiated wildtype and Adig mice were reconstituted with bone marrow deficient for β2-microglobulin (β2M⁻/⁻) so that only radioresistant cells were capable of interacting with CD8+ lymphocytes. Chimerism was confirmed both by blood typing and functionally by observing that 8.3 T cells failed to proliferate in the pancreatic lymph nodes of nontransgenic β2M⁻/⁻ reconstituted mice (Figure 2.4B). In contrast, 8.3 T cells continued to proliferate in all secondary lymphoid organs of Adig β2M⁻/⁻ reconstituted mice at 3 days, and all divided 8.3 T cells had been deleted by 14 days (Figure 2.4B, C). While 8.3 cell division was less robust at day 3 in β2M⁻/⁻ chimeric Adig mice when compared to unirradiated Adig mice, antigen-specific cell death at day 14 was even more dramatic in this setting (Figure 2.4A vs. B).

To clearly delineate whether eTACs can directly interact with T cells, two-photon microscopy of explanted lymph nodes was employed. GFP+ cells were observed uniquely in all examined lymph nodes of Adig mice (Movie s1; movies can be viewed or downloaded online at www.sciencemag.org/cgi/content/full/sci;321/5890/843/DC1), in a distribution that mirrored the localization of eTACs observed by immunofluorescent
Figure 2.4. eTACs directly interact with autoreactive lymphocytes and mediate deletional tolerance. (a) Flow cytometry of CFSE-labeled and adoptively cotransferred 8.3 CD8+ T cells (Thy1.1) and polyclonal CD8+ T cells (Thy 1.2). Cells were harvested at day 3 (left) and day 14 (right) post-transfer (b) Adoptive transfer of the same donor populations as (a) into lethally irradiated wildtype (top) and Adig (bottom) recipients reconstituted with β2M−/− bone marrow. (c) Quantitation of antigen-specific deletion after adoptive transfer at day 14 in (a) and (b), showing the ratio of 8.3:polyclonal CD8+ T cells in wildtype (black) and Adig (white) NOD recipients. Representative of at least three mice each. (d-g) Two-photon imaging of 8.3 and polyclonal CD8+ T cells in axillary lymph nodes 4 hours after adoptive transfer into Adig NOD recipients. (d) 10-minute displacement analysis of all 8.3 CD8+ T cell tracks (left) and polyclonal CD8+ T cell tracks (right). (e) Representative images of interaction between 8.3 CD8+ T cells (red), polyclonal CD8+ T cells (yellow) and eTACs (green) (f) Average T cell track speed (left), percent of time in which a T cell is stopped (middle), and percent of time in which a T cell is making contact with an eTAC (right) among polyclonal (Poly) and 8.3 (8.3) CD8 T cells. ** P<0.001. (g) Histogram displaying the duration of individual T cell-eTAC interaction times per contact for polyclonal (black bars) and 8.3 (white bars) CD8+ T cells.
Figure 2.4

(a) WT vs Adig

(b) B2M-/BM

(c) 8.3 CD8+ Polyclonal CD8+

(d) T-cell velocity

(e) T-cell stopping

(f) eTAC-T cell contact

(g) Contact time per contact
Figure S2.5. The relative absence of 8.3 T cells after adoptive transfer into Adig mice is not due to egress (a) Representative flow cytometric analysis of CD4+, CD62+, CD69lo thymocytes stained with anti-S1P1 (red) or isotype (green) in wildtype (middle panel) or Adig (left and right panels) recipients treated with saline (left panel) or FTY 720 (middle and right panels) every 2 days for 14 days. (b) Representative CFSE and Thy1.1 levels of CFSE-labeled and adoptively cotransferred 8.3 CD8+ T cells (Thy1.1) and polyclonal CD8+ T cells (Thy 1.2) pre-gated on forward/side scatter and CD4- CD8+ status. Cells were harvested after 14 days in either wildtype (top panels) or Adig NOD mice (bottom panels) treated with FTY 720 during incubation. (c) Quantitation of antigen-specific deletion after adoptive transfer at day 14 in (b), showing the ratio of 8.3:Polyclonal CD8+ T cells in wildtype (black) and Adig (white) recipients; representative of at least four mice per group.
Figure S2.5

(a) Adig + Saline, WT + FTY720, Adig + FTY720

(b) Cervical LN, Inguinal LN, Pancreatic LN

WT + FTY720

<table>
<thead>
<tr>
<th>Location</th>
<th>Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cervical LN</td>
<td>1.38</td>
</tr>
<tr>
<td>Inguinal LN</td>
<td>1.34</td>
</tr>
<tr>
<td>Pancreatic LN</td>
<td>2.29</td>
</tr>
</tbody>
</table>

Adig + FTY720

<table>
<thead>
<tr>
<th>Location</th>
<th>Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cervical LN</td>
<td>0.19</td>
</tr>
<tr>
<td>Inguinal LN</td>
<td>0.32</td>
</tr>
<tr>
<td>Pancreatic LN</td>
<td>0.14</td>
</tr>
</tbody>
</table>

(c) 8.3 Polyclonal CD8 Ratio

WT  Adig

<table>
<thead>
<tr>
<th>Location</th>
<th>Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ingu LN</td>
<td></td>
</tr>
<tr>
<td>Cerv LN</td>
<td></td>
</tr>
<tr>
<td>Panc LN</td>
<td></td>
</tr>
</tbody>
</table>
staining (Movie s2, Figure 2.2A). Adoptive cotransfer of fluorophore-labeled 8.3 and polyclonal CD8+ T cells demonstrated sustained antigen-specific association between naïve 8.3 T cells and eTACs as early as four hours post-transfer (Figure 2.4D, 2.4E, Movies s3-s4). 8.3 T cells exhibited distinct reductions in speed and total displacement relative to polyclonal CD8+ T cells (Figure 2.4D, F), and 8.3 T cells spent significantly more time both stopped and in direct contact with eTACs (Figure 2.4F). Indeed, the upper limit of this interaction time is unknown, as many 8.3 T cells spent the entire 30-minute duration of the acquisition periods in continuous contact (Figure 2.4G, Movie s5). Some GFP+ cells in the lymph node appeared highly motile, but 8.3 T cells were able to maintain antigen-specific interactions despite this motility (Figure 2.4E, Movie s6). Together, these results suggested that eTACs can form early, stable, long-term contacts with naïve autoreactive T cells entering the lymph node, and that such interaction leads to rapid proliferation and deletion of these T cells.

Discussion

Here we have identified a novel population of extrathymic Aire-expressing cells (eTACs) that may play a significant and previously uncharacterized role in self-tolerance via the deletion of autoreactive T cells. Indeed eTACs share certain characteristics with mTECs, including being equipped to act as professional antigen-presenting cells and the Aire-regulated expression of unique tissue-specific antigens (TSAs). Interestingly, the set of Aire-regulated TSAs expressed in eTACs appears to have little overlap with thymic
Aire-regulated antigens, which may explain why previous efforts examining known thymic TSAs for expression in secondary lymphoid organs have been inconsistent or conflicting. The lack of overlap suggests that there may be a higher order of Aire-dependent transcriptional regulation of TSA expression, whether direct or indirect, that differs between the thymus and the periphery. Many important questions remain, including the developmental origin of eTACs, and their relationship with other possible radioresistant APC populations (9). In this regard, the precise identification of eTACs will provide the framework for further exploring these issues. Further, it will be important to determine the physiologic relevance of this cell population in a non-transgenic setting, given the modest levels of TSA expression and and Aire-dependent gene upregulation in eTACs (approximately two-fold). However, it is notable that similar analyses of Aire-expressing thymic epithelial cells (mTECs) have demonstrated that TSAs are expressed at low levels in these cells (2, 4), but even this low level of expression has proven critical for the maintenance of immune tolerance (4, 22). Indeed, our findings suggest that eTACs may represent a “safety net” within the entire immunologic periphery which functions to screen out naïve autoreactive T cell clones that escape thymic negative selection. Finally, we speculate that eTACs may play an increasingly significant role with advancing age, as the thymus involutes and the burden of maintaining self-tolerance shifts to the periphery.

Supplementary movies and movie legends can be viewed online at: www.sciencemag.org/cgi/content/full/sci;321/5890/843/DC1
Materials and Methods

Transgene Construction, BAC Recombineering, and Purification

Aire-driven Igrp-Gfp (Adig) transgenic mice were generated by standard methods using a bacterial artificial chromosome (BAC) recombineering and transgenesis strategy. Briefly, we first generated a plasmid for BAC-targeted recombineering, JDLNL, which contained 5' and 3' Aire homology arms flanking the IGRP-GFP fusion protein sequence. The green fluorescent protein and SV40 polyadenylation sequence were cloned from the vector eGFP-N3 (Clontech) through polymerase chain reaction. The 5' and 3' Aire homology arms were cloned from murine genomic DNA. To stabilize transgene expression, a β-globin splice donor and acceptor cassette were placed in the first exon of the Aire gene just upstream of the ATG translation initiation site. The Igrp-Gfp fusion/SV40 sequence was inserted immediately downstream of this β-globin splice site. All inserted fragments were produced through polymerase chain reaction and cloned into the pcDNA vector via compatible restriction ends.

This targeting construct, JDLNL, was then inserted via standard recombineering (23) into a BAC clone from the Children’s Hospital of Oakland Research Institute (CHORI) BACPAC Resource Center, clone 461e7 from the RPCI 23 Mouse BAC Library, which contained the Aire gene and approximately 90Kb of flanking sequence both upstream and downstream. The BAC identity was verified by PCR and restriction digestion, then purified and transfected via electroporation using standard techniques into the heat-inducible recombinase-competent and arabinose-inducible Cre-expressing bacterial strain EL350. The loxp site in the eBAC3.6 vector was first removed by targeted homologous recombination. Heat-induced recombination was achieved by culturing the bacteria at 42°C, rapidly cooling, then electroporating in the presence of linearized JDLNL plasmid. After selection and PCR-screening of recombinants, Cre expression was induced in positive clones by culturing in 0.1% arabinose for three hours at 30°C. Cre-recombinant clones were screened by replica-plating for acquisition of kanamycin sensitivity. Positive clones were then rescreened by Southern blot using KpnI and SpeI digests and a 600-bp probe downstream of Aire exon 3 generated by the primers 5’-TCTCGTCTCCTCAAGAGTGCC-3’ and 5’-GTCATGTTGACGGATCCA-3’.
Highly purified BAC DNA was prepared for oocyte injection by high-speed centrifugation in a CsCl gradient. Bulk DNA was extracted from 2L of overnight bacterial culture at 32°C by alkaline lysis and isopropanol/ethanol precipitation. This bulk DNA was then resuspended in TE plus 1.05g/mL CsCl with .01% Ethidium Bromide and ultracentrifuged at 65,000 rpm for 18 hours without brake. After centrifugation, BAC DNA was clearly visible as a band distinct from bacterial genomic DNA. This DNA was gently extracted via 18-gauge needle aspiration, ethanol-precipitated, and resuspended in injection buffer (10mM Tris-HCL, 0.1 mM EDTA, pH 7.5). Resuspended BAC DNA was then injected into fertilized oocytes by the UCSF Mouse Transgenic Core with the assistance of J. Dietrich and N. Killeen.

Mice and Genotyping

*Adig* transgenic NOD and C57BL/6/d2 founder mice (two founders each) were generated as described above. Founders were bred into their respective backgrounds and offspring were screened for the presence of the IGRP-GFP transgene using the genotyping primers 5’-AAGTTCATCTGCACCACC-3’ and 5’-TCCTTGAAGAAGATGGTGCG-3’. Of the initial four founders generated, the two NOD founders had slightly higher levels of transgene expression, and these two lines were propagated and used for all subsequent analysis. The *Adig* transgene was maintained in heterozygosity for all experiments. TCR-transgenic 8.3 NOD mice were acquired from J. Bluestone and Q. Tang and also maintained in heterozygosity, and were screened for the presence of the 8.3 TCR transgene by peripheral blood FACS using a clonotype-specific antibody against the Vβ8.1 chain of the TCR (BD Pharmingen). Clonotype-specific antibody staining allowed us to genotype animals which were 8.3/*Adig* double-transgenic, as these animals retained high levels of Vβ8.1 usage despite the loss of tetramer-reactivity due to thymic negative selection of IGRP-reactive clones. Mice were genotyped for *Aire* status using the primers 5’-GTCCCTGAGGACAAGTTCCA-3’ and 5’-TCTTTTGAGCCAGAGTTGCT-3’.

All mice were maintained in microisolator cages and treated in accordance with NIH and American Association of Laboratory Animal Care standards, and consistent with the animal care and use regulations of the University of California, San Francisco.
Flow Cytometry and Cell Sorting

All antibodies were purchased from BD Pharmingen, eBioscience, Invitrogen, or Southern Biotech with the exception of 2.4G2 and I-Ag7, which were purified and donated by J. Bluestone, and EpCAM, which was purified and biotinylated by K. Johannes. Stromal cells were prepared for FACS by mincing with surgical razor blades followed by mechanical disruption and enzymatic digestion in 0.125% Collagenase D (Roche) and 20ug/mL DNase I (Roche). Subsequently 10ug/ml Dispase I (Roche) was added to ensure complete digestion. Digested cells were then resuspended in PBS with 0.5% BSA and 2mM EDTA, and passed through a 70μm cell-strainer. Density-gradient centrifugation using a three-layer Percoll gradient (GE Healthcare) with specific gravities of 1.115, 1.065, and 1.0 was used to enrich for stromal cells, which reside in the light fraction. Cells isolated from the Percoll-light fraction, between the 1.065 and 1.0 layers, were then resuspended in FACS buffer and counted. Prior to antibody staining, cells were incubated with anti-Fc receptor blocking antibody clone 2.4G2 for ten minutes. Cells were then incubated with antibody cocktails for 20 minutes on ice, washed three times in PBS and re-filtered. To exclude dead cells, either 4’,6-diamidino-2-phenylindole (DAPI) or Propidium Iodide (PI) was added prior to acquisition. Immunostained cells were analyzed by flow cytometry on an LSR II (BD Biosciences), and analyzed using FloJo data analysis software (Tree Star). To sort specific cell populations we followed the same preparation and staining protocol as above, but used a MoFlo fluorescent cell sorting machine (Dako) with the assistance of S. Jiang. We sorted cells directly into cold DMEM with 50% FCS.

Lymphocytes for flow cytometry were prepared by mashing thymi, lymph nodes, or spleens, filtering these cells through a 70μm cell-strainer, lysing red blood cells by two minutes’ incubation in ACK buffer (spleen only; 0.15 M NH₄Cl, 10 mM KHCO₃, 0.1 mM Na₂EDTA), resuspending in anti-Fc receptor blocking antibody clone 2.4G2 for ten minutes, then incubating on ice with antibody cocktails for twenty minutes. For peptide/class I MHC tetramer staining, cells were incubated on ice with antibody cocktail along with either IGRP mimetope/class I MHC tetramer NRP-V7-PE (KYNKANVFL/Kd) or with irrelevant tetramer TUM-PE (KYQAVTTTL/Kd, NIAID
MHC Tetramer Core Facility) for one hour, then washed and analyzed by flow cytometry as described above.

Isolation of RNA, Microarray and Real-Time PCR

Specific subpopulations of stromal cells which had been purified by cell-sorting were stored on ice during the collection period and immediately lysed for RNA extraction upon completion of the sort. RNA was purified using the Absolutely RNA Microprep kit (Stratagene) and quantitated using a NanoDrop spectrophotometer (Thermo Fisher Scientific). For Microarray analysis, RNA was then processed by the Gladstone Institute Genomics Core. Briefly, RNA was first analyzed for quality and sample degradation using the Eukaryote Total RNA Pico Series II chip on a 2100 Bioanalyzer (Agilent). Because of small sample sizes, RNA samples were then amplified using the Ribo-SPIA process (NuGen Technologies). In vitro transcription was then performed to produce biotinylated cRNA, which was subsequently fragmented by partial hydrolysis in the presence of Mg++ and high temperature before hybridization onto GeneChip® Mouse Genome 430 2.0 arrays (Affymetrix). Array data was deposited into the Gene Expression Omnibus public database.

For real-time PCR, stromal cells were isolated from thymus, spleen, and pooled lymph nodes as described above. eTACs, mTECs, and DCs were sorted from nontransgenic Aire-wildtype and Aire-knockout mice between 3 and 6 weeks of age based on the following surface markers: eTACs and mTECs: PI-, CD45-, CD11c-, MHC II+, EpCAM+; bulk DCs: PI-, CD45+, CD11c+, MHC II+, EpCAM-. RNA was purified using the Absolutely RNA Microprep kit (Stratagene) and quantitated using a NanoDrop spectrophotometer (Thermo Fisher Scientific). After quantitation, RNA was reverse-transcribed into cDNA using oligo-dT (Invitrogen) and Sensiscript reverse transcriptase (Qiagen). Equivalent reactions without reverse transcriptase were run for each sample. To confirm the identity of the Aire-regulated genes in eTACs, we used TaqMan® Gene Expression Assays (Applied Biosystems) for gulonolactone-(L) oxidase (Gulo), ras-related associated with diabetes (Rrad), glutamate receptor, ionotropic, NMDA2C (Grin2c), ladinin (Lad1), and desmoglein 1 alpha (Dsg1a). Cyclophilin was used as an endogenous control, for which we employed the primers 5'–
CAGACGCCACTGTCGCTTT-3’ and 5’-TGTCTTTGGAACTTTGTCTGCAA-3’ and the FAM/BHQ probe 5’-CCCTTGGGCCGCCTCTCCTTT-3’. Aire expression was quantitated using the knockout-distinguishing primers 5’-CAGCCGCCTGCATAGCAT-3’ and 5’-GGCTCCTCCAGTGCTTTTCTCT-3’ and the FAM/BHQ probe 5’-GGCTTCCCAAAGATGTGGACCTAAA-3’. PCR reactions and data acquisition were performed with the 7500 Fast Real-Time PCR System (Applied Biosystems) run for 50 cycles, and data analysis was performed using Excel (Microsoft).

For real-time PCR analysis of Aire, Igrp, and insulin transcripts in the thymus and pancreas, whole pancreas and CD45-depleted thymus (Miltenyi AutoMACS-depletion) were lysed and RNA-extracted using the Absolutely RNA Microprep kit (Stratagene), then reverse-transcribed to cDNA as described above. Real-time PCR was run on thymic and pancreatic cDNA samples for Aire (primers/probe as above), Igrp (forward: 5’-GCAGTTTCCTACTACGTGTGAAACA-3’, reverse: 5’-ACGCACGATGAGCCCAATT-3’, FAM/TAMRA probe: 5’-CCCAGGAAGTCCATCTGGCCACG-3’), and insulin (forward: 5’-CTTCAGACCTTGGCGTTGGA-3’, reverse: 5’-ATGCTGGTGCAGCAGCAGCAGCATT-3’, FAM/TAMRA probe: 5’-CCCGGCAGAAGCGTGCCATT-3’).

**Microarray Data Analysis**

Expression data was processed with Robust Multichip Analysis (RMA) normalization in GeneSpring (Agilent). Genes were then filtered for expression of greater than 200 in at least 50% of the samples. Significance analysis of microarrays (SAM) was used to identify genes differentially expressed in Aire-wildtype and Aire-knockout eTACs. 109 genes were induced and 61 genes were repressed in Aire-wildtype eTACs relative to Aire-knockout eTACs (FDR<0.15). Expression values for each gene were mean-centered across all of the arrays and unsupervised hierarchical clustering was carried out with the Cluster software and displayed with Treeview software (24). The same analysis with the same parameters was performed to identify genes differentially expressed in Aire-wildtype and Aire-knockout mTECs from previously published expression profiles that were...
performed on the same array platform (GSE8563) (25). 1343 genes were induced and 499 genes were repressed in Aire-wildtype mTECs relative to Aire-knockout mTECs (FDR<0.15).

Tissue-specific self-antigens (TSAs) were defined based on previously published expression data across 34 different mouse tissues (GSE1133) (26). This expression data was processed with RMA normalization in GeneSpring. Genes with expression greater than 200 in one to five tissues were defined as TSAs. Each of the following was considered a single tissue: 1) all central nervous system tissues; 2) small and large intestine; and 3) all epidermal tissues. Tissue from embryos was excluded from the analysis. Additionally, genes in which tissue-specificity corresponded to the tissue from which the sample was taken (e.g. lymph node, thymus, spleen) were excluded from analysis.

Expression of antigen processing and presentation genes was determined for eTACs as well as mTECs, DCs, T cells, and B cells (GSE8563 and GSE6259) (3, 27). The level of expression of each gene in each sample was normalized by median centering to the expression of all genes in each array, and unsupervised hierarchical clustering was carried out on the genes with Cluster software and displayed with Treeview software (Error! Bookmark not defined.).

The expression profiles of the eTACs were used to evaluate their similarity to other immune cells, specifically mTECs, cTECs, dendritic cells, and macrophages. Based on previously published expression profiles of mTECs, cTECs, dendritic cells, and macrophages (GSE2585) (3), centroids were defined for each of these immune cells that distinguish each cell type using multi-class SAM analysis. Pearson correlations were calculated for each centroid with our eTACs expression profile as well as an independent mTECs expression profile (GSE8563, Error! Bookmark not defined.).

**Immunofluorescent Staining and Quantitation**

All primary and secondary antibodies were purchased from AbCam, BD Pharmingen, Invitrogen, or eBioscience, with the exception of anti-gp38 and anti-S1P1, which were generous gifts from J. Cyster, and the anti-Aire antibodies 5C-11 and 5H-12, which were gifts of H. Scott. Organs were harvested from experimental animals and embedded
in Tissue-Tek Optimal Cutting Temperature (OCT) media (Fisher), then frozen to -80 C for storage. 8μm frozen sections were cut using a CM3050S Cryostat (Leica) and allowed to dry for 30 minutes at room temperature. Sections were then fixed in -20 C acetone for 10 minutes and dried at room temperature for thirty minutes before storage at -80 C or immediate staining. Slides were washed three times in PBS and incubated in 10% secondary serum for thirty minutes at room temperature to block. Primary antibody cocktails diluted in 3% BSA in PBS were then added directly to blocking solution on the tissue section and incubated for one hour at room temperature. Slides were washed three times in PBS and then incubated in secondary antibody cocktail in 3% BSA in PBS for one hour. When used (for anti-Aire staining in the thymus and periphery), tertiary antibody solutions were similarly applied. Slides were mounted in Vectashild mounting medium (Vector Laboratories) and visualized on an Axioskop 2 Plus Widefield Scope (Leica) attached to a C4742-95 digital camera (Hamamatsu). Images were acquired using OpenLab software (Improvision), and analyzed, processed via linear contrast adjustment, and merged with Photoshop CS3 (Adobe).

For quantitation of Aire/GFP localization in the thymus and the periphery, frozen tissue sections from multiple independent founders were co-stained for GFP and Aire using two independent anti-Aire monoclonal antibodies (clones 5C11 and 5H12). Per-cell correlation was then analyzed by independent observers for each condition (Aire antibody, founder) in duplicate, with each count totaling greater than 100 cells. The results were pooled to generate average values.

Bone Marrow Chimeras
Reciprocal bone marrow chimeras were generated using Adig and wildtype NOD mice as recipients. All recipient mice received 1300 rads during two irradiation cycles of 900 and 400 rads each, separated by a minimum of six hours. Between irradiation cycles, marrow was harvested from β2-microglobulin knockout (β2M-/-) mice by removal and flushing of the long bones (femurs, tibia, humeri) and filtration of marrow suspension through a 70μm cell-strainer. Bone marrow cells were then depleted of T lymphocytes by incubation for 15 minutes on ice in the presence of anti-CD4 (clone GK1.5) and anti-CD8 (clone 3.155) antibodies, followed by the addition of rabbit complement in pre-
warmed RPMI and incubation for an additional hour at 37 degrees. Cells were then washed three times in PBS, counted, and resuspended in Hank’s BSS media for injection. After the second (400 rad) irradiation of recipient mice, 10e7 donor-derived bone marrow cells were introduced into each recipient via tail vein injection. Uninjected controls were included in each experiment. Mice were allowed to reconstitute for 8 weeks, confirmed for chimerism in both the lymphocyte and DC populations by blood typing of class I MHC expression on B220+, and CD11c+ cells.

**Purification, CFSE and CMTMR-labeling, and Adoptive Transfer of T cells**

For adoptive transfer of naive 8.3 and polyclonal CD8+ T cells, the spleen and all major peripheral lymph nodes except pancreatic lymph nodes were harvested from nondiabetic donors, pooled by group, ACK-lysed and purified by negative selection using an AutoMACS (Miltenyi). Cells were incubated for fifteen minutes with a cocktail of biotinylated anti-CD19, anti-Ly6G, anti-MHC II, anti-CD24, anti-CD117, and anti-CD4 (Southern Biotech), washed and incubated for fifteen minutes with anti-biotin tetrameric antibody complex (StemCell Technologies). Magnetic colloid was then added (StemCell Technologies), and cells were incubated an additional fifteen minutes before being washed, recounted, and run through a single AutoMACS depletion cycle. Cells were subsequently washed, recounted, and samples set aside for FACS confirmation of purity.

When labeling for FACS, AutoMACS-purified cells were pooled in a ~5:1 ratio of 8.3 T cells:polycolonal CD8 T cells then labeled in 2.5μM CFSE (Invitrogen) at room temperature for 5 minutes. Labeling was quenched with an equal volume of FCS, cells were washed twice in DMEM and once in Hank’s BSS, counted and injected at 5e6 cells/recipient via the tail vein. When labeling for two-photon imaging, cell populations were kept separate and labeled with either 2.5μM CFSE alone or 2.5μM CFSE and 20μM CMTMR for 30 minutes at 37 degrees, then quenched with an equal volume of FCS. Cells were washed twice in DMEM and once in Hank’s BSS, then pooled in a 1:1 ratio of 8.3 T cells:polycolonal CD8 T cells and injected via the tail vein at 5e6 total cells/recipient. Reciprocal labeling experiments were performed for both cell populations.
After transfer, animals were followed for the indicated periods and analyzed as
described. For egress-inhibition experiments, mice were treated every 48 hours with
1mg/kg FTY 720 (a gift of J. Cyster) in saline, beginning one day after adoptive transfer
and continuing for the duration of the two-week incubation period.

**Two-Photon Laser Scanning Microscopy Imaging and Analysis**

A custom resonant-scanning instrument based on published designs (28) containing a
four–photomultiplier tube (PMT) array operating at video rate was used for two-photon
microscopy. Axillary lymph nodes were immobilized on coverslips with the efferent
lymphatics facing away from the objective, and imaged through the capsule. Lymph
nodes were maintained at 36 °C in RPMI medium perfused with 95% O₂/5% CO₂.
Samples were excited with a 10-W MaiTai TiSaphire laser (SpectraPhysics) tuned to a
wavelength of 910 nm, and emission wavelengths of 455–495 nm (for second-harmonic
emission), 500–520 nm (for GFP and CFSE), 528-556 nm (for CFSE and
autofluorescence) and 567–640 nm (for CMTMR) were collected. To improve detection
of GFP+ cells, the 500-520 nm channel was collected using a high-gain PMT module
(H7422P, Hamamatsu). A custom four-dimensional acquisition module in the
VideoSavant digital video recording software (IO Industries) was used for image
acquisition. For time-lapse image acquisition, each xy plane spanned 313μm x 261μm at
a resolution of 0.653μm/pixel. 20-30 video-rate frames were averaged, giving effective
collection times of approximately 0.5-1 second per plane. Images of up to 30 xy μm planes
with 3μm Z-spacing were acquired every 30 sec for 30 min.

Data was visualized and analyzed using Imaris 5.7.2 Software (Bitplane). CMTMR +
CFSE double-labeled cells were identified by colocalization of signal in the 500-520nm
and 567-640nm channels using Imaris software. Single-channel fluorescence from
double-labeled cells and autofluorescence in the 500-520nm and 567-640nm channels
were eliminated by linear unmixing using Imaris and MATLAB (Mathworks) software.
Individual cells were identified and tracked by Imaris, and cell speed and displacement
were calculated from tracks. Cell-cell interaction and stopping of tracked cells were
manually scored. Statistical analysis of speeds, stopping times, and interaction times was

87
done using Prism 4.0 (GraphPad Software) employing an unpaired t-test with Welch’s correction and a two-tailed 95% confidence interval.

References


Chapter III
Self-Antigen Expression in eTACs Prevents Autoimmunity
Introduction

Clonal diversity within the adaptive immune system, while endowing organisms with the ability to respond to a broad range of potential pathogens, presents a substantial risk for autoimmunity. Numerous complementary mechanisms have evolved to curtail such deleterious outcomes, and to establish and maintain appropriate tolerance to self. Thymic selection is an essential component of this process, and relies in part on the display of a diverse set of self-antigens by medullary thymic epithelial cells (mTECs) (1, 2).

Much self-antigen expression in mTECs in mice and humans is dependent on the activity of the autoimmune regulator (Aire) gene. AIRE was first identified in humans by positional cloning as the defective gene in the monogenic, autosomal recessive disease Autoimmune Polyglandular Syndrome Type I (3, 4) (APS-1). Like APS-1 patients, Aire−knockout mice develop severe, pleiotropic, multi-organ autoimmunity (5, 6). Recent work has demonstrated that thymic Aire expression promotes the transcription of a host of tissue-specific antigens (TSAs) like insulin (5), inter-photoreceptor retinoid binding protein (7) (IRBP), and vomeromodulin (8) (VM), and that such thymic TSA expression is essential to the prevention of autoimmunity.

In addition to its role in the thymus, growing evidence now suggests that expression of both Aire and a diverse set of TSAs may also occur in the secondary lymphoid organs. Aire expression has been detected at the transcript level in the secondary lymphoid organs by a number of groups (5, 9−11), and more recently, radioresistant populations in these tissues have been shown to express putative TSAs.
including intestinal fatty acid binding protein (10), glucagon (12), and the melanocyte antigen tyrosinase (13). It has also been suggested that the levels of TSA expression in the pancreatic lymph nodes correlate chronologically with disease progression in non-obese diabetic (NOD) mice (12).

Recently, using a transcriptional Aire-reporter system, we identified a discrete population of extrathymic Aire-expressing cells in the secondary lymphoid organs (11). Like mTECs, eTACs are a radioresistant MHC class II+ population expressing a host of TSAs, but surprisingly the genes regulated by Aire in this population appear to be distinct from those regulated by Aire in the thymus (11). These findings, consistent with other reports showing cell type-specific effects of Aire expression (14), suggest that such extrathymic Aire-expressing cells might enforce tolerance by eliminating autoreactive T cells that evade thymic selection. Although evidence is thus accumulating that expression of both Aire and diverse TSAs occurs in the secondary lymphoid organs, the ability of self-antigen expression in these populations to directly prevent autoimmunity remains unknown. Furthermore, the high levels of MHC class II expression on eTACs suggest that, like mTECs, these cells may interact directly with CD4+ T cells, and that such interaction could have functional consequences for immune tolerance. Studies to date, however, have shown only interactions between CD8+ T cells and these radioresistant cells of the secondary lymphoid organs (10, 11, 13).

Here we describe protection from autoimmune diabetes by self-antigen expression in extrathymic Aire-expressing cells (eTACs) using two independent models. First, using
a novel transgenic system in which the \textit{Aire} promoter drives expression of a mimetope peptide recognized by the islet-specific CD4+ T cell clone BDC2.5, we show that eTACs can directly interact with CD4+ T cells, and that such self-antigen expression in eTACs leads to functional inactivation of cognate CD4+ T cells and protection from autoimmune diabetes. We demonstrate that eTAC-CD4 interactions also lead to an enrichment of FoxP3+ regulatory T cells, but that tolerance induction does not depend on such regulatory T cell populations. Rather, eTAC interaction induces a functional inactivation of CD4+ effectors that is stable when transferred serially into immunodeficient secondary hosts. Subsequently, using a system in which the \textit{Aire} promoter drives expression of the pancreatic antigen islet-specific glucose-6-phosphatase related protein (IGRP), we show that IGRP expression in eTACs leads to protection from autoimmune diabetes mediated by the IGRP-specific CD8+ T cell clone 8.3. We demonstrate that this protection can be mediated by a radioresistant cell population, and, as argued previously, that such eTAC-CD8+ interactions induce tolerance through deletion of CD8+ effectors. Together these results identify self-antigen expression in eTACs as a robust potential mechanism for the physiologic and therapeutic prevention of autoimmunity.

\textbf{Results}

Transgenic \textit{Aire}-driven BDC peptide is expressed in mTECs and eTACs
Growing evidence now suggests that both *Aire* and TSA expression are hallmarks of radioresistant populations in the secondary lymphoid organs (9-13). Given the high levels of MHC class II expression on eTACs (11), and prevalence and significance of CD4+ T cells among peripheral lymphocytes, we hypothesized that eTACs might also have the ability to interact directly with such populations, and that such interactions might promote immunologic self-tolerance. To investigate this, we used an established murine diabetes model, the BDC2.5 TCR-transgenic mouse, and a BDC2.5 mimetope antigen, the p31 peptide. BDC2.5 T cells recognize a pancreatic antigen, chromogranin A (ChrA) (15), and can adoptively transfer diabetes into secondary hosts (16, 17). Prior to the recent identification of ChrA as the cognate antigen, mimetope agonist peptides had been identified by library screening which induced activation of BDC2.5 T cells *in vitro* (17, 18), and bound BDC2.5 T cells in the context of an I-Ag7 tetramer (19).

To drive expression of one such BDC2.5 agonist peptide, 1040-31 (referred to as p31) in mTECs and eTACs, we used a bacterial artificial chromosome (BAC) transgenic construct to express the murine Invariant Chain (Ii; CD74) under transcriptional control of the *Aire* promoter, replacing the CLIP peptide sequence with the sequence coding for p31 (Fig. 3.1a). Similar strategies of CLIP peptide replacement have been used previously to target peptide antigens into APC populations (20). The bicistronic BAC construct also included a 3’ internal ribosomal entry site (IRES)- enhanced green fluorescent protein (EGFP) cassette to identify the *Aire*-expressing populations and to monitor the specificity of transgene expression. We termed this mouse *Aire*-driven BDC-
Figure 3.1. The *Adbig* transgene recapitulates *Aire* expression in mTECs and eTACs. (a) Schematic of *Aire*-driven BDC peptide Invariant Chain-GFP construct targeting the bacterial artificial chromosome (BAC) containing the murine *Aire* locus. (b) Representative flow cytometric analysis and gating from wildtype and *Adbig* NOD thymus, spleen, and lymph node stroma analyzed for CD45, DAPI, MHC II, and GFP. (c) Immunofluorescent staining of *Adbig* thymus, spleen, and lymph node with anti-GFP (green; all panels), B220 (red; spleen and lymph node left panels), cytokeratin 5 (red; thymus left panel) and anti-AIRE (red, right panels) co-staining of thymus, spleen. (d) Flow cytometric analysis of DAPI-negative, CD45-low, GFP+ populations from the thymus (T), spleen (S), and lymph node (L) of *Adig* (blue) and *Adbig* (red) mice for the indicated markers or stained with isotype control (black).
Invariant Chain GFP (Adbig). As in other Aire reporter lines (11), we detected MHC II-high, CD45-low, GFP-positive cells in both the thymus and secondary lymphoid organs of Adbig mice (Fig. 3.1b). In the thymus, GFP expression was restricted to the medulla, and expressed in cells containing Aire protein in nuclear speckles (Fig. 3.1c). In the secondary lymphoid organs, GFP expression was restricted to cells localized to the T cell-B cell boundary regions, and nuclear Aire protein was also detected within this population (Fig. 3.1c). Additionally, sorted mTECs and eTACs from Adbig mice were significantly enriched for Aire transcript (Fig. S3.1). To determine whether GFP+ cells in the primary and secondary lymphoid organs represented the same eTAC populations previously described using Aire-driven IGRP-GFP (Adig) mice (11), we compared surface marker expression of GFP+ cells from the thymus, spleen, and lymph nodes of Adig and Adbig mice. We found that mTECs and eTACs from both Aire-reporter lines showed similar expression of all surface markers examined (Fig. 3.1d). Notably, eTACs expressed high levels of the epithelial cell marker EpCAM, as well as CD40 and PD-L1, but unlike mTECs, eTACs did not express CD80 or PD-L2. Together, these results confirm that the Adbig transgene faithfully recapitulates endogenous Aire expression in mTECs and eTACs, and that eTACs represent a unique Aire-expressing population in the secondary lymphoid organs.

BDC mimotope expression in eTACs induces functional inactivation and regulatory cell generation in BDC2.5 T cells
**Figure S3.1.** GFP+ mTECs and eTACs from *Adbig* mice are significantly enriched for *Aire* transcript. Real-time PCR analysis of cDNA isolated from eTACs (DAPI-, CD45-, MHCII+, CD11c-, GFP+) and peripheral DCs (PDC; DAPI-, CD45+, MHCII+, CD11c+) from the spleen and lymph nodes and mTECs (DAPI-, CD45-, MHCII+, CD11c-, GFP+) and thymic DCs (TDC; DAPI-, CD45+, MHCII+, CD11c+) from the thymus of *Adbig* mice. Values represent *Aire* transcript normalized to actin endogenous control signal, and are set relative to mTEC *Aire* signal.
Figure S3.1

Relative Aire transcript (normalized to Actin)

- eTAC
- mTEC
- PDC
- TDC

p<.01
To test whether eTACs can present antigen directly to CD4+ T cells, we employed an adoptive cotransfer system using CFSE-labeled Thy1.1+ BDC2.5 CD4+ T cells and Thy1.2+ polyclonal CD4+ T cells. Three days post-adoptive transfer, wildtype recipients induced proliferation of BDC2.5 T cells only in the pancreatic lymph nodes, while Adbig recipients, in contrast, induced robust proliferation of BDC2.5 T cells in all secondary lymphoid organs examined (Fig. 3.2a). Surprisingly, many proliferating BDC2.5 T cells in Adbig hosts also appeared to downregulate CD90, a phenomenon not observed in BDC2.5 T cells proliferating in the pancreatic lymph nodes of wildtype hosts. While proliferating BDC2.5 T cells in Adbig recipients underwent contraction by two weeks post-transfer, significant residual populations remained which had completely diluted CFSE (Fig. 3.2a). Residual BDC2.5 T cells in Adbig mice appeared to collect most prominently in the spleen relative to Thy1.2+ polyclonal T cells, though some preferential enrichment in the pancreatic lymph nodes was also observed (Fig. 3.2b).

Previously we had described eTACs as a radioresistant population (11). To determine whether the proliferation of BDC2.5 T cells in the secondary lymphoid organs was due to direct interaction with eTACs or a result of antigen transfer to other professional APC populations, we lethally irradiated and reconstituted wildtype and Adbig NOD mice with MHC class II-deficient bone marrow prior to adoptive transfer. Reconstitution of the hematopoietic compartment was confirmed by lack of class II expression on B cells and DCs (Fig. S3.2) and by the failure of BDC2.5 T cells to proliferate in the pancreatic lymph nodes of wildtype MHC class II-deficient chimeric
Figure 3.2. eTACs directly interact with CD4+ T cells and induce functional T-cell unresponsiveness. (a) Flow cytometric analysis of CD4+ lymphocyte populations in wildtype (top) and Adbig (bottom) hosts at 3 (left) and 14 days (right) post adoptive co-transfer of CFSE-labeled Thy1.1+ BDC2.5 T cells and Thy1.2+ polyclonal T cells. (b) Quantitation of the total residual populations in (a) of Thy1.1+ BDC2.5 T cells (black) and polyclonal CD4+ T cells (white) at day 14 post-adoptive transfer. (c) Flow cytometric analysis of CD4+ lymphocyte populations in wildtype (top) and Adbig (bottom) bone-marrow chimeric hosts reconstituted with MHC II-knockout bone marrow at three (left) and fourteen days (right) post-adoptive co-transfer of CFSE-labeled Thy1.1+ BDC2.5 T cells and Thy1.2+ polyclonal T cells. (d) Flow cytometric analysis of I-Ag7-p31 tetramer avidity among residual Thy1.1+ BDC2.5 T cells at day 14 post-adoptive transfer into wildtype (blue) or Adbig (red) hosts compared with mock I-Ag7-CLIP tetramer (black) (e) FoxP3 staining of CD4+ Thy1.1+ BDC2.5 T cells 14 days after adoptive transfer into wildtype or Adbig hosts. (f) Quantitation of (e) showing percentage of Thy1.1+ CD4+ cells that are FoxP3+ (left) and total number of FoxP3+ cells (right) in wildtype (white) or Adbig (black) recipients. (g) Schematic illustration of p31/CFA immunization protocol after adoptive transfer. (h) IFN-γ production among CD4+ Thy1.1+ BDC2.5 T cells isolated from mice indicated in (g); bar graph shows quantitation of pooled data with N=4 for each group.
Figure 3.2

a) (Day 3 and Day 14)

Spleen | Ing LN | Panc LN
---|---|---
WT | Adbig | WT | Adbig

b) (Graph showing Total Cell Number)

<table>
<thead>
<tr>
<th>Adbig</th>
<th>WT</th>
<th>Adbig</th>
<th>WT</th>
<th>Adbig</th>
<th>WT</th>
<th>Adbig</th>
<th>WT</th>
</tr>
</thead>
<tbody>
<tr>
<td>SPL</td>
<td>SPL</td>
<td>ILN</td>
<td>ILN</td>
<td>PLN</td>
<td>PLN</td>
<td>SPL</td>
<td>SPL</td>
</tr>
</tbody>
</table>

Tetramer

<table>
<thead>
<tr>
<th>Tetr</th>
<th>Mock</th>
<th>WT p31</th>
<th>Adbig p31</th>
</tr>
</thead>
<tbody>
<tr>
<td>MHC II</td>
<td>WT</td>
<td>Adbig</td>
<td>Adbig</td>
</tr>
<tr>
<td>WT</td>
<td>SPL</td>
<td>Adbig</td>
<td>Adbig</td>
</tr>
<tr>
<td>PLN</td>
<td>Adbig</td>
<td>WT</td>
<td>WT</td>
</tr>
<tr>
<td>SPL</td>
<td>WT</td>
<td>Adbig</td>
<td>Adbig</td>
</tr>
</tbody>
</table>

f) (Graph showing % FoxP3+ T cells)

<table>
<thead>
<tr>
<th>Adbig</th>
<th>WT</th>
<th>Adbig</th>
<th>WT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spleen</td>
<td>Ing LN</td>
<td>Panc LN</td>
<td>Spleen</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Total # FoxP3+ T cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spleen</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Adbig</th>
<th>WT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spl</td>
<td>WT</td>
</tr>
</tbody>
</table>

h) (Graph showing Percent IFNγ+)

<table>
<thead>
<tr>
<th>Adbig</th>
<th>WT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spl</td>
<td>WT</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>WT</th>
<th>Adbig</th>
</tr>
</thead>
<tbody>
<tr>
<td>p&lt;.01</td>
<td>p&lt;.01</td>
</tr>
</tbody>
</table>

BDC2.5

Adoptive transfer

day 0

Adbig

Adbig

Adbig

Adbig

Adbig
Figure S3.2. Efficiency of reconstitution in wildtype and *Adbig* NOD mice lethally irradiated and reconstituted with MHC II-/- bone marrow. Representative flow cytometric analysis of MHC II staining among B220+ B cells (left) or CD11c+ DCs (right) from the secondary lymphoid organs of *Adbig* NOD (black), MHC II-/- NOD (blue), or MHC II-/- bone-marrow chimeric *Adbig* NOD mice (red).
Figure S3.2

B Cell

DC

97.9
2.56
0.29

97.0
1.70
0.08

MHC II

Adbig
MHC II KO NOD
MHC II BM Chimeric Adbig
recipients (Fig. 3.2c). Despite this absence of MHC class II expression on hematopoietic cells, bone-marrow chimeric Adbig recipients continued to induce robust proliferation of BDC2.5 T cells in all secondary lymphoid organs (Fig. 3.2c). As in non-chimeric recipients, a residual population of BDC2.5 T cells remained at two weeks post-transfer which had completely diluted CFSE. Thus, a radioresistant population of eTACs in the secondary lymphoid organs is able to interact directly with CD4+ T cells. However in contrast to interactions between eTACs and CD8+ T cells—which lead to proliferation followed by deletion of antigen-specific CD8+ T cells (11)—interactions between BDC mimetope-expressing eTACs and BDC2.5 CD4+ T cells lead to the persistence of residual populations of antigen-specific CD4+ T cells.

We then attempted to characterize the phenotype and function of these residual populations of BDC2.5 T cells in Adbig hosts. Despite prolonged interaction with antigen-bearing eTACs, residual BDC2.5 T cells retained significant avidity for I-Ag7-p31 tetramer (Fig. 3.2d), suggesting that the surviving T cells in this context had not lost their antigen-specificity or undergone T-cell receptor (TCR) downregulation. These residual BDC2.5 T cells, however, were significantly enriched for FoxP3+ regulatory T cells (Fig. 3.2e) despite pre-transfer CD25 depletion. This enrichment was observed in non-antigen draining lymph nodes and in the spleen (Fig. 3.2e, f), suggesting that in the absence of interaction with antigen-draining DCs in the pancreatic lymph node, eTAC interaction may favor the preferential expansion, retention, or survival of regulatory cells over effectors.
To directly test the functional ability of these residual BDC2.5 T cells to respond to antigen, \textit{Adbig} and wildtype NOD adoptive transfer recipients were immunized at day 14 post-transfer with p31 peptide in complete Freund’s adjuvant (CFA), and donor cytokine production was measured three days post-immunization (Fig. 3.2g). Whereas BDC2.5 T cells isolated from wildtype hosts retained the ability to produce interferon gamma in response to peptide challenge, BDC2.5 T cells isolated from \textit{Adbig} mice remained largely unresponsive, suggesting that this population may be rendered functionally inactive in \textit{Adbig} hosts (Fig. 3.2h). Thus, it appears that eTAC interaction induces both functional inactivation of effectors and selective enrichment for FoxP3+ regulatory T cell populations.

BDC mimetope expression in eTACs prevents autoimmune diabetes mediated by BDC2.5 T cells

To determine whether the observed interaction between BDC2.5 T cells and \textit{Adbig} eTACs had functional relevance for the progression of autoimmune disease, we tested whether cognate antigen expression in eTACs could directly impact BDC2.5-mediated autoimmune diabetes. Purified populations of naïve, CD25-depleted BDC2.5 T cells rapidly and effectively transfer diabetes into NOD severe combined immunodeficiency (SCID) recipients (Fig. 3.3a). Strikingly, \textit{Adbig} SCID recipients were completely protected from such adoptive transfer of diabetes and remained normoglycemic (Fig. 3.3a). This protection occurred despite a massive proliferation of BDC2.5 T cells in
Figure 3.3. Cognate antigen expression in eTACs prevents BDC2.5-mediated insulitis and autoimmune diabetes. (a) Blood sugar values (mg/dl) among wildtype SCID and Adbig SCID adoptive transfer recipients of CD25-depleted, CD4-enriched Thy1.1+ BDC2.5 T cells. (b) Flow cytometric analysis of peripheral blood from wildtype and Adbig SCID adoptive transfer recipients from (a) at indicated timepoints. (c) Hematoxylin and eosin-stained pancreatic islet histology of wildtype and Adbig SCID adoptive transfer recipients at day 10 post-transfer.
Figure 3.3

(a) Blood glucose levels over days post-transfer for SCID (N=6) and Adbig SCID (N=7) mice.

(b) Images of CD4+ cell counts for WT SCID and Adbig SCID mice at day 3, day 7, and day 10 post-transfer.

(c) Histological images of WT SCID and Adbig SCID mice, showing a comparison of tissue structure at 10x and 40x magnification.
Adbig SCID hosts, which could be seen to mobilize into the peripheral blood (Fig. 3.3b). In spite of the robust proliferation of BDC2.5 T cells in Adbig SCID recipients and their mobilization into the peripheral blood, the pancreatic islets of Adbig SCID mice were completely devoid of lymphocytic infiltrates or peri-insulitis (Fig. 3.3c), suggesting that proliferating BDC2.5 T cells in Adbig SCID recipients were unable to reach target organs and died or remained functionally sequestered in the blood and secondary lymphoid organs. Together, these data suggest that antigen specific eTAC-CD4 interactions lead to rapid proliferation and subsequent inactivation of adoptively transferred CD4+ T cell populations, and can result in protection from both insulitis and autoimmune diabetes.

eTAC interaction induces functional inactivation of naïve BDC2.5 T cells in a regulatory T cell-independent fashion

To determine the relative contributions of functional inactivation versus regulatory T cell induction in establishing this tolerance, and to define whether the disease protection in Adbig SCID recipients represented a stable T cell phenotype or required continuous exposure to antigen-expressing eTACs, we next employed a serial co-transfer system. Ten days after adoptive transfer of CD25-depleted Thy1.1+ BDC2.5 T cells into wildtype and Adbig SCID hosts, lymphocytes were harvested, purified, and re-transferred into new wildtype lymphopenic recipients either alone or mixed 1:1 with freshly isolated naïve, CD25-depleted BDC2.5 T cells (Fig. 3.4a). BDC2.5 lymphocytes transferred
**Figure 3.4.** eTAC-induced self-tolerance in BDC2.5 T cells is cell-intrinsic and does not require the presence of regulatory T cell populations. (a) Schematic illustration of BDC2.5 serial adoptive transfer strategy. CD25-depleted, CD4-enriched BDC2.5 T cells were transferred into wildtype SCID and *Adbig* SCID mice; at day 10, lymphocytes were re-harvested, purified, and serially transferred into wildtype SCID secondary hosts alone or in 1:1 mixture with fresh, CD25-depleted, CD4-enriched BDC2.5 T cells. (b) Diabetes incidence after adoptive transfer among serial recipient NOD SCID groups indicated in (a). (c) Blood sugar values (mg/dl) among DT-treated wildtype SCID and *Adbig* SCID hosts after adoptive transfer of CD4-enriched, DT-treated BDC2.5 FoxP3-DTR T cells. Asterisks indicate premature deaths. (d) Hematoxylin and eosin-stained pancreatic islet histology of wildtype SCID and *Adbig* SCID recipients in (c) day 20 post-transfer.
Figure 3.4

(a) Schematic representation of the experimental setup involving BDC2.5, Adbig SCID, WT SCID, A only, B only, W only, W+B only, and A+B only groups over 20 days post-transfer.

(b) Graph showing percent non-diabetic across different treatments with B Only (N=6), W Only (N=6), A Only (N=6), W+B (N=6), and A+B (N=6) groups.

(c) Graph depicting blood glucose levels over days post-transfer for WT SCID (N=4) and Adbig SCID (N=4) groups.

(d) Microscopic images of WT SCID and Adbig SCID tissues.
from wildtype SCID mice (“W only”) again induced diabetes in secondary SCID hosts, while lymphocytes from Adbig SCID mice (“A only”) failed to induce diabetes despite the absence of continued exposure to cognate antigen-loaded eTACs (Fig. 3.4b). This suggests that the observed functional inactivation of effector T cells is a stable phenotype, and does not require continuous eTAC interaction. Conversely, BDC2.5 T cells harvested from either wildtype or Adbig SCID hosts did not appear to have acquired “dominant” tolerance, as serial co-transfer of purified CD4+ lymphocytes mixed 1:1 with freshly isolated naïve BDC2.5 T cells failed to suppress or delay disease onset (Fig. 3.4b). Together, these data suggest that functional inactivation of effectors in cis, and not dominant tolerance in trans, may account for the disease protection observed in this model.

To confirm that functional inactivation of effector T cells alone is sufficient to explain eTAC-induced CD4+ T cell tolerance, we crossed BDC2.5 TCR-transgenic mice with NOD FoxP3-diphtheria toxin receptor (DTR) transgenic mice, which selectively deplete FoxP3+ cells upon exposure to diphtheria toxin (21) (Fig. S3.3). Adoptive transfer of BDC2.5+ FoxP3-DTR+ T cells into wildtype or Adbig SCID mice treated continuously with diphtheria toxin revealed that while wildtype SCID hosts progressed rapidly to diabetes after adoptive transfer, Adbig SCID recipients remained disease-free (Fig. 3.4c). Furthermore, the islets of such Adbig SCID hosts remained devoid of T-cell infiltrates, suggesting that the inability of eTAC-experienced BDC2.5 T
Figure S3.3. Efficiency of depletion of FoxP3+ regulatory T cells in FoxP3-DTR BDC2.5 mice. Flow cytometric analysis of FoxP3 staining among CD4+ T cells from wildtype and FoxP3-DTR mice treated with a single dose of PBS or DT (50ug/kg), one day post-treatment.
Figure S3.3

![Graph showing the percent of maximum FoxP3 for different treatments: WT + PBS, WT + DT, FoxP3-DTR + PBS, FoxP3-DTR + DT. The values for each group are 8.15, 9.05, 9.13, and 0.70, respectively.](image)
cells to reach the target organ was not dependent on regulatory T cell populations (Fig. 3.4d).

Peripheral CD4+ tolerance induced by eTACs is not altered by CD40/TLR stimulus or PD-L1 blockade

While a number of antigen-presenting cell populations have been demonstrated to induce peripheral T-cell tolerance, many of these interactions can be abrogated or converted from tolerogenic to immunogenic upon stimulation of cell-surface receptors such as CD40, toll-like receptors (TLRs), or blockade of PD-1/PD-L1 interactions (22-26). To determine whether eTAC-mediated tolerance could also be interrupted by such perturbations, we first treated Adbig mice with anti-CD40/polyI:C and observed whether such stimulus could induce a maturation similar to that observed among DC populations. While anti-CD40/PolyI:C treatment induced activation and upregulation of CD80 on CD11c+ dendritic cells, eTACs failed to upregulate CD80 in response to treatment (Fig. 3.5a) despite the presence of high levels of surface CD40. Likewise, anti-CD40/polyI:C pretreatment of Adbig SCID mice failed to impact eTAC-mediated T cell tolerance, and anti-CD40/PolyI:C-treated Adbig SCID mice remained completely protected from adoptive diabetes transfer mediated by BDC2.5 T cells (Fig. 3.5b). This suggests that eTACs may be resistant to maturation in the context of inflammatory stimuli that induce other APC populations to convert from tolerance to immunogenicity.
Figure 3.5. eTAC-mediated tolerance induction in BDC2.5 T cells is not abrogated by CD40/TLR stimulus or PD-L1 blockade. (a) Representative flow cytometric analysis of CD80 staining in DAPI-, CD45+, CD11c+ dendritic cells and DAPI-, CD45-, MHCII+, GFP+ eTACs in response to anti-CD40/PolyI:C stimulus; quantitation of MFI shifts shown at right. (b) Blood sugar values (mg/dl) among anti-CD40/PolyI:C treated wildtype SCID and Adbig SCID hosts after adoptive transfer of 200,000 CD25-depleted, CD4-enriched, BDC2.5 T cells. (c) Blood sugar values (mg/dl) among anti-PD-L1 treated wildtype SCID and Adbig SCID hosts after adoptive transfer of 200,000 CD25-depleted, CD4-enriched, BDC2.5 T cells. (d) Hematoxylin and eosin-stained pancreatic islet histology of wildtype SCID and Adbig SCID recipients in (c) day 14 post-transfer.
Figure 3.5

a

DC
eTAC

CD80

CD40

Isotype
PBS
α-CD40/Poly I:C

b

Blood Glucose

Days Post-Transfer

WT SCID

αCD40/Poly I:C

αPDL1 Adbig

αPDL1 Adbig SCID

Blood Glucose

Days Post-Transfer

Iso SCID (N=4)
αPDL1 SCID (N=4)
αPDL1 Adbig (N=4)

αPDL1 Adbig SCID

No Tx CD40

CD40

αTAC

αCD40 SCID (N=4)
αCD40 Adbig (N=4)
PD-1/PD-L1 interactions have also been shown to be essential in the maintenance of peripheral tolerance in many experimental systems and notably play a key role in preventing autoimmune diabetes (25-27). To determine whether such interactions also regulate eTAC-mediated tolerance, we treated wildtype and Adbig SCID mice with anti-PD-L1 before and during adoptive transfer. Despite the efficacy of this regimen in breaking islet self-tolerance in wildtype NOD mice (Fig. S3.4), anti-PD-L1-treated Adbig SCID mice remained entirely resistant to BDC2.5-induced diabetes (Fig. 3.5c). This suggests that PD-L1 is not required for eTAC-mediated tolerance, and furthermore that eTAC-experienced CD4+ T cells do not require PD-1/PD-L1 interaction on the target tissue to prevent autoimmunity. Consistent with this, the pancreata of both anti-CD40/Poly I:C- and anti-PD-L1-treated Adbig SCID mice remained free of peri-islet infiltrates, suggesting that despite these perturbations, eTAC-CD4 interactions prevented autoreactive effector T cells from reaching their target organ altogether (Fig. 3.5d). These results demonstrate that CD4+ T cell inactivation induced by eTACs is resistant to perturbations affecting many other peripheral tolerance mechanisms; such resistance may be important if eTACs do in fact serve as self-antigen expressing APCs at sites of lymphocyte priming in the secondary lymphoid organs.

eTAC-mediated tolerance is unique from that induced by other tolerogenic APC populations.
Figure S3.4. Anti-PD-L1 treatment regimen induces rapid diabetes onset in wildtype NOD mice. Blood sugar levels among wildtype NOD mice receiving 200ug/mouse anti-PD-L1 (red) or isotype (blue) beginning at day 0.
Figure S3.4

Isotype (N=4)
α-PDL1 (N=4)

Days
Blood Glucose

0 2 4 6 8 10 12
0 100 200 300 400 500 600 700

Isotype (N=4)
α-PDL1 (N=4)
Despite these results, it remained unclear whether such CD4+ T-cell tolerance reflected a unique property of eTAC-CD4+ interactions, or if the same outcome would be observed when naïve CD4+ T cells encountered cognate antigen on other APC populations. To directly compare the outcome of BDC2.5-eTAC encounter to interaction with another putative tolerogenic APC population, we employed an antibody-mediated system to target a BDC mimetope peptide to DEC205+ dendritic cells (DCs). DEC205+ DCs can promote tolerogenic interactions and functional inactivation of naïve effectors if given without proinflammatory signals, and antibody-mediated targeting of peptide antigens to DEC205+ DC populations has previously been shown to induce interaction with cognate CD4+ and CD8+ T cells, resulting in functional T-cell unresponsiveness via anergy or deletion (22, 23, 28). Importantly, targeting of self antigen to these DCs has not been shown to induce functional tolerance of CD4+ T cells in the context of ongoing autoimmunity. To this end, we employed a fusion antibody containing anti-DEC205 coupled to the BDC mimetope peptide 1040-55 (17), which has a similar EC_{50} to 1040-p31 (17), and which we termed αDEC1040.

As in Adbig recipients, pre-treatment of wildtype NOD mice with αDEC1040 before adoptive transfer of BDC2.5 T cells induced rapid antigen-specific BDC2.5 proliferation in all secondary lymphoid organs, while PBS-treated mice induced proliferation only in the pancreatic lymph node (Fig. 3.6a). Although BDC2.5 proliferation appeared slightly more rapid in Adbig mice than in αDEC1040-treated mice, both induced robust proliferation in all secondary lymphoid organs and >95% of
Figure 3.6. αDEC1040 treatment induces proliferation but not tolerance of BDC2.5 T cells. (a) CFSE dilution among CD4+ Thy1.1+ BDC2.5 T cells transferred into wildtype NOD mice treated with PBS (green) or αDEC1040 (blue), or into Adbig mice (red). (b) IFN-γ production among CD4+ Thy1.1+ BDC2.5 T cells isolated from indicated mice, quantitated in bar graph on right showing lymph nodes (white) and spleen (black). (c) Flow cytometric analysis of peripheral blood from NOD SCID mice treated with PBS or αDEC1040, or Adbig SCID mice, following adoptive transfer of BDC2.5 T cells. (d) Blood sugar values (mg/dl) among NOD SCID mice treated with PBS (green) or αDEC1040 (blue) or Adbig SCID mice (red) following adoptive transfer of BDC2.5 T cells.
Figure 3.6

(a) Ing LN
(b) Spleen

(c) WT SCID+PBS (N=5) WT SCID+αDEC1040 (N=5) Adbig SCID (N=4)

(d) Blood Glucose

CFSE IFN-γ Thy1.1
cells eventually divided in both protocols when later time points were measured (data not shown). This suggested that the BDC mimetope antigen was being correctly processed and presented after administration of αDEC1040, and that adoptively transferred BDC2.5 T cells were able to effectively interact with these populations. However despite this rapid proliferation in both Adbig and αDEC1040-treated mice, we observed a marked difference in the functional outcomes for interacting BDC2.5 T cells. While BDC2.5 T cells in Adbig mice again failed to produce interferon gamma in response to secondary immunization, residual BDC2.5 T cells in αDEC1040-treated mice produced high levels if interferon similar to or greater than those observed in PBS-treated wildtype hosts (Fig. 3.6b).

We also tested whether such BDC2.5 interaction with DEC205+ DCs would have a similar protective effect on adoptive transfer of diabetes. We found, however, that despite robust proliferation in both Adbig and αDEC1040 SCID mice, continuous treatment with αDEC1040 did not induce a subsequent contraction of T cells after the initial proliferation (Fig. 3.6c). Furthermore, αDEC1040 treatment did not prevent or delay adoptive transfer of disease mediated by BDC2.5 T cells, while Adbig SCID mice remained completely protected from diabetes (Fig. 3.6d). Together these results suggest that eTACs may serve as more than simply a reservoir for self-antigen, as BDC2.5 cognate antigen presented in the context of a distinct but putatively non-immunogenic APC population is unable to induce tolerance or prevent disease in this autoimmune setting.
Expression of IGRP in eTACs prevents CD8+ T cell-mediated autoimmune diabetes

We previously described eTACs in the secondary lymphoid organs using the transgenic *Aire*-driven IGRP-GFP (*Adig*) mouse, which expresses a fusion protein of islet-specific glucose 6-phosphatase related protein (IGRP) conjugated to GFP under the control of the *Aire* promoter (11). eTACs in *Adig* mice also express detectable nuclear Aire protein (Fig. 3.7a), and adoptive transfer of naïve IGRP-specific CD8+ T cells from TCR-transgenic 8.3 mice into *Adig* recipients leads to rapid proliferation and subsequent deletion of 8.3 T cells in all secondary lymphoid organs (11). But whether such eTAC-CD8 interactions also result in immunologic tolerance, and specifically whether this leads to protection from autoimmune diabetes, is not known. While purified naïve 8.3 T cells alone do not adoptively transfer disease even into SCID recipients (data not shown), mice expressing the 8.3 TCR transgene itself do spontaneously develop accelerated diabetes (29).

To directly test whether IGRP expression in eTACs is sufficient to prevent 8.3-mediated diabetes in the absence of thymic negative selection, we developed a system in which a permissive thymic environment for 8.3 development was generated in *Adig* mice by thymectomy and simultaneous thymic transplantation, followed by lethal irradiation and reconstitution with 8.3+ Thy1.1+ TCR-transgenic bone marrow (Fig. 3.7b). FACS analysis six weeks after bone-marrow transplant revealed complete reconstitution of hosts (Fig. S3.5) and a lack of thymic negative selection in both groups, with equivalent
Figure 3.7. IGRP expression in eTACs leads to peripheral deletion of 8.3 T cells and prevention of CD8-mediated diabetes. (a) Immunofluorescent staining of eTACs from Adig NOD lymph nodes stained for GFP (green) and AIRE (red) and counterstained with DAPI (blue). (b) Schematic illustration of Adig/8.3 thymectomy/thymic transplant/bone-marrow chimera strategy. (c) Representative flow cytometric analysis of thymocytes and lymphocytes from experimental mice described in (b). CD4/CD8 plots are pregated on FSC/SSC. Tetramer histograms are pre-gated on FSC/SSC and CD4-CD8+, and represent total cell number on Y axis for wildtype mock tetramer (green), wildtype NRP-V7 mimotope tetramer (blue), and Adig NRP-V7 tetramer (red). Insets show Adig populations alone as a percent of maximum. (d) Quantitation of total cell numbers in (c) for organs indicated, ±SD; 3 mice per group. NS, not significant (e) Diabetes incidence curves for cohorts of wildtype and Adig mice described in (b), shown as weeks post BM-reconstitution.
Figure 3.7

a

b

Thymectomy/
Thymus Transplant

Irradiation/
Bone Marrow Reconstitution

8.3+ Bone Marrow

WT    WT (N=8)

WT    TG  (N=8)

38.45  34.63

7.20   2.89

18.27  18.30

18.30  4.66

Thymus

Spleen

Cerv. LN

Panc. LN

CD4

CD8

WT

Adig

Adig

Adig

Adig

WT NRP-V7

WT mock

p<.01

p<.01

p<.01

128
Figure S3.5. Efficiency of reconstitution in Adig mice lethally irradiated and reconstituted with Thy1.1+ 8.3 bone marrow. Representative flow cytometric analysis of MHC II staining among CD8+ thymocytes from wildtype NOD (black), Thy1.1+ 8.3 bone-marrow chimeric wildtype NOD (blue), and Thy1.1+ 8.3 bone marrow chimeric Adig NOD mice (red).
Figure S3.5

Adig chimera
WT chimera
WT NOD

% of Max

Thy1.1

96.56
97.88
0.40
numbers of total Thy1.1+ CD8 single-positive thymocytes, and similar tetramer-reactivity (Fig. 3.7c, d). This suggests that transgenic IGRP antigen was not being trafficked back to the transplanted thymus, creating differential thymic selection environments. In the secondary lymphoid organs, by contrast, the number of CD8+ T cells was dramatically reduced in Adig recipients, and the tetramer-reactivity of those remaining CD8+ Thy1.1+ T cells was markedly decreased (Fig. 3.7c, d). Thus, after egress from a permissive thymic selection environment, high-affinity 8.3 CD8+ T cells in Adig recipients appeared to undergo deletion upon eTAC encounter, leaving predominantly low IGRP-affinity CD8+ T cells in these mice (Fig. 3.7d). Importantly, whereas wildtype recipients of transplanted thymi and 8.3 bone marrow progressed gradually to completely penetrant autoimmune diabetes, Adig recipients were entirely protected from such disease (Fig. 3.7e). Together, these results suggest that self-antigen expression in eTACs can induce deletional tolerance of endogenously arising CD8+ T cells, and that eTAC interactions with autoreactive CD4+ and CD8+ T cell populations are sufficient to prevent anti-islet autoimmunity.

Discussion

The recent description of Aire-expressing cells and ectopic TSA transcription in the secondary lymphoid organs (10, 11, 13, 30) has raised the question of whether self-antigen expression in these populations can directly prevent autoimmune disease. Here, using transgenic systems in both the CD4+ and CD8+ T cell contexts, we describe a role
for extrathymic *Aire*-expressing cells in preventing autoimmune diabetes. The *Aire*-driven peripheral expression of pancreas-specific antigens recognized by either the islet-specific CD4+ T cell clone BDC2.5 or the IGRP-specific CD8+ T cell clone 8.3 induces a robust T-cell tolerance in both populations, and protects such transgenic mice from cognate T cell-mediated diabetes. Of note, this tolerance occurs even in the setting of lymphopenia, which is often thought to provoke autoimmunity in the context of antigen encounter (31–33). These results demonstrate that self-antigen expression in eTACs is sufficient to prevent autoimmunity mediated by diverse antigen-specific T cells, and provide evidence for a novel mechanism contributing to the maintenance of peripheral tolerance.

Previous descriptions of putatively tolerogenic radioresistant populations in the secondary lymphoid organs have focused on interactions with CD8+ T cells (10, 11, 13), but given the ubiquity of class I MHC expression on all nucleated cells, it was not clear to us whether the observed deletion of cognate CD8+ T cells in these systems represented a unique feature of these populations or was merely a byproduct of self-antigen expression in any cell population lacking appropriate inflammatory or costimulatory signals. Based on the high levels of class II MHC expressed on eTACs (11), and the significance of CD4+ T cell populations in autoimmune disease (34, 35), we chose to investigate whether eTACs might play a unique role in peripheral tolerance induction by interacting with both CD4+ and CD8+ T cells. Indeed BDC2.5 T cells adoptively transferred into *Adbig* mice proliferate in all secondary lymphoid organs, and this interaction is preserved even in the absence of class II MHC expression on hematopoietic cells. In such bone-
marrow MHC II-deficient chimeric animals, while BDC2.5 interaction with endogenous DCs draining antigen from the pancreatic lymph node is completely abrogated, BDC2.5-eTAC interactions are sustained in all secondary lymphoid organs of Adbig mice. This suggests that eTACs can directly interact with CD4+ T cells, a novel role for a radioresistant population in the secondary lymphoid organs. It is important to note that the nature of the Adbig transgenic system facilitates loading of the BDC2.5 mimotope peptide directly into the class II MHC pathway through the modified Invariant chain, and may differ from the pathway normally used by eTACs to cell-autonomously process and present antigen. It will therefore be important in future studies to determine if eTACs can similarly process and present their own tissue-specific antigens via class II MHC in such a cell-autonomous fashion. Along these lines there is recent evidence that autophagy plays a role in antigen processing and presentation in mTECs (36), and it will be of interest to determine whether the same is true in eTACs.

Interestingly, whereas eTAC-CD8 interaction induces T-cell deletion, interaction of BDC2.5 CD4+ T cells with eTACs results in the persistence of a residual population consisting of functionally inactive effectors and FoxP3+ regulatory T cells. While both functional inactivation of effectors and enrichment of regulatory T cells may play a role in eTAC-mediated CD4+ tolerance, it appears that functional inactivation alone is sufficient to prevent autoimmunity. The evidence for this is twofold. First, BDC2.5 FoxP3-DTR+ T cells continuously depleted of regulatory T cells remain unable to transfer disease into Adbig SCID recipients. Second, eTAC-experienced BDC2.5 T
cells are unable to transfer disease serially in cis into secondary lymphopenic hosts, but also cannot suppress adoptive transfer of disease by other naïve BDC2.5 T cells in trans. Together these results support the idea that the primary mechanism of eTAC-mediated disease prevention in this model is recessive—a functional inactivation of effectors as opposed to a preferential enrichment of regulatory T cells.

Our results also suggest that eTACs have a unique tolerogenic capacity, and serve as more than simply an antigen reservoir in the periphery. In support of this, targeting of a BDC mimetope peptide to another putative tolerogenic APC population, DEC205+ DCs, induces proliferation of adoptively transferred BDC2.5 T cells similar to that seen in Adbig recipients, but does not prevent such transferred BDC2.5 T cells from producing effector cytokines in response to secondary peptide immunization. Nor does targeting the BDC mimetope peptide to DEC205+ DCs protect or delay SCID mice from adoptively transferred diabetes. One possible difference between delivery of antigen via αDEC1040 and Adbig mice may be the dose and length of antigen exposure, which could affect tolerance induction. But given the established role for immature DEC205+ DCs in tolerance induction (22, 23, 28), it is unclear precisely why BDC2.5 T cells fail to become tolerant after such interaction. However, evidence suggests that DCs in NOD mice may have defects in tolerance induction (37), and unlike eTACs, DCs do respond to inflammatory environmental changes, and may lose the ability to induce CD4+ tolerance in NOD mice. Although tolerance of islet-specific CD8+ T cells via DEC205+ DCs has been observed in NOD mice, induction of tolerance for CD4+ T cells appears to be more
sensitive to the genetic and environmental changes that occur in autoimmune NOD mice.

The unique nature of eTAC-mediated tolerance leads us to speculate whether diabetes protection in this setting may act via a novel mechanism, as it appears insensitive to the perturbations that mitigate many forms of peripheral tolerance. For example, it is striking that self-antigen expression in eTACs induces robust tolerance even in lymphopenic SCID mice, while many similar systems of peripheral antigen display switch from tolerogenic to immunogenic in the context of lymphopenia (31-33). Likewise, while T cell tolerance established by “immature” DC populations is commonly abrogated by maturation signals such as CD40 and TLR stimulus (22, 23), these same signals do not appear to induce maturation of eTACs, nor do such stimuli interfere with the observed disease protection in Adbig SCID mice. Finally, PD-1/PD-L1 interactions have been shown to play an essential role in peripheral tolerance induction in numerous settings (24-27), but appear to have no effect on eTAC-mediated CD4+ T cell tolerance. Together these findings suggest that self-antigen expression in eTACs induces a remarkably robust T-cell tolerance that is highly resistant to conversion from tolerance to immunogenicity. If indeed eTACs serve as a source of diverse self-antigen in the secondary lymphoid tissues, such resistance to immunogenicity may be important in preventing cross-priming of self-reactive T cells. Further defining the mechanism of this tolerance will be of significant future interest, but it is interesting to note that despite the massive proliferation of BDC2.5 T cells in Adbig SCID mice, and the mobilization of
these cells into the peripheral blood, the pancreata remain completely free of infiltrate and the majority of the residual T cells are found in the spleen. This suggests that perhaps eTAC interaction interferes with trans-endothelial migration of activated CD4+ T cells into target tissue, leading to their sequestration within the secondary lymphoid system and peripheral blood. The lack of the classical costimulatory molecules CD80 and CD86 on eTACs (11) also suggests that the observed aberrant activation of CD4+ T cells may result from the absence of appropriate second signals delivered by eTACs.

Together these results suggest that pancreatic self-antigen expression in extrathymic Aire-expressing cells can mediate robust peripheral self-tolerance and provide protection from autoimmune diabetes, but also raise many important questions. For example, it will be important to determine whether endogenous antigens expressed in eTACs can mediate a similar protection from disease, and naturally whether Aire plays a role in this process. Though Aire has been suggested to induce the expression of a novel array of self-antigens in eTACs, a physiologic role for such endogenously Aire-regulated antigens outside the thymus has yet to be defined. Similarly, it will be of significant interest to determine what role eTACs play in normal homeostasis, and whether their absence leads to a predisposition toward autoimmunity. As we come to better understand the role of this population in immune tolerance, it will also be important to define the fundamental biology of these cells, both their origin and their relationship to other characterized APC populations. The recent report that populations of Aire-expressing cells reside in human secondary lymphoid organs (30) makes this inquiry all the more
relevant for understanding human immunologic tolerance, and for therapeutic intervention in autoimmunity.

Methods

Transgene construction, BAC recombineering, and purification

*Aire*-driven BDC2.5 peptide Invariant Chain GFP (*Adbig*) transgenic mice were generated by standard cloning methods using a bacterial artificial chromosome (BAC) recombineering and transgenesis strategy. Briefly, the 1040–31 (p31) peptide (YVRPLWVRME) coding sequence was introduced in place of the CLIP sequence of the Invariant Chain using overlapping bi-directional PCR from the pTIM vector (a gift of H. Van Santen) with the forward/reverse primer pairs 5’-AGAATTCCTAGAGGCTAGAGCC-3’/ 5’-tcgtacgtaCACAGGTTTGGCAGATTTC-3’ (product 1) and 5’-acgtacgaccactatgggtacgaatggaaCGTCCAATGtccatggat-3’/ 5’-ggcgtgaactggaagatct-3’ (product 2). These two PCR products were sub-cloned into pCR-Blunt II TOPO vectors (Invitrogen), sequenced, and digested with EcoR1 and BsiW1 (product one) or BglII and BsiW1 (product two), and ligated sequentially into pLitmus28i (New England Biolabs) to generate a complete p31-containing fragment. This EcoR1/BglII fragment was then inserted into the pTIM vector via EcoR1 partial and BglII complete digest, generating the pBDCTIM vector. The complete iI-BDC construct was amplified from pBDCTIM by PCR using the primers 5’-cgcGGATCCTTAATTAAatggatgaccaacgcgac-3’/5’-cgcGGATCCtcacagggtacttgacc-3’, and this product was subcloned into the pCR-Blunt II TOPO vector for sequencing. This iI-BDC fragment was inserted into the BamH1 site of pIRES2-EGFP (Clontech), generating the pIi-BDC-IRES2-EGFP vector.

The iI-BDC-IRES-EGFP fragment was then extracted by PacI/NotI digest and ligated into pAireFNF, a BAC-targeting plasmid containing 5’ and 3’ homology arms to the mouse *Aire* gene. pAireFNF itself was generated from JDFNF, an *Aire* BAC-targeting expression construct previously described(11). To generate pAireFNF, the multiple cloning site from the vector pLitmus 38i (New England Biolabs) was amplified.
with the primers 5’-GGTTAATTAACTTCTCTGCAGGATATCTG-3’/5’-GGCCTGCAGGGCCTTGACTAGAGGGTC-3’, subcloned into pCR-BluntII-TOPO, sequenced, and ligated by NotI partial/HindIII complete digest into JDFNF. Ligation of the Ii-BDC-IRES-EGFP fragment into pAireFNF generated the construct pAireFNF-Ii-BDC.

This targeting construct, pAireFNF-Ii-BDC, was then inserted via standard recombineering(38) into a BAC clone from the Children’s Hospital of Oakland Research Institute (CHORI) BACPAC Resource Center, clone 461e7 from the RPCI 23 Mouse BAC Library, which contained the Aire gene and approximately 90Kb of flanking sequence both upstream and downstream. The BAC identity was previously verified by PCR and restriction digestion, then purified and transfected via electroporation using standard techniques into the heat-inducible recombinase-competent and arabinose-inducible Flpe-expressing bacterial strain SW105. The loxP site in the eBAC3.6 vector was first removed by targeted homologous recombination. Heat-induced recombination was achieved by culturing the bacteria at 42°C, rapidly cooling, then electroporating in the presence of linearized pAireFNF-BDC-Ii plasmid. After selection and PCR-screening of recombinants, Flpe expression was induced in positive clones by culturing in 0.1% arabinose for three hours at 30°C. Flpe-recombinant clones were screened by replica-plating for acquisition of kanamycin sensitivity. Positive clones were then rescreened by Southern blot using SpeI digest and a 600-bp probe downstream of Aire exon 3 generated by the primers 5’-TCTCGTCCTCAAGAGTGCC-3’ and 5’-GTCATGTTGACGGATCCA-3’.

Highly purified Ii-BDC-Aire BAC DNA was carefully prepared for fertilized oocyte injection by column purification using a modified Midiprep kit protocol (Qiagen). 100ml of clonal liquid culture was pelleted, gently alkaline-lysed, protein-precipitated, and centrifuged. Supernatant was applied to equilibrated Midiprep columns, washed according to manufacturer’s instructions, and eluted with prewarmed 65-degree Buffer QF (Qiagen). BAC DNA was precipitated and pelleted in an ultracentrifuge (Sorvall). Pellets were washed, centrifuged, and allowed to air-dry, then gently resuspended in injection buffer (10mM Tris-HCL, 0.1 mM EDTA, pH 7.5), and evaluated for integrity by KpnI digestion and gel electrophoresis. Resuspended BAC DNA was injected into
fertilized NOD oocytes by the UCSF Mouse Transgenic Core with the assistance of H. Lu and N. Killeen.

Mice and genotyping

*Adbig* transgenic NOD mice were screened by real-time PCR using the primers 5’-CTGCTGCCCACAACCA-3’ and 5’-TGTGATCGCGCTTCTCGTT-3’ and the probe Cy5-TACCTGAGCACCCAGTCCGCCCCT-BHQ along with an endogenous control reaction for CD86 using the primers 5’-CTTGATAGTGTGAATGCCAAGTACCT-3’ and 5’-TGATCTGAACATTTGTGAAGTCTTAGA-3’ and the probe FAM-CGCACAGCAGTTGACAGGAACAAGCT-TAMRA. This same reaction was used to genotype *Adig* mice, as it detects genomic GFP present in both transgenes. Both *Adig* and *Adbig* transgenes were maintained in heterozygosity for all experiments.

TCR-transgenic BDC2.5 NOD mice and TCR-transgenic 8.3 NOD mice were acquired from J. Bluestone and Q. Tang and crossed onto CD90.1 congenic NOD strains. Both TCR transgenes were maintained in heterozygosity, and were FACS-genotyped by usage of the Vβ4 (BDC2.5) or Vβ8.1 (8.3) clonotype specific antibodies (BD Pharmingen) among peripheral blood CD4s (BDC2.5) or CD8s (8.3). FoxP3-DTR NOD mice were acquired from D. Mathis and C. Benoist and the Center on Immunological Tolerance in Type-1 Diabetes at Jackson Laboratories. NOD MHC II-knockout mice were obtained from Jackson Laboratories (stock# 004256).

All mice were maintained in microisolator cages and treated in accordance with NIH and American Association of Laboratory Animal Care standards, and consistent with the animal care and use regulations of the University of California, San Francisco.

Flow cytometry and cell sorting

All FACS antibodies were purchased from BD Pharmingen, eBioscience, Invitrogen, or Southern Biotech with the exception of anti-CD32/16 (clone 2.4G2), which was purified by the UCSF hybridoma core, and anti-EpCAM (clone G8.8), which was purified and biotinylated by K. Johannes. Stromal cells were prepared for FACS as described(11). Lymphocytes for flow cytometry were prepared by mashing thymi, lymph
nodes, or spleens, filtering these cells through a 70μm cell-strainer, lysing red blood cells by incubation in ACK buffer (spleen only; 0.15 M NH₄Cl, 10 mM KHCO₃, 0.1 mM Na₂EDTA), counting by trypan blue exclusion, resuspending in anti-Fc receptor blocking antibody clone 2.4G2 in FACS buffer for ten minutes, then incubating on ice with antibody cocktails for twenty minutes. For peptide/class I MHC tetramer staining, cells were incubated on ice with antibody cocktail along with either IGRP mimetope/class I MHC tetramer NRP-V7-PE (KYNKANVFL/Kd) or with mock tetramer TUM-PE (KYQAVTTTL/Kd, NIAID MHC Tetramer Core Facility) for one hour, then washed and analyzed by flow cytometry. For peptide/class II MHC tetramer staining, cells were incubated on ice with antibody cocktail with either BDC2.5 mimetope/class II MHC tetramer p31-PE (RTRPLWVRME/I-Ag7) or with irrelevant tetramer CLIP-PE (PVSKMRMATPLLMQA/I-Ag7, NIAID MHC Tetramer Core Facility) for one hour, then washed and analyzed by flow cytometry as described. For intracellular FoxP3 staining, lymphocytes were first stained for cell-surface markers, then fixed and permeabilized according to the instructions of the FoxP3 staining buffer set (eBioscience) and incubated for 30 minutes with anti-FoxP3 (eBioscience), washed in permeabilization buffer and then FACS buffer, and analyzed by FACS.

Isolation of RNA and real-time PCR

For real-time PCR, stromal cells were isolated from thymus, spleen, and pooled lymph nodes as described above. eTACs, mTECs, and DCs were sorted from nontransgenic Adbig mice based on the following surface markers: eTACs and mTECs: PI-, CD45-, CD11c-, MHC II+, GFP+; DCs: PI-, CD45+, CD11c+, MHC II+. RNA was purified using the Absolutely RNA Microprep kit (Stratagene) and quantitated using a NanoDrop spectrophotometer (Thermo Fisher Scientific). After quantitation, RNA was reverse-transcribed into cDNA using oligo-dT (Invitrogen) and Superscript III reverse transcriptase (Qiagen). Equivalent reactions without reverse transcriptase (-RT) were run for each sample. Aire transcript levels were assessed by real-time PCR using the Exon2-3 amplifying primers 5’-CAGCCGCTGCATAGCA-3’ and 5’-CTTTCCGGGACTGGTTAGGT-3’ and probe FAM-CCTGGACCGGCTTCCCCAAAAGATGTG-BHQ. Sample quantities were
normalized to Actin signal, detected using SYBR green master mix (Applied Biosystems) and the primers 5’-ACGGCCAGGTACACTATTG-3’ and 5’-AGGATTTCATACCAAGAAGGAA-3’. Real-time PCR reactions were run on a 7500 Fast Real-Time PCR System (Applied Biosystems).

Statistical Analysis

Statistical analysis of data was performed with Excel 2003 (Microsoft) and Prism 4.0 (GraphPad). Statistical comparisons were made using a Student’s two-tailed T-test, and results with p<0.05 were considered statistically significant.

Histology, immunofluorescent staining and quantitation

All primary and secondary antibodies for histology were purchased from AbCam, BD Pharmingen, Invitrogen, Jackson, or eBioscience, with the exception of the anti-AIRE antibodies 5C-11 and 5H-12, which were gifts of H. Scott. For Adig mice, organs were harvested from experimental animals and embedded in Tissue-Tek Optimal Cutting Temperature (OCT) media (Fisher), then processed as described (11). Slides were mounted in Vectashield mounting medium (Vector Laboratories) and visualized with an SP2-AOBS Confocal Microscope (Leica). Images were acquired using Leica Confocal Software (Leica).

For Adbig mice, fixation conditions were modified to properly fix cytoplasmic GFP. Organs were harvested from experimental animals and directly fixed in a 1.5% paraformaldehyde (Fisher) solution at 4°C for 3 hours. Tissues were then transferred to a 30% sucrose solution and left at 4°C for 3 hours prior to embedding in OCT. Sections were cut as before, and GFP was then labeled using a Tyramide Signal Amplification kit (Perkin Elmer) according to the manufacturer’s protocol. Following GFP signal amplification, additional markers were labeled using the standard immunostaining procedure described above. Slides were mounted in Vectashield mounting medium (Vector Laboratories) and visualized on an Axioskop 2 Plus Widefield Scope (Leica) attached to a C4742-95 digital camera (Hamamatsu). Images were acquired using AxioVision 4.6 (Zeiss) and analyzed, processed via linear contrast adjustment, and merged with Photoshop CS3 (Adobe).
For hematoxylin and eosin staining of pancreatic sections, tissues were fixed overnight in formalin at 4°C, then dehydrated in 30% ethanol for 30 minutes and stored in 70% ethanol prior to embedding in paraffin. 10-micron sections were cut, stained with hematoxylin and eosin as described (REF) and visualized with an AxioImager Brightfield microscope (Zeiss) using AxioVision 4.6 (Zeiss) acquisition software. All microscopy image merging, contrast-adjustment, or formatting was applied equivalently to control and experimental images using Photoshop CS3 (Adobe).

**Purification, CFSE-labeling, and adoptive transfer/serial transfer of T cells**

For adoptive transfer of naïve, CD25-depleted, CD4-enriched T cells, the spleen and all major peripheral lymph nodes except pancreatic were harvested from nondiabetic donors, pooled by group, ACK-lysed and counted. Cells were then CD25-depleted by addition of anti-CD25 hybridoma 7D4 supernatant, incubated for 25 minutes on ice, then incubated with rabbit complement in DMEM for 50 minutes in 37-degree rotator. Cells were washed, counted, and resuspended in Robosep buffer (StemCell Technologies) with 5% rat serum before CD4 enrichment using Mouse CD4+ Negative Selection Kit in the Robosep 20000 (StemCell Technologies) with the 1-Quadrant High Recovery protocol. Aliquots at each step were used to confirm depletion or purification. Cells were counted, and for disease transfer were resuspended in Hank’s Buffered Salt Solution (HBSS) without Phenol Red at 1e6 cells/ml, then 200ul was injected IV per recipient by tail vein. For CFSE labeling prior to adoptive transfer, purified cells were pooled in a ~1:1 ratio of BDC2.5 T cells:polycolonal CD4+ T cells then labeled in 2.5μM CFSE (Invitrogen) at room temperature for 5 minutes. Labeling was quenched with an equal volume of FCS, cells were washed twice in DMEM and once in HBSS, counted and injected at 1-2e6 cells/recipient via the tail vein. For adoptive transfer of diabetes into SCID and Adbig SCID recipients, the same protocol was followed but purified BDC2.5 T cells were not CFSE-labeled or mixed with polyclonal cells, simply resuspended to 1e6 cells/ml and injected at 200uL per mouse via tail vein.

Serial co-transfer of T cells was performed at day 10 post-primary transfer. Non-pancreatic lymph nodes and spleen were harvested from SCID and Adbig SCID primary recipients, pooled, ACK-lysed, and counted. These cells were counted and purified for
CD4+ T cells as described above. Simultaneously, naïve BDC2.5 T cells were harvested from unmanipulated BDC2.5 mice and purified by CD25-depletion and CD4-enrichment as described above. Purified serially transferred CD4+ T cells were injected alone or mixed 1:1 with naïve BDC2.5 T cells and injected at 200,000 cells/recipient into secondary immunodeficient hosts, which were followed for diabetes as described below.

**Treatment and analysis of adoptive transfer recipients**

Indicated recipient SCID and *Adbig* SCID mice were treated with 200ug/mouse of anti-PD-L1 (clone 9G2; Bio-Express), a 1:1 mixture of anti-CD40 (clone FGK4.5; UCSF Hybridoma Core) and poly I:C (Sigma), or isotype rat IgG (Bio-Express). Mice were injected intraperitoneally one day before and one day after adoptive transfer (for anti-CD40/PolyI:C) or one day before and continuously every other day after (for anti-PD-L1 and isotype). Disease transfer SCID and *Adbig* SCID mice receiving *FoxP3-DTR*+ BDC2.5 T cells were treated with 50ug/kg diphtheria toxin (DT) in PBS injected intraperitoneally the day of adoptive transfer and at day 2 post-transfer, then every three days over the course of observation. Recipient mice were monitored for diabetes onset at the indicated timepoints by serial analysis of blood glucose using an Ascensia Elite XL blood glucometer (Bayer). For incidence curves mice were considered diabetic after two successive blood glucose readings >350mg/dl. For αDEC1040 experiments, wildtype NOD mice were injected with 400ng of αDEC1040 or an equivalent volume of PBS one day prior to transfer of 1e6 BDC2.5 T cells, and were analyzed for CFSE dilution 40 hours post-transfer. NOD SCID mice were treated with 100ng αDEC1040 or PBS one day prior to adoptive transfer of BDC2.5 T cells, and then re-treated with 100ng every three days throughout the course of observation.

For peptide/CFA immunization experiments at day 14 post-adoptive transfer, mice were injected subcutaneously with p31 peptide emulsified in Complete Freund's Adjuvant (CFA), made from Incomplete Freund's Adjuvant (Sigma) with 4mg/ml H37RA tuberculosis (DIFCO). Acetylated p31 peptide (Genscript) was added to CFA to a final concentration of 500ug/ml. The p31/CFA solution was emulsified by sonication, and injected subcutaneously at 100ul/mouse. Three days post-immunization, lymphocytes and spleen were harvested, ACK-lysed, and plated at 5e6 cells/well in 1ml
complete DMEM + 10% FCS plus 0.5uM p31 peptide. After four hours of incubation at 37 degrees in 5% CO₂, 1.33uL GolgiStop (BD Biosciences) was added and cells incubated an additional six hours. Cells were then washed, stained with CD4/CD90.1 antibodies, then fixed in 4% PFA, permeabilized with permeabilization buffer (eBioscience) and stained intracellularly for interferon gamma or isotype.

**Generation of αDEC-1040 reagent**

Hybrid antibodies were prepared similarly to Hawiger, et al.(28) Plasmid containing the anti-DEC-205 V region heavy-chain linked to the 1040-55 peptide (RVRPLWVRME(17)) were transfected into 293T cells together with a second plasmid containing the kappa chain recognizing DEC-205. 293T cells were maintained in high glucose DMEM containing L-glutamine and 110 mg/L sodium pyruvate, 10% Low IgG FBS, 100U/mL penicillin, 100μg/mL streptomycin, and 50μg/mL gentamicin (all from Gibco except gentamicin from Quality Biologicals). Four to six days after transfection supernatants were harvested and antibody was purified over Protein G-sepharose columns (GE Healthcare). Antibodies were dialyzed overnight to PBS and examined for LPS contamination by LAL assay (Lonza) and for purity by SDS-PAGE and GelCode Blue staining (Pierce). LPS levels below 0.1 EU/mL were considered endotoxin-free. Antibody concentration was determined by spectrophotometric analysis.

**Thymectomy and thymic transplantation**

One week prior to thymectomy/thymic transplant, donor thymi were harvested from 2-3 day-old wildtype NOD pups and incubated in 12-well Costar transwell plates (Corning) in complete DMEM + 10% FCS and 1.35mM 2-deoxyguanosine (Sigma). One day before transplant, media was changed to complete DMEM + 10% FCS without 2-DG.

Thymectomy and thymic transplantation was performed on 4-6 week-old wildtype or Adig NOD mice as previously described(7, 39). Briefly, mice were anesthetized with Ketamine (80mg/kg) and Xylazine (10mg/kg), and thymectomy was performed by surgical accession of the superior mediastinum followed by vacuum aspiration of the thymic lobes. Completeness of thymectomy was confirmed before wound closure and again at the time of autopsy. Immediately after thymectomy,
transplantation of thymi was performed under the kidney capsule by surgical accession of the peritoneum, incision of the kidney capsule with a 25-gauge needle, and mechanical implantation of both thymic lobes to a subcapsular site distal to the incision with sterile 0.51mm silastic laboratory tubing (Dow Corning). Capsule incisions were cauterized with a portable Bovie electrocautery (Aaron Medical) before wound closure. Transplants were evaluated at the time of autopsy for growth and by thymocyte flow cytometry for CD4 and CD8 expression supporting normal T-cell development. Skin staples were removed within two weeks of surgery, and all experimental mice were monitored and treated continuously with post-operative analgesia consistent with IACUC procedures.

References


145
22. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the


Chapter IV

The \textit{AireDTR} Mouse and Autoimmunity
Introduction

The previous chapters have described the identification of eTACs, have demonstrated that Aire regulates a unique set of self-antigens in this population, and that such interactions promote immune self-tolerance. While these results indicate that eTACs are sources of TSA expression in the periphery, and that self-antigen expression in eTACs is sufficient to induce immune self-tolerance, they do not strictly identify a role for eTACs in the normal maintenance of tolerance. Likewise, in the thymus, despite the well-establish role of Aire established by knockout mice, the precise role of Aire-expressing mTECs remains uncertain. To directly study the contribution of eTACs and Aire-expressing mTECs to the maintenance of immune tolerance, we have generated a novel transgenic mouse in which we can specifically and temporally delete Aire-expressing cells. This chapter will describe the development and preliminary findings related to this mouse model, and discuss ongoing and proposed experiments for this system.

Cell-type specific deletion of defined populations has been used in diverse settings from immunology to developmental biology to study the contribution of specific cells to normal homeostasis. One common approach to achieve such deletion exploits the human heparin-binding EGF-like growth factor (HBEGF) gene, also known as the diphtheria toxin receptor (DTR), which binds with high affinity to diphtheria toxin (DT), a translational inhibitor. While the mouse shares a homologous Hbgef gene, the tissue-selectivity of this approach is conferred because murine Hbgef has 10^3-10^5-fold lower affinity for diphtheria toxin (DT) than its human counterpart (reviewed in [1]). Thus,
mice can systemically tolerate significantly higher dosage of DT than humans, allowing for relatively low nonspecific toxicity in non DTR-expressing mouse cells.

Expression of the human HBGEF gene under control of a cell-type specific promoter in mice thus confers upon that population a high sensitivity to diphtheria toxin, and this approach has been used to successfully deplete a diverse range of cells including FoxP3+ regulatory T cells (2), CD11b+ monocytes and macrophages (3), and CD11c+ or Langerlin+ DCs (4, 5), among many others. Cell death after DT internalization is generally believed to occur via apoptosis, purportedly reducing the risk that such death itself will cause inflammation and contribute to immune perturbation (3). However cell-death related artifacts are certainly to be considered when interpreting any data related to such systems. Further, this approach has additional limitations that should be noted, most prominently: (1) DT itself is immunogenic, and thus mice continuously exposed to DT will gradually generate an anti-DT antibody response, which can potentially limit the effective treatment window; and (2) despite the lower affinity for the mouse Hbgef gene, DT retains significant nonspecific toxicity at higher doses, particularly in young mice. Despite these potential limitations, DTR-transgenic mice have been essential in dissecting the role of diverse cell populations of the immune system, and we hope an AireDTR mouse will provide significant insight into the role of mTECs and eTACs.

Results

The AireDTR Mouse Faithfully Recapitulates Aire Expression in mTECs and eTACs
In order to express the diphtheria toxin receptor specifically in mTECs and eTACs, we used a bacterial artificial chromosome (BAC)-targeting approach similar to those described previously (6) in the generation of the Adig (7) and Adbig (Chapter III) mouse strains. Employing a homologous recombineering strategy, we inserted the DTR-EGFP cassette in place of exons 1-3 of the mouse Aire gene in a BAC containing ~90 kilobases of flanking DNA in either direction, and injected this construct (Fig. 4.1a) into fertilized oocytes. We generated NOD founders which we termed AireDTR mice. As in previous Aire-driven transgenic lines, we used GFP to evaluate the pattern of transgene expression. Immunofluorescent staining demonstrated that in the thymus, GFP expression was largely restricted to cytokeratin 5-positive cells of the medulla, and colocalized with Aire protein (Fig. 4.1b). In the secondary lymphoid organs, GFP expression was restricted to populations residing at T-B boundary regions in the interfolicular ridges of lymph nodes (Fig. 4.1b) and at similar T-B boundaries between the PALS and the B-cell follicle in the spleen (data not shown). This pattern of expression in the thymus and secondary lymphoid organs is consistent with that observed in both the Adig and Adbig reporter mouse lines. Similarly, FACS analysis of the thymus and secondary lymphoid organs revealed populations of class II MHC+, GFP+ cells unique to transgenic animals, though expression in both organs was noticeably lower than seen in other Aire-reporter strains (Fig. 4.1c). This lower expression is perhaps not surprising given that other strains using the same DTR-EGFP construct have also shown very low GFP expression by FACS (4).
Figure 4.1. The *AireDTR* transgene is expressed in mTECs and eTACs. (a) Schematic illustration of homologous recombineering to target the DTR-EGFP construct into the first three exons of a BAC containing the mouse *Aire* gene. (b) Immunofluorescent staining of thymus and lymph node frozen sections from *AireDTR* mice using the antibodies indicated. (c) Flow cytometric analysis of Percoll-light stromal fractions from wildtype and *AireDTR* thymus and lymph nodes pre-gated for FSC/SSC, CD45-low, and DAPI-negative status.
Figure 4.1

a

![Diagram showing the gene structure with Aire Exons 1, 2, and 3, B-globin splice, SV40 pA, and DTR-EGFPNeo. The diagram also indicates the distance between Aire Exons 1, 2, and 3 as 90kb and 85kb.](image)

b

![Images showing thymus and lymph node with GFP/Aire and GFP/B220 staining.](image)

c

![Heatmaps showing wildtype and AireDTR in thymus and lymph node with measurements of 0.09, 8.70, 0.07, and 0.40.](image)
Together these results suggest that the DTR-EGFP transgene is being faithfully expressed in mTECs and eTACs in the AireDTR mouse.

Diphtheria Toxin Administration Rapidly and Effectively Depletes mTECs and eTACs

We next tested the ability of the AireDTR transgene to deplete mTECs and eTACs upon DT exposure. Wildtype, Adbig, and AireDTR mice were treated for two consecutive days with 50ug/kg DT injected intraperitoneally and then harvested on day three. In the thymus, FACS analysis revealed an essentially complete depletion of MHCII+, GFP+ mTECs in AireDTR mice, while Adbig mice were unaffected (Fig. 4.2a). Importantly, in such analysis we could distinguish between completely GFP+-depleted AireDTR mice and mis-genotyped mice both by immunofluorescent nuclear Aire staining (Fig. 4.2c) and by the frequency of MHCII-high, CD45-low cells in the thymus by FACS, which are uniquely depleted in DT-treated AireDTR mice (Fig. 4.2b). In the secondary lymphoid organs, an equally complete and transgene-specific depletion was observed among MHCII+ GFP+ eTACs (Fig. 4.2c).

Immunofluorescent staining of frozen sections with an anti-GFP antibody also revealed a complete absence of transgene signal after DT treatment in both the thymus and secondary lymphoid organs (Fig. 4.2d). The complete absence of anti-GFP reactivity in DT-treated AireDTR mice also suggests that fragmentary GFP may not be disseminated broadly in this mouse distinct from functional DTR, as treatment ablates all reactivity to the polyclonal GFP antibody (although fragmentary GFP may also be
Figure 4.2. DT administration induces effective depletion of *AireDTR* transgene-expressing cells in the thymus and secondary lymphoid organs. (a) Flow cytometric analysis of Percoll-light stromal fractions from thymi treated for two days as indicated, pre-gated for FSC/SSC, CD45-low, and DAPI-negative status. (b) Flow cytometric analysis of Percoll-light stromal fractions in (a) pre-gated just for FSC/SSC and DAPI-negative status. (c) Flow cytometric analysis of the same mice as (a) showing lymph nodes. (d) Immunofluorescent staining of thymus and lymph node frozen sections from *AireDTR* mice treated for two days as indicated; stained for GFP (green) and Aire (red; thymus only).
Figure 4.2

(a) WT + DT vs. Adbig + DT

Thymus

WT + DT

AIRE DTR + dH2O

AIRE DTR + DT

Lymph Node

WT + DT

AIRE DTR + dH2O

AIRE DTR + DT

(b) WT + DT vs. Adbig + DT

(c) WT + DT vs. Adbig + DT

(d) No Tx vs. DT

thymus

lymph node
present but simply lost during staining). Finally, immunofluorescent anti-Aire staining in the thymus indicated that in addition to a complete absence of GFP in DT-treated *AireDTR* mice, we were also largely unable to detect Aire protein after two days of treatment (Fig. 4.2d), suggesting that the transgene is inducing depletion of essentially all endogenous Aire-expressing cells. Thus, the *AireDTR* construct appears to be faithfully expressed in mTECs and eTACs, and exposure to DT rapidly and completely depletes both cell populations.

**Pharmacokinetics of DT administration**

Validation of both transgene expression and efficacy of deletion in the *AireDTR* mouse suggested that the mouse might provide an appropriate tool for further studies of Aire-expressing cells. Before proceeding to longitudinal depletion experiments, dose-response titrations, mTEC and eTAC regeneration kinetics, and serum anti-DT antibody resistance kinetics were evaluated.

First, dose-response experiments were conducted to define the minimum dose required to achieve complete depletion of Aire-expressing mTECs and eTACs. Complete depletion in the thymus proved to require a higher dose than similar depletion in the periphery (data not shown), and therefore complete depletion in the thymus was used as the minimum standard for dose-response experiments. Treatment of *AireDTR* mice with a range of concentrations indicated clearly that an intermediate dose (25ug/kg) achieved maximal depletion (Fig. 4.3a), and that higher doses of 50 or 100ug/kg did not confer
Figure 4.3. Kinetics of DT depletion and recovery. (a) Flow cytometric analysis of AireDTR thymi treated with the indicated doses of DT (ug/kg) for two consecutive days prior to analysis; pre-gated on FSC/SSC, CD45-low, and DAPI-negative. Numbers next to the gate indicate cell number in the gate. Graph shows number of GFP+ cells relative to an untreated AireDTR mouse as a function of DT dose. (b) Number of GFP+ cells in the thymus, spleen, and lymph nodes of AireDTR mice as a function of time (days) after ending two days of depletion with 50ug/kg DT, displayed relative to the number observed in an untreated AireDTR mouse. (c) Immunofluorescent staining of AireDTR thymi treated continuously every other day for indicated times with 50ug/kg DT for cytokeratin 8 (K8; red) and GFP (green).
Figure 4.3

**a**

- WT: 2
- No Tx: 127
- 3 µg: 35
- 6 µg: 20
- cell # in gate: 12.5, 25, 50, 0

**b**

- Thymus (black)
- Spleen (red)
- LN (blue)

**c**

- Day 13
- Day 17

K8/GFP
any additional benefit. Thus, for future experiments and for longitudinal disease studies, we believe 25ug/kg is an appropriate dose for complete depletion of mTECs and eTACs in the AireDTR mouse.

The kinetics of mTEC and eTAC regeneration after complete depletion were also studied to determine the required frequency of dosing. Mice were dosed for two consecutive days and then analyzed consecutively by FACS for GFP-expressing mTECs and eTACs. Surprisingly, mTEC recovery in the thymus was extremely rapid, with restoration of near-normal numbers of GFP+ cells by day three post-depletion, and an “overshoot” excess of cells at day five that normalized by day seven (Fig. 4.3b). These results are generally consistent with, though slightly more rapid than, the recovery seen in cyclophosphamide-induced Aire+ mTEC depletion (8). In the spleen and lymph nodes, eTAC recovery was much more gradual, and even by seven days post-depletion we observed only partial restoration of GFP signal (Fig. 4.3b). These results indicate that frequent dosing may be required to achieve continuous depletion of mTECs, while eTACs ablation might be maintained by more widely spaced dose intervals. Furthermore, they suggest that Aire-expressing mTECs repopulate the thymus more quickly than eTACs do in the periphery. It will be of interest to determine whether this difference reflects simply the higher levels of Aire (and thus transgene) expression in mTECs, or perhaps suggests something about either the rate of division and differentiation, or even the anatomic location, of the progenitor cells for each population.
Finally, serial treatment of *AireDTR* mice was undertaken to determine the maximum treatment duration before the development of functional anti-DT blocking serum antibodies. Because of the rapid recovery of GFP+ mTECs, we used immunofluorescent thymic GFP signal as a readout for loss of DT efficacy. Mice were treated continuously at 50ug/kg on alternating days, and thymic GFP expression remained completely undetectable for up to thirteen days. However by day 17, we observed the re-emergence of some GFP+ cells in cytokeratin(K8)-negative regions (Fig. 4.3c), suggesting that the effective treatment window for complete ablation in adult mice at this dosage may be approximately two weeks. The calculation of this effective window should likely be repeated, however, in part because lower dosing (25ug/kg) may alter the development of resistance. Furthermore, there is some controversy over the degree to which serum anti-DT antibodies are reported to interfere with DT function (9). Together these results indicate that complete ablation of *Aire*-expressing cells in *AireDTR* mice requires frequent dosing at 25ug/kg, which can effectively deplete these populations for a window of approximately two weeks. To extend this effective window in future experiments we may also consider using IgH-knockout mouse strains or bone marrow or antibody-mediated B cell depletion.

**Unique thymic structural phenotype observed after prolonged depletion of Aire+ mTEC**

In addition to the expected loss of GFP+ *Aire*-expressing mTECs, the continuous DT-treatment of *AireDTR* mice led to an unexpected thymic structural phenotype.
Cytokeratin 5 (K5) and cytokeratin 8 (K8) normally demarcate medullary and cortical thymic epithelial regions, respectively (Fig. 4.4a), and we therefore used these markers while monitoring re-emergence of GFP expression in DT-treated thymi to ensure that we were indeed examining medullary regions in each section. While K5/GFP staining in AireDTR thymi DT-treated for just one day showed an essentially normal thymic architecture with an absence of GFP+ cells, AireDTR thymi treated for nine days had a distinctly altered cytokeratin distribution, with a nearly complete absence of cytokeratin 5-positive cells (or any cytokeratin-positive cells) in the putative medullary regions (Fig. 4.4a). These large medullary “holes,” essentially devoid of epithelium, were nevertheless filled with thymocytes, and indeed remained enriched for CD11c+ DCs, suggesting that they retained some medullary characteristics (Fig. 4.4b). Indeed those few K5-expressing cells remaining after prolonged DT treatment appeared to cluster in subcapsular regions at the outer edge of the medulla, an atypical site for K5 expression.

FACS analysis confirmed that prolonged treatment of AireDTR mice for nine days led to significant depletion of UEA-1+ Ly51-negative cells, general markers of medullary epithelium (Fig. 4.4c). Together these results suggest that prolonged treatment of AireDTR mice with diphtheria toxin leads to the near-complete absence of thymic medullary epithelium. Given that Aire is only thought to be expressed in ~30-40% of mTECs (7, 10, 11), and furthermore only in terminally differentiated, putatively postmitotic mTECs (10), it was a surprise to observe such complete medullary epithelial depletion after a modest period of DT treatment. This absence of medullary epithelium
Figure 4.4. Continuous depletion of Aire-expressing cells in the thymus induces complete loss of medullary epithelium and architecture. (a) Immunofluorescent staining of thymi from indicated mice for cytokeratin 5 (K5; red) and cytokeratin 8 (K8; green). (b) Immunofluorescent staining of thymi from indicated mice for K5 (red, top panels), K8 (green, top panels) and of serial sections for CD11c (red, bottom panels) and CD4 (blue, bottom panels). (c) Representative flow cytometric analysis of indicated thymi, pre-gated as FSC/SSC, CD45-low, and DAPI-negative, and stained for the epithelial antigen EpCAM and with a medullary epithelium-specific agglutinin UEA-1. Numbers indicate percent of parent.
Figure 4.4

a  \hspace{1cm} AireDTR+ 1 day DT \hspace{1cm} AireDTR+ 9 days DT

b  \hspace{1cm} WT + 9 days DT \hspace{1cm} AireDTR+ 9 days DT

c  \hspace{1cm} WT \hspace{1cm} WT+DT \hspace{1cm} AireDTR+DT

\begin{center}
\begin{tabular}{ccc}
\textbf{WT} & \textbf{WT+DT} & \textbf{AireDTR+DT} \\
5.74 & 5.88 & 1.02
\end{tabular}
\end{center}
led us to question whether such architectural changes also had an impact on thymocyte maturation.

Thymocyte profile in “amedullary” *AireDTR* thymi is globally intact, with reduced percentages of FoxP3+ cells

The near-complete absence of medullary epithelium in *AireDTR* mice treated for nine days with DT led us to believe that thymocyte maturation might be impacted in these mice. Despite these massive architectural changes, however, to our surprise the global distribution of single-positive and double-positive CD4+ and CD8+ T cells was indistinguishable between wildtype and *AireDTR* mice treated with PBS or DT for this same period (Fig. 4.5a). Likewise, progression of thymocytes through the DN1-DN4 stages appeared unaltered (data not shown), although being a primarily cortical phenomenon (12), this is perhaps expected. Despite these global similarities, thymocyte development in DT-treated *AireDTR* thymi was notably distinct from controls in that the percent of FoxP3+ regulatory T cells among single-positive CD4+ T cells was decreased (Fig. 4.5b). Consistent with this, the percentage of CD25+ cells among CD4 single-positive cells was also decreased (Fig. 4.5b). These data suggest that the absence of medullary epithelium may lead to a relative deficiency in thymic Treg frequency. Multiple factors could of course influence these ratios, including failure of Treg development, increased Treg death or egress, or increased retention, development, or proliferation of non-regulatory single-positive CD4 T cells. However given the existing evidence
Figure 4.5. Thymocyte profile is globally normal in “amedullary” AireDTR thymi, but shows decreased CD4+ Tregs. (a) Flow cytometric analysis of thymocytes from indicated mice stained for CD4 and CD8; treated mice had been treated continuously every other day for 9 days with 50μg/kg DT. Top and bottom rows are duplicate mice in each group. (b) Flow cytometric analysis of thymocytes in (a), pregated on CD4+, CD8- T cells and stained for FoxP3 (top) or CD25/CD44 (bottom). Numbers indicate percent of parent.
Figure 4.5

(a) WT, WT+DT, AireDTR+DT

(b) WT, WT+DT, AireDTR+DT
suggesting that self-antigen expression in Aire-expressing mTECs promotes Treg development (13), it is conceivable that the complete lack of mTECs directly impedes Treg development. Further, because we have observed this phenomenon after only a short period of mTEC absence, it is possible that the phenotype will be more exaggerated after prolonged absence of these populations. With proper validation, we believe this system could serve as the first functional model to study thymocyte development in the absence of mTECs.

**Treatment of AireDTR cohorts: preliminary data**

We next investigated whether continuous treatment of AireDTR mice would predispose to autoimmunity. Because DT resistance appears to develop after approximately two weeks of treatment, because of the nonspecific DT toxicity, and because of the data suggesting that Aire’s most significant role may be in the perinatal and neonatal time period (14), we attempted to treat an initial litter of AireDTR+ and AireDTR− mice every other day from birth to weaning (day 21). However despite reports suggesting that this higher dosing (50ug/kg every other day) was tolerable in neonates (2), this entire cohort rapidly lost weight after ~10 days regardless of genotype, and was euthanized by day 18 (data not shown). We then treated a second cohort of mice beginning at day 7 and continuing through day 21 with the same regimen, and these mice survived the treatment, although weight gain was uniformly and measurably retarded until treatment was discontinued (Fig. 4.6a, arrows).
Figure 4.6. AireDTR NOD mice treated with DT from weeks 1-3 do not show growth retardation or mortality but are predisposed to autoimmunity. (a) Mean weight values for cohorts of wildtype (blue) and AireDTR (red) mice treated as described. Arrows indicate the start and end of the treatment window. (b) Flow cytometric analysis of peripheral lymphocytes from the cohorts described in (a), pre-gated as lymphocytes (FSC/SSC) and CD4+, and stained for CD44 and CD62L (top) or CD4/FoxP3 (bottom). Numbers indicate percent of parent; bar graphs show mean and SD values for the entire cohort. (c) Hematoxylin and eosin-stained lacrimal glands from indicated mice and collected scores from the entire cohort assigned values 0-4 by trained and blinded observer.
Figure 4.6

(a) Weight (g) vs. Age (days) for WT and AireDTR+ mice.

(b) Flow cytometry analysis of CD62L and CD44 in WT and AireDTR mice. The graphs show the percentage of CD62L low, CD44 high cells, with significant differences indicated by p<0.01.

(c) Lacrimal infiltrate score comparison between WT and AireDTR mice, with a significant difference indicated by p<0.05.
Treated wildtype and AireDTR mice remained indistinguishable with regard to weight gain even when aged to >100 days (Fig. 4.6a), but organs were harvested from these mice at 13 weeks, and lymphocytes stained for activation markers and for FoxP3 expression. Surprisingly, AireDTR+ mice uniformly showed elevation in the percentages of activated CD62L-low, CD44-high cells among total CD4+ populations, and also showed elevation in the percentage of FoxP3+ cells among CD4s (Fig. 4.6b). This suggested that perhaps these mice were experiencing some underlying autoimmunity not manifesting in weight loss or overall mortality. We did, however, notice erythematous inflammation around the eye of one AireDTR mouse. Consistent with this, preliminary examination of tissue histology confirmed that the AireDTR mice in this cohort experience significant lymphocytic infiltration and destruction of the lacrimal glands (Fig. 4.6c). Other organ histology has been unremarkable to date, but while the full range of tissue damage in this model is not yet clear, we will eagerly anticipate further phenotyping of the nature and spectrum of potential autoimmunity in these mice. Taken together, we believe these very preliminary findings suggest the AireDTR mouse may serve as a novel and informative model of autoimmunity, and may shed light on the contribution of both mTECs and eTACs to the maintenance of self-tolerance.

**Discussion**

Here we have described the development and initial validation of the AireDTR mouse, and while this work is still preliminary, we hope this tool will be useful in a broad range
of future immunologic inquiry. Transgene expression in the *AireDTR* mouse appears to faithfully recapitulate *Aire* expression in mTECs and eTACs, and administration of DT leads to rapid and complete depletion of both populations.

In addition to the expected depletion of *Aire*-expressing mTECs, we were surprised to discover that prolonged DT treatment led to the complete loss of thymic medullary epithelium and a broad disorganization of thymic architecture. A wide range of possibilities could account for this phenomenon, some of which could be artifactual, while others might have significant implications for our understanding of mTEC development and biology. First, it is possible that this phenomenon is simply an artifact of the system. The synchronized death of 30-40% of the mTEC population in an adult thymus may interrupt thymic architecture, as mTECs interact with one another in a three-dimensional network that might be significantly interrupted by such absences. Similarly, the high local concentration of dying cells after DT treatment may be toxic to neighboring mTECs, causing bystander toxicity (though this seems less likely given that Aire expression itself may induce apoptosis in mTECs (10), and moreover given the abundant thymocyte cell death normally occurring in the medulla). A related possibility is that Aire-negative mTECs may acquire functional DTR from dying Aire-positive mTECs, and thus acquire DT-sensitivity for the next treatment. In support of this, autophagy has been shown to play a significant role in mTEC biology (15), but it is unclear that such a mechanism would be able to account for such a rapid and complete depletion of all mTECs, or that DTR acquired through autophagy would retain
functionality. Likewise, the iterative depletion of Aire-expressing mTECs could also gradually eliminate all mTECs simply by depleting the precursor pool through repeated rounds of deletion and repopulation. For example, if loss of Aire-expressing mTECs induces transit-amplifying precursors to rapidly and repeatedly differentiate into Aire-expressing cells, and then these cells themselves are killed, this situation could eventually deplete earlier and earlier stages of mTECs. A more interesting possibility is that Aire-expressing mTECs may play some instructive role in organizing and specifying medullary epithelial differentiation or localization, either by direct cell-cell contact or by local secretion of organizing or trophic factors. Finally, it remains possible that Aire expression is not in fact a hallmark of terminally differentiated mTECs, but identifies a precursor population whose loss leads to the depletion of Aire-negative daughter mTECs. While it is beyond the scope of this chapter to fully pursue and distinguish such lines of inquiry into mTEC development, we believe these are interesting and important questions, and believe that a number of these possibilities might be readily differentiated through experiments ranging from description of the fundamental kinetics and phenotyping of mTEC populations that recover after DT withdrawal (and their relationship to Aire-reporter expression), to attempts at rescue by mixed reaggregate fetal thymic organ culture (RFTOC). The proper characterization of these phenomena could shed significant light on medullary epithelial development and its relationship to Aire expression, and we eagerly anticipate these developments.
These results also suggest that DT-treated AireDTR mice can progress to develop autoimmunity. However the nature of this autoimmunity, both in terms of its extent and its pathogenesis, remains obscure. “Amedullary” AireDTR thymi have a relative deficiency of CD25+ FoxP3+ regulatory T cells, indicating that in the absence of mTECs these regulatory populations may fail to develop properly. Further, the treatment of AireDTR mice from weeks 1-3 appears to predispose to autoimmunity, as revealed through increased peripheral lymphocyte activation (CD44hi, CD62Llow) and an increased frequency of regulatory T cells among CD4+ T cells. This is further supported by the preliminary finding that AireDTR mice display increased lymphocytic infiltration and destruction of the lacrimal glands, indicating that the loss of Aire-expressing cells directly or indirectly predisposes to autoimmunity. Moving forward, TCR-transgenic systems specific for Aire-regulated and non-regulated thymic antigens should be of significant future value in dissecting the impact of loss of mTECs on thymocyte selection. The use of Rag-GFP reporter mice might also be useful for future thymocyte selection experiments to identify and track recent thymic emigrants after mTEC ablation, particularly when combined with such TCR-transgenic systems.

While this novel mouse model clearly presents manifold tantalizing future directions for experimentation, we are specifically interested in examining the role of eTACs in normal immune homeostasis. The AireDTR transgene is currently being crossed to the NOD FoxN1-deficient (“Nude”) mouse strain, which fail to develop endogenous thymi that can support T cell maturation. As we refine the autoimmune
phenotype observed in DT-treated *AireDTR* mice, it will be useful to map this phenotype to specific *Aire*-expressing populations. Reciprocal transplantation of wildtype or *AireDTR*+ thymi into wildtype Nude or *AireDTR*+ Nude recipient mice will allow us to selectively deplete mTECs, eTACs, or both in selected mice. Similarly, thymectomy and simultaneous reciprocal thymic transplantation between wildtype and *AireDTR* mice is being employed to achieve similar results. As a technical note, in the latter experiment it will likely be useful after thymectomy and thymic transplantation to lethally irradiate and reconstitute these mice, and to DT-deplete during reconstitution, as a requirement for systemic Aire in adult mice can be revealed by irradiation-induced lymphopenia (14). If prolonged DT depletion is required in this setting, it may also help to reconstitute these mice with IgH-/− bone marrow in place of wildtype. Finally, as we have not ruled out the possibility that eTACs are a radioresistant but hematopoietic population, reciprocal bone marrow chimeras could also be useful in such mapping studies. Given that DT-treated *AireDTR* mice develop a predisposition to autoimmunity, it will now be of interest both to try and extend treatment to exaggerate this phenotype, and to map this phenotype to specific populations of *Aire*-expressing cells.

Finally, the *AireDTR* mouse may provide a valuable tool for studying eTAC-mediated TSA expression and T-cell tolerance to such endogenous antigens. Recent evidence has suggested that a number of TCR-transgenic T cell lines become tolerized to self in the secondary lymphoid organs ((16, 17), N. Wada, personal communication). While eTACs are a potential source of such tolerance induction, this has not yet been
demonstrated and it remains possible that other populations are the source of these antigens. For those cognate antigens whose expression is detectable in eTACs, however, the *AireDTR* mouse may allow us to test whether tissue-specific self-antigen expression in the secondary lymphoid organs is dependent on the presence of eTACs, and moreover whether this population is necessary to maintain peripheral tolerance to such antigens.

Speculation regarding future research directions for this system could, of course, continue indefinitely. We are hopeful that the development and validation of this mouse as a model for mTEC and eTAC development, thymic selection, tissue-specific antigen-expression, and immune tolerance will afford significant future insight into immune homeostasis.

**Methods**

Transgene construction, BAC recombineering, and purification

*Aire*-driven Diphtheria Toxin Receptor-EGFP (*AireDTR*) transgenic mice were generated by standard cloning methods using a bacterial artificial chromosome (BAC) recombineering and transgenesis strategy. Briefly, the DTR-EGFP sequence was amplified from the pCD11c-DTR-EGFP vector using the primers 5’-TTAATTTAAGGACCATGAAGCTGCTGC-3’ and 5’-CGCGGCCGCTTTACTTGTA-3’. This PCR products was sub-cloned into pCR-Blunt II TOPO vectors (Invitrogen), sequenced, then digested with PacI and NotI and inserted into pAireFNF.

This targeting construct, pAireFNF-DTR-EGFP, was then inserted via standard recombineering (18) into a BAC clone from the Children’s Hospital of Oakland Research Institute (CHORI) BACPAC Resource Center, clone 461e7 from the RPCI 23 Mouse BAC Library, as described in the previous chapter.
Highly purified i-BDC-Aire BAC DNA was carefully prepared as described in the previous chapter and evaluated for integrity by KpnI digestion and gel electrophoresis. Resuspended BAC DNA was injected into fertilized NOD oocytes by the UCSF Mouse Transgenic Core with the assistance of H. Lu and N. Killeen.

**Mice and genotyping**

*AireDTR* transgenic NOD mice were screened by real-time PCR using the primers 5’-CTGCTGCCCAGACACCA-3’ and 5’-TGTGATCGCTTTCTCGTT-3’ and the probe Cy5-TACCTGAGCCAGTCGCCCCT-BHQ along with an endogenous control reaction for CD86 using the primers 5’-CTTGATAGTGAATGCCAAGTACCT-3’ and 5’-TGATCTGAACATTTGTAAGCTGTA-GA-3’ and the probe FAM-CGCACGAGCTTTGACAGGAACACT-TAMRA. This same reaction was used to genotype *Adig* and *Adbig* mice, as it detects genomic GFP present in both transgenes. The *AireDTR* transgene was maintained in heterozygosity for all experiments.

**Preparation of stroma and lymphocytes for flow cytometry**

Preparation of lymphocytes and stroma, antibody staining, and flow cytometry were performed as described (7). FACS data was acquired on LSR II and FACSCalibur flow cytometers (BD), and data was analyzed using FloJo 7.2.4 (TreeStar).

**DT-Mediated Depletion of mTECs and eTACs**

Depletion of *Aire*-expressing cells in *AireDTR* mice was achieved by intraperitoneal injection of diphtheria toxin (Sigma) at the doses indicated in each experiment (25-50ug/kg in PBS). Mice were monitored by weight during administration and were sacked or treatment was discontinued if they experienced significant weight loss.

**Statistical Analysis**

Statistical analysis of data was performed with Excel 2003 (Microsoft) and Prism 4.0 (GraphPad). Statistical comparisons were made using a Student’s two-tailed T-test, and results with p<0.05 were considered statistically significant.
Histology, immunofluorescent staining and quantitation

All primary and secondary antibodies for histology were purchased from AbCam, BD Pharmingen, Invitrogen, Jackson, or eBioscience, with the exception of the anti-AIRE antibodies 5C-11 and 5H-12, which were gifts of H. Scott. For AireDTR mice, organs were harvested from experimental animals and embedded in Tissue-Tek Optimal Cutting Temperature (OCT) media (Fisher), then processed as described (7). Slides were mounted in Vectashield mounting medium (Vector Laboratories) and visualized with an SP2-AOBS Confocal Microscope (Leica). Images were acquired using Leica Confocal Software (Leica), and analyzed and merged in Photoshop CS3 (Adobe). Linear contrast adjustment was applied equally to all samples and controls. For hematoxylin and eosin staining of pancreatic sections, tissues were fixed as described in Chapter III. Tissue infiltrate scores were assigned by a trained and blinded observer.

References


Chapter V

Discussion
The maintenance of self-tolerance in the adaptive immune system requires the coordination of multiple overlapping mechanisms to prevent the escape and activation of autoreactive clones. While the notion of selective immune education as a component of self-tolerance is as old as clonal selection theory (1) the paradigm that centralized sites of T-cell education might be specifically engineered to express the diversity of an organism’s entire transcriptome, and that such broad self-expression might be essential to the prevention of autoimmunity, is much more recent. Lines of evidence ranging from tissue-specific promoter expression studies (2, 3) to TCR-transgenic deletion data (4, 5) to real-time PCR analysis (6) had suggested for some time that the thymus was a site of immunologically relevant TSA expression, but the Aire-knockout mouse codified for the first time this idea that deficiencies of such thymic TSA expression could be directly linked to autoimmunity in both mice and humans (7-9).

In this context, it is tempting to draw parallels with recent reports describing TSA expression in the secondary lymphoid organs. Preliminary studies employing tissue-specific antigen reporters (10), TCR-transgenic systems (11), and RT-PCR data (12) have now begun to suggest that TSA expression may also be a hallmark of the secondary lymphoid system. Likewise, Aire expression has been reported outside the thymus (8, 10, 13), although the populations involved, the presence and role of Aire in these cells, and their potential function has remained unclear.

Here we have identified a population of extrathymic Aire-expressing cells in the secondary lymphoid organs. We have demonstrated that such cells express Aire and a
host of Aire-regulated TSAs, and can interact with both CD4+ and CD8+ T cells. Further, we have shown that eTAC-T cell interactions lead to T-cell tolerance and prevent T cell-mediated autoimmunity, and that such antigen-expressing eTACs are uniquely resistant to conversion from tolerance to immunogenicity. Finally, we have recently developed a novel AireDTR mouse model which may help define the role of eTACs (and mTECs) in the normal maintenance of immunologic tolerance. In this discussion we will briefly summarize the findings described in the previous chapters, and then discuss some of the implications and complications of this work, as well as suggest future directions for this research.

**eTACs exist in the secondary lymphoid organs and express diverse TSAs**

In chapter two, we described the identification of extrathymic Aire-expressing cells (eTACs) that definitively express both Aire transcript and Aire protein, and found that as in the thymus, Aire protein in these cells was detected in characteristic nuclear speckles. By surface marker phenotyping this population appears broadly homogeneous, and shares some similarity with mTECs (MHCII-hi, CD45-low-intermediate, EpCAM+) but also some differences (absence of CD80, CD86 and presence of ICOS-L on eTACs). eTACs also appear to be distinct from other APCs like B cells (B220-negative), dendritic cells (CD11c-negative), macrophages (CD11b-negative, F4/80 negative; data not shown), or from stromal populations like FRCs (gp38-negative) or FDCs (CD35-negative, FDC-
M2-negative; data not shown). This population is also radioresistant, though this does not preclude it being hematopoietic in origin as we will discuss.

Microarray analysis reveals that eTACs express a number of genes characteristic of antigen-presenting cells, and sorting eTACs from Aire-wildtype and -knockout animals identified a role for Aire in regulating gene expression in these cells. As in mTECs, the set of Aire-regulated genes in eTACs appeared significantly enriched for TSAs, though surprisingly this set of Aire-regulated TSAs in eTACs was unique from those seen in mTECs. Finally, the transgenic expression of a pancreas-specific autoantigen, IGRP, in eTACs allowed us to examine interaction of eTACs with autoreactive IGRP-specific CD8+ TCR-transgenic T cells, which engaged in immediate and prolonged contact with eTACs, causing T-cell proliferation followed by deletion.

These results suggested that eTACs were a distinct population of Aire-expressing cells capable of expressing a diverse repertoire of self-antigens, and that naïve autoreactive CD8+ T cells encountering such self antigen-expressing eTACs might be induced to die after aberrant activation. Despite these results, we wondered whether such self-antigen expression in eTACs would be sufficient to directly prevent autoimmunity. Further, we questioned whether such aberrant T cell activation was a distinct feature of eTACs per se or would be observed if the same antigen were expressed in any cell, and whether eTACs, expressing high levels of MHC II, could also interact with CD4+ T cells like other professional APCs. Thus we examined the ability of self antigen-expressing eTACs to directly prevent autoimmune disease mediated by both CD4+ and CD8+ T cells.
eTAC interactions with T cells are tolerogenic and prevent autoimmunity

To directly study eTAC-CD4+ interactions we generated transgenic Adbig mice expressing p31, a mimetope antigen for the BDC2.5 pancreas-specific CD4+ TCR-transgenic T cell, under transcriptional control of the Aire promoter. As in the eTAC-CD8+ system we observed direct interaction between eTACs and BDC2.5 CD4+ T cells which persisted even when mice were irradiated and reconstituted with MHCII-/ bone marrow. This interaction caused similarly rapid and antigen-specific proliferation, but unlike eTAC-CD8+ interactions, eTAC-BDC2.5 interaction led to the persistence of significant residual CD4+ T cell populations. These residual T cells were functionally unresponsive to secondary immunization, and were also enriched for FoxP3-expressing T cells. Importantly, this interaction also led to protection from BDC2.5-mediated adoptive transfer of diabetes in SCID mice.

Serial cotransfer experiments revealed that the tolerance induced among BDC2.5 T cells was stable and did not require continuous eTAC interaction or the presence of regulatory T cells, suggesting that functional inactivation of effectors may be a primary mechanism. Efforts to break this disease protection through perturbations known to convert other characterized peripheral tolerance mechanisms to immunogenicity (lymphopenia, CD40/TLR stimulus, PD-L1 blockade) were unsuccessful. This tolerance induction also appeared to be a cell type-specific function of eTACs, as antibody-mediated targeting of a BDC2.5 mimetope peptide to an independent APC population,
DEC205+ DCs, resulted in similar T-cell proliferation in all secondary lymphoid organs but failed to induce T cell-unresponsiveness or prevent BDC2.5-mediated autoimmunity, and if anything seemed to prime these responses. Finally, returning to examine eTAC-CD8+ interactions in the Adig mouse, we found that IGRP-expressing eTACs induced deletion of endogenously developing 8.3 T cells, and that these interactions prevented 8.3-mediated diabetes. Together these results suggest that self-antigen expression in eTAC induces robust tolerance in both CD4+ and CD8+ T cells.

The *AireDTR* mouse: a tool for the study of immune tolerance

To help define the role of eTACs and mTECs in the immune system, we recently generated a novel *AireDTR* mouse which allows us to selectively deplete these populations by administration of diphtheria toxin (DT). Validation suggested that the transgene permits effective and specific depletion of these populations, though the window of depletion may be limited by nonspecific DT toxicity and by the development of anti-DT antibodies. Interestingly, prolonged depletion of *Aire*-expressing mTECs leads to a nearly complete absence of thymic medullary epithelium and a disruption of thymic architecture, along with a relative deficiency of FoxP3+ regulatory cells. Treatment of young *AireDTR* mice from weeks 1-3 of age also leads to a mild autoimmune phenotype still being characterized which includes increased lymphocyte activation and regulatory cell numbers, as well as lymphocytic infiltration and destruction of the lacrimal glands. These results suggest that the loss of *Aire*-expressing cells
predisposes to autoimmunity, and it will be of significant future interest to define and expand this phenotype.

The apparent ablation of all mTECs in continuously treated DT-treated thymi could be instructive to rigorously define the stages of mTEC development (after DT treatment is stopped and these cells repopulate the medulla) and gain insight into the role that \textit{Aire}-expressing mTECs play relative to the general medullary epithelium. Additionally, because these “amedullary” mice appear to exhibit a relative defect in FoxP3+ Treg development, this model could provide significant insight into the role of CD4+/mTEC interaction in this process. Finally, we believe it will be helpful to expand and define the nature of autoimmunity in these mice by treating younger mice and for longer periods of time with the properly titrated (25\textmu g/kg) dosing. Given that we observed uniform T-cell activation and autoimmune destruction of at least one organ system after ablating from weeks 1-3, we expect that longer dosing might yield a more pronounced phenotype.

With regard to eTAC function, we are currently using both Nude (FoxN1-/-) and thymectomy/thymic transplant approaches to generate mice that selectively express the AireDTR construct only in mTECs or eTACs. Lethal irradiation and reconstitution of these mice with either wildtype, IgH-/- (if longer treatment is desired), or AireDTR (if depletion of hematopoietic cells is desired) bone marrow will allow us to map this autoimmune phenotype to specific compartments, and may also exaggerate the autoimmunity as such radiation-induced lymphopenia has been shown to reveal Aire-
sensitivity in adult mice (14). Finally, we hope to combine this AireDTR system with an appropriate TSA-specific TCR-transgenic model that undergoes negative selection in the secondary lymphoid organs, to determine whether eTACs play a role in this process. One such candidate system using T cells specific for desmoglein 3 (the autoantigen in pemphigus vulgaris, (15)) is currently being investigated for these purposes.

The mechanism of eTAC-mediated T-cell tolerance
While eTAC interaction appears to induce tolerance in both CD4+ and CD8+ T cells in this system, it remains unclear whether the same mechanism applies to both cell populations. One primary difference is the outcome of eTAC encounter for the T cell. Whereas CD8+ T cells appear to be largely deleted by two weeks post-transfer, significant residual populations of CD4+ T cells remain that are either functionally inactive or FoxP3+ regulatory T cells. This divergence may reflect the nature of CD4+ and CD8+ T cells themselves, the differential affinities for their relative ligands, or something fundamental about the nature of the signals delivered to CD4+ versus CD8+ T cells during eTAC interaction.

Another notable difference between these two cell types after eTAC encounter is the effect on CD90 expression. Unlike 8.3 CD8+ T cells, eTAC-experienced BDC2.5 CD4+ T cells undergo significant downregulation of the congenic CD90.1 marker during proliferation. This phenomenon appears to persist even two weeks post-transfer when BDC2.5 T cells have completely diluted CFSE, although the degree of downregulation is
difficult to assess as we lose the ability to track cells that may have downregulated their congenic marker to the degree that they become indistinguishable from the general lymphocyte pool. However this phenomenon appears to be eTAC-specific, as BDC2.5 proliferation in response to anti-DEC1040-loaded dendritic cells does not produce similar CD90 downregulation, despite similarly rapid proliferation. The role of CD90 remains somewhat obscure, and the immunologic phenotype of the CD90 knockout mouse has been considered mild with only slight impairment in T-cell proliferation and cytokine production (16). But the fact that this phenomenon is both eTAC-specific (i.e. not observed when BDC2.5 T cells interact with DEC205+ DCs) and preferentially seen in the non-regulatory, functionally inactive effector populations (i.e. not observed to the same degree in BDC2.5 T cells undergoing proliferation that express FoxP3) suggests that it could have some functional relevance. To our knowledge, this is a novel phenotype for proliferating T cells and we are not aware of the same phenomenon observed outside the context of eTAC encounter. It may be of significant future interest to further characterize this phenomenon.

The absence of the canonical costimulatory molecules CD80 and CD86 on eTACs may also contribute to this tolerance induction. TCR ligation in the absence of costimulation has classically been associated with T-cell anergy (17, 18), has been speculated to play a role in tolerance mediated by tolerogenic, immature DCs (19) and could therefore certainly contribute to eTAC-mediated tolerance. Although we are unable to induce CD80 upregulation on eTACs through conventional DC-stimulatory
means, *in vitro* culture of sorted eTACs from *Adig* or *Adbig* mice with cognate T cells in
the presence or absence of anti-CD28, followed by a secondary culture with peptide-
pulsed APCs, might suggest whether provision of an artificial second signal converts this
primary interaction from tolerance to activation. However one preliminary result runs
counter to this hypothesis. Reasoning that if eTAC-mediated CD4+ tolerance in the
*Adbig* mouse was a result of absence of costimulation, we first *in vitro* activated BDC2.5
T cells prior to transfer believing that such activated T cells would bypass such a
requirement. To our surprise, despite the clear evidence for successful *in vitro* activation
by cell number, size, and activation markers, and the fact that activated BDC2.5 T cells
transferred accelerated disease into wildtype SCID mice (2 mice) even more rapidly than
naive BDCs (~5 days vs. ~10), *Adbig* SCID mice (2 mice) were entirely protected from
disease, and histology showed that their islets remained free of infiltrate (data not
shown). While this does not rule out the possibility that absence of costimulation induces
tolerance in this model, it also suggests that an independent mechanism might be
operating to prevent such *in vitro* activated T cells from reaching the target organ or
cause disease.

Finally, the complete lack of pancreatic T-cell infiltration in *Adbig* SCID adoptive
transfer recipients despite the massive mobilization of BDC2.5 T cells into the blood also
suggests that there may be a defect in leukocyte vascular adhesion or trans-endothelial
migration after eTAC encounter. To this end it will be interesting to determine whether
eTAC-stimulated BDC2.5 T cells show differential expression of relevant adhesion
molecules (e.g. PSGL-1, CD18, VLA-4, CD44) relative to control (e.g. anti-DEC1040-stimulated) BDCs, or whether they might behave differently in *in vitro* or *in vivo* capture, rolling, firm adhesion, or transmigration assays. While the mechanism of eTAC-mediated tolerance in both the CD4+ and CD8+ T cell systems remains unclear, investigation of these phenomena may provide insight into novel pathways involved in T-cell tolerance.

**eTACs and Tregs**

Despite the clear results indicating that FoxP3+ cells are not required for eTAC-mediated tolerance induction of BDC2.5 T cells, the relationship between eTACs and regulatory T cell development remains of significant interest. Particularly given the enrichment for FoxP3+ cells after eTAC encounter among Treg-depleted BDC2.5 T cells, and the selective lack of CD90 downregulation on these regulatory populations, such interactions may be of physiologic significance. Much work is needed, however, to define the nature of these interactions. For example, it is currently unknown whether the FoxP3+ BDC2.5 cells that emerge after eTAC interaction in the *Adbig* mouse have acquired functional suppressive ability, and whether they otherwise resemble genuine regulatory T cells. BDC2.5-FoxP3GFP mice might be employed in adoptive transfer into *Adbig* mice to track and sort these populations so that *in vitro* and *in vivo* suppressive activity could be assessed in these populations. Likewise, simple phenotypic analysis, for example GITR upregulation, CD127 downregulation, and CpG methylation
of the FoxP3 promoter, which have been used to distinguish the condition and functionality of FoxP3+ regulatory T cells from associated populations (20), might shed some light on whether these cells represent true regulatory T cells with suppressive activity.

It also remains unclear whether such FoxP3+ cells in this setting are induced from FoxP3-negative effector populations or represent expanded natural Treg contaminants from the original population. Despite effective CD25-pre-depletion of transferred cells (data not shown), some contaminating FoxP3+ cells are certainly cotransferred in these experiments, and could be the cells ultimately constituting this pool of residual FoxP3+ cells. A more rigorous approach would be appropriate before concluding that eTAC interaction directly promotes the peripheral development of induced Treg populations. That said, one appealing possibility for the role of a tolerogenic self-antigen expressing population like eTACs in the secondary lymphoid organs would to promote the selective survival and/or development of regulatory T cells. To this end, the AireDTR mouse may provide a valuable tool to characterize the role of eTACs in this process.

The role of Aire in eTACs

Our results suggest that Aire regulates a set of tissue-specific antigens in eTACs that is distinct from the set regulated in the thymus. Suggestively, this set of TSAs includes a number of autoantigens relevant in human autoimmune diseases, including Dsg1a (pemphigus foliaceus (21)), and Lad1 (linear IgA dermatosis (22)). However the
functional significance of Aire in this population remains unclear. To date we have not found an appropriate model antigen/TCR transgenic system to study Aire-regulated peripheral T cell selection in eTACs in a manner similar to work done in the thymus (23, 24). The future study of Aire’s role in eTACs would be significantly facilitated by such model systems.

Looking more broadly at the role extrathymic Aire may play in maintaining immunologic tolerance, the significant experimental difficulty in directly evaluating the relevance of extrathymic Aire is the challenge of knocking it out selectively outside the thymus. In the absence of a genetic means to target one population (mTECs or eTACs) specifically, we have pursued two transplant-based approaches. The first involved backcrossing the FoxN1 mutation onto the autoimmune-prone NOD background, and then intercrossing with the Aire mutation to generate FoxN1-/- Aire -/- and FoxN1-/- Aire+/+ mice, which could receive thymic transplants. The difficulty in this approach has been purely in breeding, as neither gene will breed as a knockout, and NOD FoxN1-/- mice have not been successfully generated in significant numbers in our colony. Such an approach has clear advantages, however, and may be worth pursuing in a more directed fashion or in collaboration with a mouse colony successfully producing Nude mice.

A parallel strategy has been to attempt to achieve the same ends through thymectomy and thymic transplantation. This approach has significant drawbacks, including considerations of incomplete thymectomy and artifacts related to differences in the pre-thymectomy thymic selection environments, but the former can be partly
addressed by controls and by careful technique, and the latter minimized by crossing
*Aire*-knockout mice onto a T-cell deficient strain (e.g. TCRα-/-), doing thymectomy and
thymic transplantation of TCRα-/- Aire+/+ and TCRα-/- Aire-/- mice, and then
irradiating and chimerising these mice with wildtype (TCRα+/+) bone marrow only after
thymic exchange. While we have been unable to do this experiment in any significant
numbers to date, short of a genetic mechanism it may be the most successful way to
directly study this phenomenon, particularly as irradiation-induced lymphopenia has been
shown to reveal a requirement for functional Aire in adult mice (14). Naturally,
demonstration of a physiologically relevant role for extrathymic *Aire*, particularly related
to the set of peripherally Aire-regulated TSAs, would be of significant interest.

The identity and origin of eTACs

While we have shown eTACs to be a distinct, radioresistant population of cells that
partially resemble mTECs, the precise identity and origin of these cells remains
unknown. As noted in chapter two, we have also seen evidence that some hematopoietic
(or at least bone marrow-derived) cells can express these *Aire* reporter transgenes (Fig.
S2.3), and it may be that eTACs are both radioresistant in nature and hematopoietic in
origin. Given the existing data regarding their potential relevance in immune tolerance, it
will be of real interest to more thoroughly map the ontogeny and precise identity of these
cells. Reciprocal *Adig*/WT NOD bone marrow chimeras and surface marker phenotyping
should be informative to determine whether transgene-expressing bone marrow-derived
cells express characteristic eTAC surface proteins, and immunofluorescent staining should help determine if Aire protein can be detected in any such cells. Similarly, adoptive transfer of congenically labeled 8.3 T cells should demonstrate whether the transgene-expressing cells of bone marrow origin are able to induce deletion of cognate CD8+ T cells. Likewise, experiments in Adbig and Adbig SCID mice should demonstrate whether such hematopoietic cells can induce functional inactivation of BDC2.5 T cells and protect such mice from T-cell mediated autoimmune diabetes. Further characterization of the origin and identity of these cells will be of great interest.

Why eTACs?

More broadly, is there a place for specific TSA-expressing cell populations in the secondary lymphoid organs? On the one hand, the immune system clearly requires overlapping systems to prevent the escape and activation of autoreactive T cells. Furthermore, as the thymus involutes in early adulthood, mTEC-mediated selection presumably begins to play a less significant role in maintaining tolerance among the circulating lymphocyte pool. Thus eTACs might play a role in preventing the development or emergence of autoreactive clones that emerge later in life. Likewise, the secondary lymphoid organs are certainly sites supporting the generation of receptor diversity through B cell somatic hypermutation, and it is of course possible that eTACs play a role in preventing the emergence of autoreactive clones from this process. Indeed
their selective localization to T-B boundary regions suggests that interacting with B cell-
T-cell conjugation might play a relevant role in their function.

Alternatively, the unique set of Aire-regulated antigens in eTACs suggest that they may play a continuously important role throughout life, presenting a complementary version of “self” to that displayed by mTECs and eliminating those T cells that evade thymic selection for lack of antigen exposure. It is not clear, however, what the advantage of such an organization would be, and why T-cell reactivity to some antigens would be corrected during thymic development, while in other cases it would happen in the periphery. A simpler solution might seem to simply unify this process by presenting as complete a version of the peripheral self as possible in one centralized location. Conversely, it is also not clear that the secondary lymphoid organs need promiscuous gene expression to expose T cells to a diverse picture of self at all; the secondary lymphoid organs drain nearly all of the body’s tissues, and many tissue-specific antigens along with them. It seems equally likely that tolerogenic antigen-draining DCs might fill this role in the secondary lymphoid organs by simply acquiring antigen in the end organs and then trafficking back to the draining lymph nodes (25).

Further, even if we accept that such cells may play a contributory role in tolerance and operate by the mechanisms described here, such a mechanism of CD4+ tolerance would lead to the persistence of significant numbers of residual, functionally autoreactive CD4+ T cells after eTAC encounter. This seems to be a highly inefficient mechanism for disposing of such clones, though perhaps the induction or maintenance of regulatory
CD4+ populations contributes more significantly in vivo. Alternatively, however, such pools of functionally inactive but antigen-specific T cells might serve as competitive inhibitors of other autoreactive clones simply by occupying available MHC-antigen complexes and preventing functional T cells from finding similar sites for activation.

Finally, it is worth speculating on the potential hazards that this population might pose. Indeed, might not a self antigen-expressing tolerogenic population in the secondary lymphoid organs be a significant risk to the organism? On the one hand, if certain stimuli were able to convert this population from tolerance to immunogenicity, they might rapidly become a potent source for priming a diverse array of autoreactive T cells. Avoidance of such risk is at least consistent with the data suggesting that eTACs are in fact uniquely difficult to convert to immunogenicity, and indeed we been unable to do so. Conversely, however, might not such a permanently tolerogenic cell also present significant risk to host defense if such populations themselves ever became infected? If even activated T cells fail to break tolerance induced by eTACs, much less to directly attack this population, eTACs might offer a highly attractive target for infection.

**Therapeutic self-antigen expression in eTACs?**

The robust nature of eTAC-mediated tolerance induction, in concert with the recent report of detection of Aire protein in human secondary lymphoid organs, raises the attractive possibility that such cells might serve as appropriate therapeutic targets in the prevention of autoimmunity. One potential approach might be via identification of
unique surface markers for antibody-mediated antigen targeting, similar to the approach that has been used to target antigens to DEC205+ dendritic cells (19, 26). Microarray data for eTACs could be screened relative to other characterized APC populations to generate candidate eTAC-specific cell-surface markers, which could then be validated by FACS. An alternative approach would be try and generate eTAC-specific antibodies by direct immunization with eTACs, although the amounts of tissue required for such procedures are currently well beyond our capacity to isolate purified eTACs. Such antibody-mediated approaches present significant challenges including the need to target a receptor that leads to correct processing and presentation of the desired antigen, and also confirm that antibody treatment does not lead to depletion or inactivation of the target population. Regardless, such avenues might have significant future clinical promise if antibody-conjugated antigens targeted to eTACs could induce tolerance that resembled the tolerance generated by Aire-driven TSA expression in eTACs.

As a more speculative proof-of-principle experiment, it would also be of interest to test transgenic lymph node transplantation as a mechanism of tolerance induction. Based on the idea that eTACs are resident or long-lived constituents of the secondary lymphoid architecture, and that most lymphocytes circulate continuously throughout the secondary lymphoid system for extended periods before encountering cognate self-antigen and undergoing activation, theoretically even a single transplanted lymph node in which eTACs expressed a cognate autoantigen might be sufficient to impact autoimmunity. One simple test of this using existing mice would be to transplant Adig or
wildtype lymph nodes (possibly pre-depleted of replicating cells via incubation in 2-deoxyguanosine) into young 8.3 mice to determine whether Adig lymph nodes specifically reduced the total number or tetramer-reactivity of IGRP-specific 8.3 T cells, and whether such intervention could impact diabetes incidence in this model. If successful, such lymph node transplantation might have the added benefit that tolerance induction would not require targeting to every lymph node but could even be accomplished in ex vivo tissue. While speculative, such antigen targeting to eTACs in single ex vivo lymph nodes followed by re-transplantation might be a relatively simple means of generating an “immunologic sieve.”

The recent evidence that eTACs are detectable in human secondary lymphoid organs (27) also raises further interesting questions about their roles in disease tolerance. It would be interesting to determine, for instance, whether eTAC numbers increase or decrease in particular disease states, or in response to inflammation, age, or autoimmunity. Such correlative data in patients could suggest a potential role for these populations in human disease.

Clearly, the description of this discrete population of extrathymic Aire-expressing cells in the secondary lymphoid organs raises many more questions than it answers. Hopefully the further study of this novel population will provide some insight into the mechanisms that maintain self-tolerance in the immune system, and perhaps identify useful tools to more precisely manipulate such systems in the context of autoimmunity.
References


Appendix:

Selected Protocols
Thymectomy/Thymic Transplant/Bone Marrow Chimerism

(A) Thymic harvest

(1) One week before transplantation, select donor mice. The donor mice should be neonatal (pink and furless, ~1-2 days old… see image below), so if genotyping is required it should be done in the intervening week. In this case, we used 2 d.o. pups, all wt NOD.

(2) Bring mice up to lab. They will not survive too long (more than a few hours) away from mother, so only bring them up when you are ready to proceed. Prepare materials:

- Dissecting Scope
- Styrofoam dissecting board with paper towels and pins
- Scissors and two pair of tweezers
- Sterile Complete DMEM-hi
- 2-Deoxyguanosine
- 12-well plate
- Transwell Plate (Costar 12-well)

(3) Fill 12-well plate, 1 well/mouse, with 1mL of sterile complete DMEM. Harvest is done on the benchtop, then transferred to the hood when putting in the transwell plate, so the procedure overall is semi-sterile.

D10F:

General mouse lymphocyte cell culture medium (D10F), 500 mL

<table>
<thead>
<tr>
<th>reagent</th>
<th>amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>DMEM with high glucose (4.5 g/L)</td>
<td>429.5 mL</td>
</tr>
<tr>
<td>HEPES (1M)</td>
<td>5 mL</td>
</tr>
<tr>
<td>heat inactivated FCS</td>
<td>50 mL</td>
</tr>
<tr>
<td>GlutaMax-I (200mM)</td>
<td>5 mL</td>
</tr>
</tbody>
</table>
NEAA (100X) 5 mL
2-mercaptoethanol **prediluted to 50mM** (100X) 0.5 mL
Penn/Strep (100x) 5 mL
Vacuum filter through a 0.22 um membrane to ensure sterility.

(4) Cover dissecting board with paper towels. Quickly decapitate mice with scissors above the shoulders, so forelimbs remain attached.

(5) Pin the back side of the shoulders with two pins and the hindquarters with one pin. Make two cuts with scissors along the sides of the ribcage, cutting from the trachea outward to just inside the forelimbs and down the length of the ribcage (but cutting outside the ribcage itself).

(6) Using foreceps, pull open the ribcage, exposing the thorax. Under the dissecting scope (or not), the two thymic lobes should be obviously visible as large white ovals sitting on top of the heart. Remove the thymi intact with foreceps, trying not to tear them in the process. Place both thymic lobes in one well of DMEM in the 12-well plate. Also if you want to genotype, remember to **CUT THE TAIL** into a PCR tube labeled to correspond to the thymic well, and get the tail processed for genotyping. In this case there is no need, as they are all wildtype NOD mice.
(7) Once all thymi are removed, make up 2-DG media for depletion of lymphocytes in the hood:

1.35mM 2-deoxyguanosine in complete DMEM-10.

(2-DG: 285.26g/mole, so 36mg/100mL)

Sterile-filter using a steriflip.

(8) In the hood, pipette 2mL/well of 2-DG media into the BOTTOM wells of the 12-well transwell plate. Place 1-2 drops of media in top well just for your own peace of mind (although it will equilibrate on its own). Transfer thymic lobes onto the mesh of the upper well, 1 well/donor.

(9) Culture at 37 degrees for 7 days.

(10) The evening before transplant, replace 2-DG media with regular complete DMEM.

(B) Thymectomy/kidney capsule thymic transplant

A surgical procedure for thymectomy of mice followed by transplantation of thymi under the kidney capsule. We are using wt thymi that have been cultured for a week in 2-deoxyguanosine-containing media (see above).

(1) Prepare necessary reagents:

Sterile drape
Autoclaved or sterilized tools (fine foreceps, stapler, foreceps with teeth, scissors)
Fine silicone tubing
Alcohol Prep Pads
Heating pad
Thymi in 12-well Costar transwell plate in DMEM
Fine-gauge Corning Silastic tubing (to push thymus under capsule)
Electrocautery
Anesthetic/Analgesic
Sterile suture (6-0 silk is good)
Nair
Sterile Q-tips
Vial of sterile PBS
25-gauge needle tip
Ehrlemeyer flask and surgical tubing to hook up to vacuum apparatus
Clean styrofoam operating board
Rubber Bands (4-6 large)
Insulin syringes (3-4)
Alcohol Prep Pads
Razor Blades (2-3)
5mL pipettes (4-5)
P1000 tips, NON-barrier

(2) Prepare appropriate drug formulations for anesthesia and analgesia:
   Anesthetic: Ketamine /Xylazine (80mg/kg/ 10mg/kg)
   Analgesic: Buprenorphine/Flunixin (0.05mg/kg)

Average mouse weight ~0.025kg, so want to inject 2mg Ket and 0.25mg Xyl per mouse in 100uL. For smaller mice, adjust dosage (70uL works well for ~50do mice; 100uL works well for ~90do mice) Thus, final concentrations should be:
   20mg/mL Ket
   2.5mg/mL Xyl

Stock solutions of both at 100mg/mL. Thus, in 1mL final solution, should have:
   200uL Ket
   25uL Xyl
   775uL sterile saline

(3) Bring all materials down to procedure room. Select recipient mice
(4) Prepare a 5mL pipette to accept P1000 tips for suction. Break 5mL pipette in half, discard the front (tapered) half, and remove cotton plug from back half. Attach one end of this pipette to the surgical tubing connected to the Ehrlenmeyer vacuum flask.

In order to fit inside a P1000 tip, the new tip of this pipette must be “shaved” down slightly using a razor blade:

It’s also helpful to **CUT A SMALL HOLE** in the side of the 5ml pipette tip with the razor blade that can be occluded with your finger during suction. This allows for much greater control of the amount of suction at the appropriate times.

(5) Prepare P1000 tips for thymic suction by cutting a larger opening with a sterile razor blade on a sterile drape.

For immunosufficient thymi, you need a relatively large-diameter tip opening to suck the thymus, but apparently you don’t want it to be either too large or too small—based on Helene’s cuts, the hole should be large enough that the end of a P20 Pipetman can just fit inside. Cut enough to have at least one per animal, with some to spare. Store these tips in a sealed container until use. However, for SCID mice, which have a very small thymus, you need a much smaller-diameter tip, small enough that a P10 Pipetman can just fit inside. A small-diameter tip can also be useful for thymectomy of replete hosts, if you want to use the suction to “grab” the thymus and then pull it out manually with forceps.
(6) Bring all reagents in plastic sheath down to the mouse house. Need to use a procedure room with a vacuum attachment, and the only one accessible on our floor is in the first hallway, all the way down near the end of the hall on the left. This room is communal, so if you want to use it a specific time you should SIGN UP in advance on the sheet of paper on the room’s door.

(7) Put down sterile drapes on bench. Set up styrofoam surgery board covered with a sterile drape and three rubber bands to restrain the mice as displayed below (only after removal of hair on left flank; restrain before step 12). Note there is an error in diagram below—horizontal rubber band (head restraint) should be ABOVE vertical restraint bands.

(8) Anesthetize mice using Ketamine/Xylazine mixture, 100uL/~25g mouse. Inject INTRAMUSCULAR or SUB-Q, not IP, as this has faster onset and longer duration. Wait until mouse is completely anesthetized before proceeding. Test paw withdrawal reflex after light pinch on all four limbs.

(9) Set up “sterile” field. Turn on lamp above field reasonably close to provide additional heat. Wash hands with EtOH.
(10) Order of operations is as follows: Shave and Nair left flank, then thymectomize, then thymic transplant. Begin by removing hair around left-side flank and back region using clippers and then Nair, making sure the Nair gets rubbed into the follicle bases to completely remove hair from the field. Flank should be just clean pink skin on the mouse’s left side in an area about the size of a quarter, stretching from the bottom of the ribage down to the innominate bone, and stretching back to almost the vertebra.

(11) Wash area with EtOH and clean up remaining Nair.

(12) Wet chest and neck area thoroughly with alcohol prep pad. Using scissors, make a 2cm-incision from middle of neck to middle of chest, below the 3rd rib line (see both diagrams below). Spread the incision on either side by cutting away at the subcutaneous connective tissue:

(13) This will expose the salivary glands on the rostral side of the incision, and the rib cage on the caudal side of the incision. Cut the connective tissue away from the bottom of the salivary glands and reflect them up and out of the incision toward the head. Some small amount of bleeding may occur during this cutting. Use a sterile q-tip to blot away any blood.

(14) Using a pair of sharp scissors, make a single cut in the ribcage down the midline to the 3rd rib. This point is defined by a small white line or chevron pointing rostrally:
(15) Prepare other reagents needed for actual thymectomy: curved dull forceps, curved sharp forceps, active (1/2 strength) vacuum with cut tip, stapler with staples.

(16) Using dull curved forceps, pull up on the left side of the rib cage. Insert the vacuum tip into the chest cavity deep enough to draw out the thymus, being careful to avoid vessels and the heart, and not completely occluding the opening so as to prevent a pneumothorax. The SCID thymus is very small, while wt thymi at this age are quite large. Depending on preference, you can either use vacuum to suck out thymus or can remove manually with forceps after “grabbing” it with suction. For SCIDs you must grab it and manually remove, for wt animals you can do either. Make sure you get BOTH LOBES INTACT out of the chest, and spread them out on a paper towel to confirm. Also vacuum the opening again after you think it’s out to make sure nothing else comes out when you apply suction. It’s better to have a dead mouse than an incomplete thymectomy.

(17) Once thymus is removed, mouse should still be breathing normally or slightly more rapidly. Immediately after thymus is out, cover the chest opening as best as possible with the salivary gland “flap,” then staple the skin closed with three staples proceeding from caudal to rostral. Check that mouse is still breathing normally, then rotate it onto its side to gain access to the shaved lateral flank.
(18) Clean the bare flank with EtOH. Using scissors, make an incision near the back, beneath the spleen and the rib cage, about 1cm long. Then make a similar but slightly shorter incision in the peritoneum beneath.

(19) Wash hands again with EtOH.

(20) Using gloved hands, palpate for the kidney within the abdomen. Should feel hard and bean-like, and be near the spine. Slowly move it up toward the incision, wiggling it past any fat if possible. Squeeze the kidney out of the incision, situating it so that it stays exposed outside the body. It may be easier to first pull out the perirenal fat, and let the kidney come with it. Using locking pickups, grab a bit of perirenal fat or connective tissue near the kidney and clamp it to keep the kidney from sliding back into the body.

(21) Wet the surface of the kidney with a PBS-moistened (or sterile media-moistened) q-tip to prevent drying.

(22) Choose thymus to transplant and place it on the kidney surface. Using sharp forceps, grab the kidney capsule and make a short incision using the tip of the 25-gauge needle to cut. Place the thymus at the edge of the incision and use the plastic tubing to push it under the capsule and away from the incision. It is best to do this process on the FLAT SIDE OF THE KIDNEY, not on the curved apex, as this makes it easier to tear when you push the thymus under.

(23) Once thymus is inserted and pushed far enough away from the incision site, cauterize the incision on the kidney lightly.

(24) Re-insert the kidney and any other externalized viscera into the body. First tuck it through the outer skin layer, then through the peritoneum.

(25) Suture the peritoneum closed using 6-0 silk sutures. Staple the skin back together.
(26) Place the mouse on a few paper towels on the heating pad. Check it's not too hot.

(27) Document the thymi transplanted into each mouse, and any notes on each procedure:

(28) Once surgery is complete, provide preventative analgesia for pain control:

   Buprenorphine/Flunixin sub-q (0.05mg/kg)

(29) Once mice begin to wake, remove them from the heating pad and place them in the cage, on the heated section of the cage. Do not put anesthetized animals in a cage with awake animals, as the awake mice may become aggressive toward the sleepers. Best to have a “recovery cage” that is also on the heating pad.

(30) Remain with animals until they awaken. Provide additional analgesia at 24 and 48 hours post-operatively. Also put some food pellets in the cage in case they can’t reach the food dispenser in the first day or two.

(31) Remove staples at TWO WEEKS post-surgery.

(C) Bone marrow chimerism of thymectomized/ transplanted mice

Mice are suitable for irradiation and BM chimerism as soon as surgical wounds have healed; since staples are removed at two weeks, this is often a good earliest time point to consider irradiation.

Primary irradiation

1. For NODs, want to give ~1300 rads of radiation in two doses, ~900 rads now and then another ~400 rads after at least three hours have passed. First, go to irradiator room on 4th floor of the LARC (near the gowning room) and get the irradiation pie. Bring it back to the mouse room and spray it down with bleach thoroughly.
2. Transfer desired RECIPIENT mice (not donor, obviously) into pie wedges, one or two per wedge. Stuff a paper towel into the open hole to block it and prevent the mice from moving the divider once you are done. Tape the lid down.

3. Take the mice down to the irradiator in the pie. Sign in on the irradiator log.

4. Remove the key from the wall safe by pressing “1248.” Turn the key to activate the system.

5. Turn on the compressor switch.

6. Place the mice in the irradiator chamber, checking of course that the source is not raised (door will not open if it’s raised, but check anyway). To open the door, press the red button atop the door and give it a bump with your hip to open it. Put the pie onto the turn wheel, seating it in the outer holes.

7. Turn on the turntable switch, and watch to make sure it is turning. Close the door firmly.

8. Set the irradiation time using the timer. Currently source production is posted on the wall of the irradiator room. To set the timer, first press the R button to reset to zero. Then press the P1 button, and then adjust the digits using the buttons below each digit. Then press E to enter. Then press P1 again to make sure your time was entered. Also check that the SECOND number that cycles through the timer says 0.00. The first should be your time, and the second should be at 0. If not, hit reset and try again. Bring a watch down so you can time it to confirm, and manually lower the source if necessary.

9. Once the time is entered, press Source Raise. Irradiation will begin. **Time the exposure** to make sure the timer is working. If it exceeds the time, you can stop by pressing Source Lower. Remove mice and return them to cages to rest.
Initial isolation of bone marrow

1. Take selected donor mice back to lab for harvesting. Wash out pie with bleach and return it to the irradiator room.

2. On benchtop, remove all long bones from the donor mice (femurs, tibia, humeri) and strip muscle from bone using scissors and kimwipes. Place appendages containing bones into a Petri dish containing DMEM (nonsterile at this point).

3. Transfer bones in dish to the hood, along with another sterile Petri dish of DMEM poured in the hood for each sample group. Clean bones further if necessary and separate them from one another. Once clean, take each bone and cut off the two ends. Then transfer the shaft (along with the two ends if large enough) to the sterile dish, draw up DMEM from the dish into an insulin syringe and flush the marrow from the bone. Do the same with the ends. The shaft should bleach white when it is clean. Discard the empty bones.

4. When all bones have been cleaned, use a 10mL pipette tip to dissociate all the clumps by pipetting up and down a few times, then transfer the media containing the BM cells into a 50mL Falcon tube, passing through a cell-strainer cap. Wash the dish with an additional 10mL of sterile media (or appropriate amount to balance tubes) and transfer this wash to the tube.

5. Centrifuge at 1200rpm for 5 min at 4 degrees. Decant supernatant and resuspend the cells in 2mL per mouse of DMEM (6mL in this case). Keep cells on ice.

Complement depletion of CD4/CD8 cells

1. Add 1uL of anti-CD4 (clone GK1.5, 4mg/ml) per mouse. Then add 1uL of anti-CD8 (clone YTS 164.5, 4mg/ml) per mouse. Incubate 15 minutes on ice, mixing every 5 minutes.
2. During incubation, warm 10mL of sterile DMEM in 37 degree water bath. Also remove one tube of rabbit complement per up to three mice and thaw on ice. For larger cohorts, split into multiple samples of three mice or less each.

3. Once incubation is complete, add pre-warmed DMEM to each sample. Then add 1mL of rabbit complement and incubate at 37 degrees for 30 minutes, in rotator inside incubator.

4. Add 30mL DMEM, spin for 5 min at 1200rpm at 4 degrees, and wash again with 30mL DMEM, spinning again. Resuspend pellet third time in 20mL sterile HBSS, filter through a 70um mesh into a new tube to remove clumps, and count cells while the tubes are spinning a final time (1200rpm, 5 min, 4 deg.).

5. Need to inject a minimum of 5 million cells per recipient, preferably 10 million, in a volume of 200uL of sterile HBSS. This means a desired concentration of 5e7 cells/ml. Also if possible, want to have a significant excess for making mistakes during injection (not that mistakes ever happen).

6. Spin cells at 1200rpm for 5 min at 4 degrees and resuspend in the appropriate volume of Hank’s BSS to achieve 5e7 cells/mL. Transfer cells to a 1.5mL eppendorfs, place in a small ice container (50mL conical) and transport them down to the LARC.

Secondary irradiation

1. Return the mice to the irradiator and repeat steps from primary irradiation, but in this case 400 rads.

2. Bring mice back to the room and transfer back to cages. Wash the pie and return it to the irradiator room.
Injection of BM

1. Remove injection restraint from drawer and clean it thoroughly. Attach it to the hood surface. Place a food pellet in the back of the restraint for the mouse to rest on; prevents them from jumping as much. Select a group of mice and warm them with the heat lamp, being careful not to overheat them. Mice should show whisker-cleaning behavior when they are warm.

2. Select an appropriate syringe: should have the bevel oriented in such a way that it is faced up when the syringe is comfortably in your hand ready to inject. Bevel orientation is random on the syringes, so if you have one with a bad orientation, throw it away and try another.

3. Using one insulin syringe per BM sample (or until it gets cloggy), draw up BM solution after flicking tube to resuspend. Select the appropriate mouse and place it securely in the restraint. Do not use plunger. Inject 200uL of solution into the tail vein. Approach the vein at a shallow angle with the tail slightly bent over your finger and rotated to access the lateral veins… otherwise it's easy to go through it. It is very superficial. Don’t try to force it, as this means you're not in the vein. Also, if you’re in the vein, you’ll see it flush all the way up when you inject.

4. Clean the wound site and return the mice to their cages. In mice where the donor cells don't take, the mice should die after about ten days. Those mice that survive should be completely reconstituted by eight weeks.
# Stromal Preparation for FACS

**Digestion Media:**

<table>
<thead>
<tr>
<th>Component</th>
<th>15 mL</th>
<th>30 mL</th>
<th>50 mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>DMEM (Hi Glucose)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2% HI FBS</td>
<td>300 uL</td>
<td>600 uL</td>
<td>1 mL</td>
</tr>
<tr>
<td>0.125% Collagenase D</td>
<td>18.75 mg</td>
<td>37.5 mg</td>
<td>62.5 mg</td>
</tr>
<tr>
<td>100 ug/mL DNase I</td>
<td>15 uL</td>
<td>30 uL</td>
<td>50 uL</td>
</tr>
<tr>
<td>100 ug/mL Collagenase/Dispase</td>
<td>15 uL</td>
<td>30 uL</td>
<td>50 uL</td>
</tr>
</tbody>
</table>

**Percoll Densities:**

<table>
<thead>
<tr>
<th>Density</th>
<th>Component</th>
<th>9 mL</th>
<th>27 mL</th>
<th>45 mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.124</td>
<td>Percoll Stock</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>10x PBS</td>
<td>1 mL</td>
<td>3 mL</td>
<td>5 mL</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Density</th>
<th>Component</th>
<th>9.274 mL</th>
<th>18.548 mL</th>
<th>27.822 mL</th>
<th>37.096 mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.115</td>
<td>1.124 Percoll</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1x PBS</td>
<td>0.726 mL</td>
<td>1.452 mL</td>
<td>2.178 mL</td>
<td>2.904 mL</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Density</th>
<th>Component</th>
<th>5.24 mL</th>
<th>10.48 mL</th>
<th>15.72 mL</th>
<th>20.96 mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.065</td>
<td>1.124 Percoll</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1x PBS</td>
<td>4.76 mL</td>
<td>9.52 mL</td>
<td>14.28 mL</td>
<td>19.04 mL</td>
</tr>
</tbody>
</table>

**Tissue Isolation and Digestion**

1. Collect thymi, pooled LNs, and spleens from each animal place into separate small Petri dishes with 5 mL digestion media (RT). Mince organs with new, clean razor blades until small enough to easily be sucked through tip of glass Pasteur pipette.
2) Transfer minced organs and media to labeled 15 mL conical tubes using glass Pasteur pipette tips. Use 3 mL of digestion media to rinse remaining tissue from Petri dishes and then add to the conical tubes.

3) Place conical tubes containing minced organ tissue and 8 mL digestion media into a 37° C water bath for 40-50 minutes with periodic mixing of contents via glass pipettes (every 10 minutes).

4) When sufficient time has passed and only clumps of connective tissue (esp. in the LNs) remains, spin down cells at 1200 rpm for 5 min at 4° C.

5) Resuspend thoroughly in 5 mL cold AutoMACS buffer (1x PBS, 0.5% BSA, 2mM EDTA) to remove clumps and stop digestion, and leave on ice for 10 minutes.

6) Spin down cells at 1200 rpm for 5 min at 4°C. During spin, coat 15ml conicals with FCS.

**Stromal Cell Isolation**

7) Resuspend cells in 4 mL dense (1.115) Percoll and transfer through 100um cell-strainer into new FCS-coated tubes.

8) Create a Percoll gradient by gently layering 2 mL of light (1.065) Percoll onto the heavy fraction, followed by 2 mL of 1x PBS.

9) Spin the tubes for 30 minutes at 2700 rpm, 4° C, with the break set to 0 and the acceleration set to 5. During the spin, the stromal cells will settle at the boundary between the light Percoll and 1x PBS, while the lymphocytes will be between the light and heavy Percoll fractions.

10) Remove the stromal fraction with a disposable transfer pipette, and save the dense lymphocyte fraction of a GFP- sample for compensation controls. Resuspend in FACS buffer to a net volume of 5 mL for stromal cells and 10 mL for lymphocytes.

11) Count cells.

**FACS Staining**
12) Identify the antibodies to be used for staining:

- [GFP] (in cells from transgenic animals)
- CD45 PerCP
- MHC Class II (I-A^7 or pan-MHC in A647)

13) Make a master mix with each antibody at 1 uL per 100 uL FACS buffer. Split lymphocyte fraction into necessary compensation control tubes.

14) Add 2.4G2 at 1:100 in FACS buffer to cells at 100 uL per 10 million cells with a minimum of 100 uL volume per tube (it is likely that all tubes will have 100 uL). Incubate on ice for 10 minutes.

15) Add an equal volume of the master mix to the tubes, and add 1 uL comp Ab to appropriate tubes. Incubate covered on ice for 20 minutes.

16) Wash 2-3 x in FACS buffer.
Publishing Agreement

It is the policy of the University to encourage the distribution of all theses, dissertations, and manuscripts. Copies of all UCSF theses, dissertations, and manuscripts will be routed to the library via the Graduate Division. The library will make all theses, dissertations, and manuscripts accessible to the public and will preserve these to the best of their abilities, in perpetuity.

I hereby grant permission to the Graduate Division of the University of California, San Francisco to release copies of my thesis, dissertation, or manuscript to the Campus Library to provide access and preservation, in whole or in part, in perpetuity.

[Signature]

Author Signature

03/25/10

Date